PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68 — A3

(11) International Publication Number: WO 98/20157

(43) International Publication Date: 14 May 1998 (14.05.98)

(21) International Application Number: PCT/CA97/00829

(22) International Filing Date: 4 November 1997 (04.11.97)

(30) Priority Data:
08/743,637 4 November 1996 (04.11.96) US

(71) Applicant *(for all designated States except US)*: INFECTIO DIAGNOSTIC (I.D.I.) INC. [CA/CA]; 4ème étage, 2050, boulevard René Lévesque Ouest, Sainte-Foy, Québec G1V 2K8 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BERGERON, Michel, G. [CA/CA]; 2069, rue Brûlard, Sillery, Québec G1T 1G2 (CA). PICARD, François, J. [CA/CA]; 1245, rue de la Sapinière, Cap-Rouge, Québec G1Y 1A1 (CA). OUELLETTE, Marc [CA/CA]; 1035 de Ploermel, Sillery, Québec G1S 3S1 (CA). ROY, Paul, H. [US/US]; 28, rue Charles Garnier, Loretteville, Québec G2A 2X8 (CA).

(74) Agents: DUBUC, Jean, H. et al.; Goudreau Gage Dubuc & Martineau Walker, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Québec H4Z 1E9 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
13 August 1998 (13.08.98)

(54) Title: SPECIES-SPECIFIC, GENUS-SPECIFIC AND UNIVERSAL DNA PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL AND FUNGAL PATHOGENS AND ASSOCIATED ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR DIAGNOSIS IN MICROBIOLOGY LABORATORIES

(57) Abstract

DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species *Streptococcus agalactiae*, *Staphylococcus saprophyticus*, *Enterococcus faecium*, *Neisseria meningitidis*, *Listeria monocytogenes* and *Candida albicans*, and (iii) any species of the genera *Streptococcus*, *Staphylococcus*, *Enterococcus*, *Neisseria* and *Candida* are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of bla_{tem}, bla_{rob}, bla_{shv}, bla_{oxa}, *blaZ*, *aadB*, *aacC1*, *aacC2*, *aacC3*, *aacA4*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *mecA*, *vanA*, *vanB*, *vanC*, *satA*, *aac(6'-aph(2'')*, *aad(6')*, *vat*, *vga*, *msrA*, *sul* and *int* are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and/or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and/or genera, and/or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

TITLE OF THE INVENTION

SPECIES-SPECIFIC, GENUS-SPECIFIC AND UNIVERSAL DNA PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL AND FUNGAL PATHOGENS AND ASSOCIATED ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR DIAGNOSIS IN MICROBIOLOGY LABORATORIES

BACKGROUND OF THE INVENTION

Classical methods for the identification and susceptibility testing of bacteria

Bacteria are classically identified by their ability to utilize different substrates as a source of carbon and nitrogen through the use of biochemical tests such as the API20E™ system (bioMérieux). For susceptibility testing, clinical microbiology laboratories use methods including disk diffusion, agar dilution and broth microdilution. Although identifications based on biochemical tests and antibacterial susceptibility tests are cost-effective, at least two days are required to obtain preliminary results due to the necessity of two successive overnight incubations to identify the bacteria from clinical specimens as well as to determine their susceptibility to antimicrobial agents. There are some commercially available automated systems (i.e. the MicroScan system from Dade Diagnostics Corp. and the Vitek system from bioMérieux) which use sophisticated and expensive apparatus for faster microbial identification and susceptibility testing (Stager and Davis, 1992, Clin. Microbiol. Rev. **5**:302-327). These systems require shorter incubation periods, thereby allowing most bacterial identifications and susceptibility testing to be performed in less than 6 hours. Nevertheless, these faster systems always require the primary isolation of the bacteria as a pure culture, a process which takes at least 18 hours for a pure culture or 2 days for a mixed culture. The fastest identification system, the autoSCAN-Walk-Away™ system (Dade Diagnostics Corp.) identifies both gram-negative and gram-positive bacterial species from standardized inoculum in as little as 2 hours and gives susceptibility patterns to most antibiotics in 5.5 hours. However, this system has a particularly high percentage (i.e. 3.3 to 40.5%) of non-conclusive identifications with bacterial species other than *Enterobacteriaceae* (Croizé J., 1995, Lett. Infectiol. **10**:109-113; York *et al.*, 1992, J. Clin. Microbiol. **30**:2903-2910). For *Enterobacteriaceae*, the percentage of non-conclusive identifications was 2.7 to 11.4%.

A wide variety of bacteria and fungi are routinely isolated and identified from clinical specimens in microbiology laboratories. Tables 1 and 2 give the incidence for the most commonly isolated bacterial and fungal pathogens from various types of clinical specimens. These pathogens are the most frequently associated with nosocomial and community-acquired human infections and are therefore considered the most clinically important.

Clinical specimens tested in clinical microbiology laboratories

Most clinical specimens received in clinical microbiology laboratories are urine and blood samples. At the microbiology laboratory of the Centre Hospitalier de l'Université Laval (CHUL), urine and blood account for approximately 55% and 30% of the specimens received, respectively (Table 3). The remaining 15% of clinical specimens comprise various biological fluids including sputum, pus, cerebrospinal fluid, synovial fluid, and others (Table 3). Infections of the urinary tract, the respiratory tract and the bloodstream are usually of bacterial etiology and require antimicrobial therapy. In fact, all clinical samples received in the clinical microbiology laboratory are tested routinely for the identification of bacteria and susceptibility testing.

Conventional pathogen identification from clinical specimens

Urine specimens

The search for pathogens in urine specimens is so preponderant in the routine microbiology laboratory that a myriad of tests have been developed. However, the gold standard remains the classical semi-quantitative plate culture method in which 1 µL of urine is streaked on plates and incubated for 18-24 hours. Colonies are then counted to determine the total number of colony forming units (CFU) per liter of urine. A bacterial urinary tract infection (UTI) is normally associated with a bacterial count of 10^7 CFU/L or more in urine. However, infections with less than 10^7 CFU/L in urine are possible, particularly in patients with a high incidence of diseases or those catheterized (Stark and Maki, 1984, N. Engl. J. Med. **311**:560-564). Importantly, approximately 80% of urine specimens tested in clinical microbiology laboratories are considered negative (i.e. bacterial count of less than 10^7 CFU/L; Table 3). Urine specimens found positive by culture are further characterized using standard biochemical tests to identify the bacterial pathogen and are also tested for susceptibility to antibiotics. The biochemical and susceptibility testing normally require 18-24 hours of incubation.

Accurate and rapid urine screening methods for bacterial pathogens would allow a faster identification of negative specimens and a more efficient treatment and care management of patients. Several rapid identification methods (Uriscreen™, UTIscreen™, Flash Track™ DNA probes and others) have been compared to slower standard biochemical methods, which are based on culture of the bacterial pathogens. Although much faster, these rapid tests showed low sensitivities and poor specificities as well as a high number of false negative and false positive results (Koening *et al.*, 1992, J. Clin. Microbiol. **30**:342-345; Pezzlo *et al.*, 1992, J. Clin. Microbiol. **30**:640-684).

Blood specimens

The blood specimens received in the microbiology laboratory are always submitted for culture. Blood culture systems may be manual, semi-automated or completely automated. The BACTEC system (from Becton Dickinson) and the

BacTAlert system (from Organon Teknika Corporation) are the two most widely used automated blood culture systems. These systems incubate blood culture bottles under optimal conditions for bacterial growth. Bacterial growth is monitored continuously to detect early positives by using highly sensitive bacterial growth detectors. Once growth is detected, a Gram stain is performed directly from the blood culture and then used to inoculate nutrient agar plates. Subsequently, bacterial identification and susceptibility testing are carried out from isolated bacterial colonies with automated systems as described previously. The bottles are normally reported as negative if no growth is detected after an incubation of 6 to 7 days. Normally, the vast majority of blood cultures are reported negative. For example, the percentage of negative blood cultures at the microbiology laboratory of the CHUL for the period February 1994-January 1995 was 93.1% (Table 3).

Other clinical samples

Upon receipt by the clinical microbiology laboratory, all body fluids other than blood and urine that are from normally sterile sites (i.e. cerebrospinal, synovial, pleural, pericardial and others) are processed for direct microscopic examination and subsequent culture. Again, most clinical samples are negative for culture (Table 3).

Regarding clinical specimens which are not from sterile sites such as sputum or stool specimens, the laboratory diagnosis by culture is more problematic because of the contamination by the normal flora. The bacterial pathogens potentially associated with the infection are purified from the contaminants and then identified as described previously. Of course, the universal detection of bacteria would not be useful for the diagnosis of bacterial infections at these non sterile sites. On the other hand, DNA-based assays for species or genus detection and identification as well as for the detection of antibiotic resistance genes from these specimens would be very useful and would offer several advantages over classical identification and susceptibility testing methods.

DNA-based assays with any clinical specimens

There is an obvious need for rapid and accurate diagnostic tests for bacterial detection and identification directly from clinical specimens. DNA-based technologies are rapid and accurate and offer a great potential to improve the diagnosis of infectious diseases (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.). The DNA probes and amplification primers which are objects of the present invention are applicable for bacterial or fungal detection and identification directly from any clinical specimens such as blood cultures, blood, urine, sputum, cerebrospinal fluid, pus and other type of specimens (Table 3). The DNA-based tests proposed in this invention are superior in terms of both rapidity and accuracy to standard biochemical methods currently used for routine diagnosis from any clinical specimens in microbiology laboratories. Since

these tests are performed in around only one hour, they provide the clinicians with new diagnostic tools which should contribute to increase the efficiency of therapies with antimicrobial agents. Clinical specimens from organisms other than humans (e.g. other primates, birds, plants, mammals, farm animals, livestock and others) may also be tested with these assays.

A high percentage of culture negative specimens

Among all the clinical specimens received for routine diagnosis, approximately 80% of urine specimens and even more (around 95%) for other types of clinical specimens are negative for the presence of bacterial pathogens (Table 3). It would also be desirable, in addition to identify bacteria at the species or genus level in a given specimen, to screen out the high proportion of negative clinical specimens with a test detecting the presence of any bacterium (i.e. universal bacterial detection). Such a screening test may be based on the DNA amplification by PCR of a highly conserved genetic target found in all bacteria. Specimens negative for bacteria would not be amplified by this assay. On the other hand, those that are positive for bacteria would give a positive amplification signal with this assay.

Towards the development of rapid DNA-based diagnostic tests

A rapid diagnostic test should have a significant impact on the management of infections. DNA probe and DNA amplification technologies offer several advantages over conventional methods for the identification of pathogens and antibiotic resistance genes from clinical samples (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.; Ehrlich and Greenberg, 1994, PCR-based Diagnostics in Infectious Disease, Blackwell Scientific Publications, Boston, MA). There is no need for culture of the bacterial pathogens, hence the organisms can be detected directly from clinical samples, thereby reducing the time associated with the isolation and identification of pathogens. Furthermore, DNA-based assays are more accurate for bacterial identification than currently used phenotypic identification systems which are based on biochemical tests. Commercially available DNA-based technologies are currently used in clinical microbiology laboratories, mainly for the detection and identification of fastidious bacterial pathogens such as *Mycobacterium tuberculosis*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae* as well as for the detection of a variety of viruses (Podzorski and Persing, Molecular detection and identification of microorganisms, *In* : P. Murray *et al.*, 1995, Manual of Clinical Microbiology, ASM press, Washington D.C.). There are also other commercially available DNA-based assays which are used for culture confirmation assays.

Others have developed DNA-based tests for the detection and identification of bacterial pathogens which are objects of the present invention: *Staphylococcus* spp. (US patent application serial No. US 5 437 978), *Neisseria* spp. (US patent application

serial No. US 5 162 199 and European patent application serial No. EP 0 337 896 131) and *Listeria monocytogenes* (US patent applications serial Nos US 5 389 513 and US 5 089 386). However, the diagnostic tests described in these patents are based either on rRNA genes or on genetic targets different from those described in the present invention.

Although there are diagnostic kits or methods already used in clinical microbiology laboratories, there is still a need for an advantageous alternative to the conventional culture identification methods in order to improve the accuracy and the speed of the diagnosis of commonly encountered bacterial infections. Besides being much faster, DNA-based diagnostic tests are more accurate than standard biochemical tests presently used for diagnosis because the bacterial genotype (e.g. DNA level) is more stable than the bacterial phenotype (e.g. metabolic level).

Knowledge of the genomic sequences of bacterial and fungal species continuously increases as testified by the number of sequences available from databases. From the sequences readily available from databases, there is no indication therefrom as to their potential for diagnostic purposes. For determining good candidates for diagnostic purposes, one could select sequences for DNA-based assays for (i) the species-specific detection and identification of commonly encountered bacterial or fungal pathogens, (ii) the genus-specific detection and identification of commonly encountered bacterial or fungal pathogens, (iii) the universal detection of bacterial or fungal pathogens and/or (iv) the specific detection and identification of antibiotic resistance genes. All of the above types of DNA-based assays may be performed directly from any type of clinical specimens or from a microbial culture.

In our co-pending U.S. (N.S. 08/526,840) and PCT (PCT/CA/95/00528) patent applications, we described DNA sequences suitable for (i) the species-specific detection and identification of 12 clinically important bacterial pathogens, (ii) the universal detection of bacteria, and (iii) the detection of 17 antibiotic resistance genes. This co-pending application described proprietary DNA sequences and DNA sequences selected from databases (in both cases, fragments of at least 100 base pairs), as well as oligonucleotide probes and amplification primers derived from these sequences. All the nucleic acid sequences described in this patent application enter the composition of diagnostic kits and methods capable of a) detecting the presence of bacteria, b) detecting specifically the presence of 12 bacterial species and 17 antibiotic resistance genes. However, these methods and kits need to be improved, since the ideal kit and method should be capable of diagnosing close to 100% of microbial pathogens and antibiotic resistance genes. For example, infections caused by *Enterococcus faecium* have become a clinical problem because of its resistance to many antibiotics. Both the detection of these bacteria and the evaluation of their

resistance profiles are desirable. Besides that, novel DNA sequences (probes and primers) capable of recognizing the same and other microbial pathogens or the same and additional antibiotic resistance genes are also desirable to aim at detecting more target genes and complement our earlier patent application.

STATEMENT OF THE INVENTION

It is an object of the present invention to provide a specific, ubiquitous and sensitive method using probes and/or amplification primers for determining the presence and/or amount of nucleic acids:

- from specific microbial species or genera selected from the group consisting of *Streptococcus* species, *Streptococcus agalactiae*, *Staphylococcus* species, *Staphylococcus saprophyticus*, *Enterococcus* species, *Enterococcus faecium*, *Neisseria* species, *Neisseria meningitidis*, *Listeria monocytogenes, Candida* species and *Candida albicans*

- from an antibiotic resistance gene selected from the group consisting of bla_{tem}, bla_{rob}, bla_{shv}, bla_{oxa}, *blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-IIa, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2"), aad(6'), vat, vga, msrA, sul* and *int*, and optionally,

- from any bacterial species

in any sample suspected of containing said nucleic acids,

wherein each of said nucleic acids or a variant or part thereof comprises a selected target region hybridizable with said probe or primers;

said method comprising the steps of contacting said sample with said probes or primers and detecting the presence and/or amount of hybridized probes or amplified products as an indication of the presence and/or amount of said any bacterial species, specific microbial species or genus and antibiotic resistance gene.

In a specific embodiment, a similar method directed to each specific microbial species or genus detection and identification, antibiotic resistance genes detection, and universal bacterial detection, separately, is provided.

In a more specific embodiment, the method makes use of DNA fragments (proprietary fragments and fragments obtained from databases), selected for their capacity to sensitively, specifically and ubiquitously detect the targeted bacterial or fungal nucleic acids.

In a particularly preferred embodiment, oligonucleotides of at least 12 nucleotides in length have been derived from the longer DNA fragments, and are used in the present method as probes or amplification primers.

The proprietary oligonucleotides (probes and primers) are also another object of the invention.

Diagnostic kits comprising probes or amplification primers for the detection of

a microbial species or genus selected from the group consisting of *Streptococcus* species, *Streptococcus agalactiae*, *Staphylococcus* species, *Staphylococcus saprophyticus*, *Enterococcus* species, *Enterococcus faecium*, *Neisseria* species, *Neisseria meningitidis*, *Listeria monocytogenes*, *Candida* species and *Candida albicans* are also objects of the present invention.

Diagnostic kits further comprising probes or amplification primers for the detection of an antibiotic resistance gene selected from the group consisting of bla_{tem}, bla_{rob}, bla_{shv}, bla_{oxa}, *blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-IIa, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2"), aad(6'), vat, vga, msrA, sul* and *int* are also objects of this invention.

Diagnostic kits further comprising probes or amplification primers for the detection of any bacterial or fungal species, comprising or not comprising those for the detection of the specific microbial species or genus listed above, and further comprising or not comprising probes and primers for the antibiotic resistance genes listed above, are also objects of this invention.

In a preferred embodiment, such a kit allows for the separate or the simultaneous detection and identification of the above-listed microbial species or genus, antibiotic resistance genes and for the detection of any bacterium.

In the above methods and kits, amplification reactions may include a) polymerase chain reaction (PCR), b) ligase chain reaction, c) nucleic acid sequence-based amplification, d) self-sustained sequence replication, e) strand displacement amplification, f) branched DNA signal amplification, g) transcription-mediated amplification, h) cycling probe technology (CPT) i) nested PCR, or j) multiplex PCR.

In a preferred embodiment, a PCR protocol is used as an amplification reaction.

In a particularly preferred embodiment, a PCR protocol is provided, comprising, for each amplification cycle, an annealing step of 30 seconds at 45-55°C and a denaturation step of only one second at 95°C, without any time allowed specifically for the elongation step. This PCR protocol has been standardized to be suitable for PCR reactions with all selected primer pairs, which greatly facilitates the testing because each clinical sample can be tested with universal, species-specific, genus-specific and antibiotic resistance gene PCR primers under uniform cycling conditions. Furthermore, various combinations of primer pairs may be used in multiplex PCR assays.

We aim at developing a rapid test or kit to discard rapidly all the samples which are negative for bacterial cells and to subsequently detect and identify the above bacterial and/or fungal species and genera and to determine rapidly the bacterial resistance to antibiotics. Although the sequences from the selected antibiotic resistance genes are available from databases and have been used to develop DNA-based tests for their detection, our approach is unique because it represents a major improvement over current gold standard diagnostic methods based on bacterial

cultures. Using an amplification method for the simultaneous bacterial detection and identification and antibiotic resistance genes detection, there is no need for culturing the clinical sample prior to testing. Moreover, a modified PCR protocol has been developed to detect all target DNA sequences in approximately one hour under uniform amplification conditions. This procedure will save lives by optimizing treatment, will diminish antibiotic resistance because less antibiotics will be prescribed, will reduce the use of broad spectrum antibiotics which are expensive, decrease overall health care costs by preventing or shortening hospitalizations, and decrease the time and costs associated with clinical laboratory testing.

In the methods and kits described herein below, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). All DNA fragments have been obtained either from proprietary fragments or from databases. DNA fragments selected from databases are newly used in a method of detection according to the present invention, since they have been selected for their diagnostic potential.

It is clear to the individual skilled in the art that other oligonucleotide sequences appropriate for (i) the universal bacterial detection, (ii) the detection and identification of the above microbial species or genus and (iii) the detection of antibiotic resistance genes other than those listed in Annex VI may also be derived from the proprietary fragments or selected database sequences. For example, the oligonucleotide primers or probes may be shorter or longer than the ones we have chosen; they may also be selected anywhere else in the proprietary DNA fragments or in the sequences selected from databases; they may be also variants of the same oligonucleotide. If the target DNA or a variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true; a given target DNA may hybridize to a variant oligonucleotide probe or be amplified by a variant oligonucleotide PCR primer. Alternatively, the oligonucleotides may be designed from any DNA fragment sequences for use in amplification methods other than PCR. Consequently, the core of this invention is the identification of universal, species-specific, genus-specific and resistance gene-specific genomic or non-genomic DNA fragments which are used as a source of specific and ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes requires much effort, it is quite possible for the individual skilled in the art to derive, from the selected DNA fragments, oligonucleotides other than the ones listed in Annex VI which are suitable for diagnostic purposes. When a proprietary fragment or a database sequence is selected for its specificity and ubiquity, it increases the probability that subsets thereof will also be specific and ubiquitous.

Since a high percentage of clinical specimens are negative for bacteria (Table

3), DNA fragments having a high potential for the selection of universal oligonucleotide probes or primers were selected from proprietary and database sequences. The amplification primers were selected from a gene highly conserved in bacteria and fungi, and are used to detect the presence of any bacterial pathogen in clinical specimens in order to determine rapidly (approximately one hour) whether it is positive or negative for bacteria. The selected gene, designated *tuf*, encodes a protein (EF-Tu) involved in the translational process during protein synthesis. The *tuf* gene sequence alignments used to derive the universal primers include both proprietary and database sequences (Example 1 and Annex I). This strategy allows the rapid screening of the numerous negative clinical specimens (around 80% of the specimens received, see Table 3) submitted for bacteriological testing. Tables 4, 5 and 6 provide a list of the bacterial or fungal species used to test the specificity of PCR primers and DNA probes. Table 7 gives a brief description of each species-specific, genus-specific and universal amplification assays which are objects of the present invention. Tables 8, 9 and 10 provide some relevant information about the proprietary and database sequences selected for diagnostic puposes.

DETAILED DESCRIPTION OF THE INVENTION

Development of species-specific, genus-specific, universal and antibiotic resistance gene-specific DNA probes and amplification primers for microorganisms

Selection from databases of sequences suitable for diagnostic purposes

In order to select sequences which are suitable for species-specific or genus-specific detection and identification of bacteria or fungi or, alternatively, for the universal detection of bacteria, the database sequences (GenBank, EMBL and Swiss-Prot) were chosen based on their potential for diagnostic purposes according to sequence information and computer analysis performed with these sequences. Initially, all sequence data available for the targeted microbial species or genus were carefully analyzed. The gene sequences which appeared the most promising for diagnostic purposes based on sequence information and on sequence comparisons with the corresponding gene in other microbial species or genera performed with the Genetics Computer Group (GCG, Wisconsin) programs were selected for testing by PCR. Optimal PCR amplification primers were chosen from the selected database sequences with the help of the Oligo™ 4.0 primer analysis software (National Biosciences Inc., Plymouth, Minn.). The chosen primers were tested in PCR assays for their specificity and ubiquity for the target microbial species or genus. In general, the identification of database sequences from which amplification primers suitable for species-specific or genus-specific detection and identification were selected involved the computer analysis and PCR testing of several candidate gene sequences before

obtaining a primer pair which is specific and ubiquitous for the target microbial species or genus. Annex VI provides a list of selected specific and ubiquitous PCR primer pairs. Annexes I to V and Examples 1 to 4 illustrate the strategy used to select genus-specific, species-specific and universal PCR primers from *tuf* sequences or from the *rec*A gene.

Oligonucleotide primers and probes design and synthesis

The DNA fragments sequenced by us or selected from databases (GenBank and EMBL) were used as sources of oligonucleotides for diagnostic purposes. For this strategy, an array of suitable oligonucleotide primers or probes derived from a variety of genomic DNA fragments (size of more than 100 bp) selected from databases were tested for their specificity and ubiquity in PCR and hybridization assays as described later. It is important to note that the database sequences were selected based on their potential for being species-specific, genus-specific or universal for the detection of bacteria or fungi according to available sequence information and extensive analysis and that, in general, several candidate database sequences had to be tested in order to obtain the desired specificity, ubiquity and sensitivity.

Oligonucleotide probes and amplification primers derived from species-specific fragments selected from database sequences were synthesized using an automated DNA synthesizer (Perkin-Elmer Corp., Applied Biosystems Division). Prior to synthesis, all oligonucleotides (probes for hybridization and primers for DNA amplification) were evaluated for their suitability for hybridization or DNA amplification by polymerase chain reaction (PCR) by computer analysis using standard programs (i.e. the Genetics Computer Group (GCG) programs and the primer analysis software Oligo™ 4.0). The potential suitability of the PCR primer pairs was also evaluated prior to the synthesis by verifying the absence of unwanted features such as long stretches of one nucleotide and a high proportion of G or C residues at the 3' end (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.).

The oligonucleotide primers or probes may be derived from either strand of the duplex DNA. The primers or probes may consist of the bases A, G, C, or T or analogs and they may be degenerated at one or more chosen nucleotide position(s). The primers or probes may be of any suitable length and may be selected anywhere within the DNA sequences from proprietary fragments or from selected database sequences which are suitable for (i) the universal detection of bacteria, (ii) the species-specific detection and identification of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae* and *Candida albicans* (iii) the genus-specific detection of *Streptococcus* species, *Enterococcus* species, *Staphylococcus* species and *Neisseria* species or (iv) the detection of the 26 above-mentioned clinically important antibiotic resistance genes.

Variants for a given target bacterial gene are naturally occurring and are attributable to sequence variation within that gene during evolution (Watson *et al.*, 1987, Molecular Biology of the Gene, 4th ed., The Benjamin/Cummings Publishing Company, Menlo Park, CA; Lewin, 1989, Genes IV, John Wiley & Sons, New York, NY). For example, different strains of the same bacterial species may have a single or more nucleotide variation(s) at the oligonucleotide hybridization site. The person skilled in the art is well aware of the existence of variant bacterial or fungal DNA sequences for a specific gene and that the frequency of sequence variations depends on the selective pressure during evolution on a given gene product. The detection of a variant sequence for a region between two PCR primers may be demonstrated by sequencing the amplification product. In order to show the presence of sequence variants at the primer hybridization site, one has to amplify a larger DNA target with PCR primers outside that hybridization site. Sequencing of this larger fragment will allow the detection of sequence variation at this site. A similar strategy may be applied to show variants at the hybridization site of a probe. Insofar as the divergence of the target sequences or a part thereof does not affect the specificity and ubiquity of the amplification primers or probes, variant bacterial DNA is under the scope of this invention. Variants of the selected primers or probes may also be used to amplify or hybridize to a variant DNA.

Sequencing of *tuf* sequences from a variety of bacterial and fungal species

The nucleotide sequence of a portion of *tuf* genes was determined for a variety of bacterial and fungal species. The amplification primers SEQ ID NOs: 107 and 108, which amplify a *tuf* gene portion of approximately 890 bp, were used for the sequencing of bacterial *tuf* sequences. The amplification primers SEQ ID NOs: 109 and 172, which amplify a *tuf* gene portion of approximately 830 bp, were used for the sequencing of fungal *tuf* sequences. Both primer pairs can amplify *tufA* and *tufB* genes. This is not surprising because these two genes are nearly identical. For example, the entire *tufA* and *tufB* genes from *E. coli* differ at only 13 nucleotide positions (Neidhardt *et al.*, 1996, *Escherichia coli* and *Salmonella*: Cellular and Molecular Biology, 2nd ed., American Society for Microbiology Press, Washington, D.C.). These amplification primers are degenerated at several nucleotide positions and contain inosines in order to allow the amplification of a wide range of *tuf* sequences. The strategy used to select these amplification primers is similar to that illustrated in Annex I for the selection of universal primers. The amplification primers SEQ ID NOs: 107 and 108 could be used to amplify the *tuf* genes from any bacterial species. The amplification primers SEQ ID NOs: 109 and 172 could be used to amplify the *tuf* genes from any fungal species.

The *tuf* genes were amplified directly from bacterial or yeast cultures using the following amplification protocol: One μL of cell suspension was transferred directly to

19 μL of a PCR reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM $MgCl_2$, 1 μM of each of the 2 primers, 200 μM of each of the four dNTPs, 0.5 unit of *Taq* DNA polymerase (Promega Corp., Madison, WI). PCR reactions were subjected to cycling using a MJ Research PTC-200 thermal cycler (MJ Research Inc., Watertown, Mass.) as follows: 3 min at 96°C followed by 30-35 cycles of 1 min at 95°C for the denaturation step, 1 min at 30-50°C for the annealing step and 1 min at 72°C for the extension step. Subsequently, twenty microliters of the PCR-amplified mixture were resolved by electrophoresis in a 1.5% agarose gel. The gel was then visualized by staining with methylene blue (Flores *et al.*, 1992, Biotechniques, **13**:203-205). The size of the amplification products was estimated by comparison with a 100-bp molecular weight ladder. The band corresponding to the specific amplification product (i.e. approximately 890 or 830 bp for bacterial or fungal *tuf* sequences, respectively) was excised from the agarose gel and purified using the QIAquick™ gel extraction kit (QIAGEN Inc., Chatsworth, CA). The gel-purified DNA fragment was then used directly in the sequencing protocol. Both strands of the *tuf* genes amplification product were sequenced by the dideoxynucleotide chain termination sequencing method by using an Applied Biosystems automated DNA sequencer (model 373A) with their PRISM™ Sequenase® Terminator Double-stranded DNA Sequencing Kit (Perkin-Elmer Corp., Applied Biosystems Division, Foster City, CA). The sequencing reactions were all performed by using the amplification primers (SEQ ID NOs: 107 to 109 and 172) and 100 ng per reaction of the gel-purified amplicon. In order to ensure that the determined sequence did not contain errors attributable to the sequencing of PCR artefacts, we have sequenced two preparations of the gel-purified *tuf* amplification product originating from two independent PCR amplifications. For all target microbial species, the sequences determined for both amplicon preparations were identical. Furthermore, the sequences of both strands were 100% complementary thereby confirming the high accuracy of the determined sequence. The *tuf* sequences determined using the above strategy are all in the Sequence Listing (i.e. SEQ ID NOs:118 to 146). Table 13 gives the originating microbial species and the source for each *tuf* sequence in the Sequence Listing.

The alignment of the *tuf* sequences determined by us or selected from databases reveals clearly that the length of the sequenced portion of the *tuf* genes is variable. There may be insertions or deletions of several amino acids. This explains why the size of the sequenced *tuf* amplification product was variable for both bacterial and fungal species. Among the *tuf* sequences determined by our group, we found insertions and deletions adding up to 5 amino acids or 15 nucleotides. Consequently, the nucleotide positions indicated on top of each of Annexes I to V do not correspond for *tuf* sequences having insertions or deletions.

It should also be noted that the various *tuf* sequences determined by us

occasionally contain degenerescences. These degenerated nucleotides correspond to sequence variations between *tufA* and *tufB* genes because the amplification primers amplify both *tuf* genes. These nucleotide variations were not attributable to nucleotide misincorporations by the *taq* DNA polymerase because the sequence of both strands were identical and also because the sequences determined with both preparations of the gel-purified *tuf* amplicons were identical.

The selection of amplification primers from *tuf* sequences

The *tuf* sequences determined by us or selected from databases were used to select PCR primers for (i) the universal detection of bacteria, (ii) the genus-specific detection and identification of *Enterococcus* spp. and *Staphylococcus* spp. and (iii) the species-specific detection and identification of *Candida albicans*. The strategy used to select these PCR primers was based on the analysis of multiple sequence alignments of various *tuf* sequences. For more details about the selection of PCR primers from *tuf* sequences, please refer to Examples 1 to 3 and Annexes I to IV.

The selection of amplification primers from *recA*

The comparison of the nucleotide sequence for the *recA* gene from various bacterial species including 5 species of streptococci allowed the selection of *Streptococcus*-specific PCR primers. For more details about the selection of PCR primers from *recA*, please refer to Example 4 and Annex V.

DNA fragment isolation from *Staphylococcus saprophyticus* by arbitrarily primed PCR

DNA sequences of unknown coding potential for the species-specific detection and identification of *Staphylococcus saprophyticus* were obtained by the method of arbitrarily primed PCR (AP-PCR).

AP-PCR is a method which can be used to generate specific DNA probes for microorganisms (Fani *et al.*, 1993, Mol. Ecol. 2:243-250). A description of the AP-PCR protocol used to isolate a species-specific genomic DNA fragment from *Staphylococcus saprophyticus* follows. Twenty different oligonucleotide primers of 10 nucleotides in length (all included in the AP-PCR kit OPAD (Operon Technologies, Inc., Alameda, CA)) were tested systematically with DNAs from 3 bacterial strains of *Staphylococcus saprophyticus* (all obtained from the American Type Culture Collection (ATCC): numbers 15305, 35552 and 43867) as well as with DNA from four other staphylococcal species (*Staphylococcus aureus* ATCC 25923, *Staphylococcus epidermidis* ATCC 14990, *Staphylococcus haemolyticus* ATCC 29970 and *Staphylococcus hominis* ATCC 35982). For all bacterial species, amplification was performed from a bacterial suspension adjusted to a standard 0.5 McFarland which corresponds to approximately 1.5 x 10^8 bacteria/mL. One μL of the standardized bacterial suspension was transferred directly to 19 μL of a PCR reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM $MgCl_2$,

1.2 μM of only one of the 20 different AP-PCR primers OPAD, 200 μM of each of the four dNTPs and 0.5 unit of *Taq* DNA polymerase (Promega Corp., Madison, WI). PCR reactions were subjected to cycling using a MJ Research PTC-200 thermal cycler (MJ Research Inc.) as follows: 3 min at 96°C followed by 35 cycles of 1 min at 95°C for the denaturation step, 1 min at 32°C for the annealing step and 1 min at 72°C for the extension step. A final extension step of 7 min at 72°C was made after the 35 cycles to ensure complete extension of PCR products. Subsequently, twenty microliters of the PCR amplified mixture were resolved by electrophoresis in a 2% agarose gel containing 0.25 μg/mL of ethidium bromide. The size of the amplification products was estimated by comparison with a 50-bp molecular weight ladder.

Amplification patterns specific for *Staphylococcus saprophyticus* were observed with the AP-PCR primer OPAD-9 (SEQ ID NO: 25). Amplification with this primer consistently showed a band corresponding to a DNA fragment of approximately 450 bp for all *Staphylococcus saprophyticus* strains tested but not for any of the four other staphylococcal species tested. This species-specific pattern was confirmed by testing 10 more clinical isolates of *S. saprophyticus* selected from the culture collection of the microbiology laboratory of the CHUL as well as strains selected from the gram-positive bacterial species listed in Table 5.

The band corresponding to the approximately 450 bp amplicon which was specific and ubiquitous for *S. saprophyticus* based on AP-PCR was excised from the agarose gel and purified using the QIAquick™ gel extraction kit (QIAGEN Inc.). The gel-purified DNA fragment was cloned into the T/A cloning site of the pCR 2.1™ plasmid vector (Invitrogen Inc.) using T4 DNA ligase (New England BioLabs). Recombinant plasmids were transformed into *E. coli* DH5α competent cells using standard procedures. Plasmid DNA isolation was done by the method of Birnboim and Doly (Nucleic Acids Res. **7**:1513-1523) for small-scale preparations. All plasmid DNA preparations were digested with the *Eco*RI restriction endonuclease to ensure the presence of the approximately 450 bp AP-PCR insert into the recombinant plasmids. Subsequently, a large-scale and highly purified plasmid DNA preparation was performed from two selected clones shown to carry the AP-PCR insert by using the QIAGEN plasmid purification kit. These plasmid preparations were used for automated DNA sequencing.

Both strands of the AP-PCR insert from the two selected clones were sequenced by the dideoxynucleotide chain termination sequencing method with SP6 and T7 sequencing primers, by using an Applied Biosystems automated DNA sequencer as described previously. The analysis of the obtained sequences revealed that the DNA sequences for both strands from each clone were 100% complementary. Furthermore, it showed that the entire sequence determined for each clone were both identical. These sequencing data confirm the 100% accuracy for the determined 438

bp sequence (SEQ ID NO: 29). Optimal amplification primers have been selected from the sequenced AP-PCR *Staphylococcus saprophyticus* DNA fragment with the help of the primer analysis software Oligo™ 4.0. The selected primer sequences have been tested in PCR assays to verify their specificity and ubiquity (Table 7). These PCR primers were specific since there was no amplification with DNA from bacterial species other than *S. saprophyticus* selected from Tables 4 and 5. Furthermore, this assay was ubiquitous since 245 of 260 strains of *S. saprophyticus* were efficiently amplified with this PCR assay. When used in combination with another *S. saprophyticus*-specific PCR assay, which is an object of our co-pending U.S. (N.S. 08/526,840) and PCT (PCT/CA/95/00528) patent applications, the ubiquity reaches 100% for these 260 strains.

DNA amplification

For DNA amplification by the widely used PCR (polymerase chain reaction) method, primer pairs were derived from proprietary DNA fragments or from database sequences. Prior to synthesis, the potential primer pairs were analyzed by using the Oligo™ 4.0 software to verify that they are good candidates for PCR amplification.

During DNA amplification by PCR, two oligonucleotide primers binding respectively to each strand of the heat-denatured target DNA from the bacterial genome are used to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing *et al*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.).

Briefly, the PCR protocols were as follow: Treated clinical specimens or standardized bacterial or fungal suspensions (see below) were amplified in a 20 μL PCR reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 2.5 mM $MgCl_2$, 0.4 μM of each primer, 200 μM of each of the four dNTPs and 0.5 unit of *Taq* DNA polymerase (Promega) combined with the TaqStart™ antibody (Clontech Laboratories Inc., Palo Alto, CA). The TaqStart™ antibody, which is a neutralizing monoclonal antibody to *Taq* DNA polymerase, was added to all PCR reactions to enhance the specificity and the sensitivity of the amplifications (Kellogg *et al.*, 1994, Biotechniques **16**:1134-1137). The treatment of the clinical specimens varies with the type of specimen tested, since the composition and the sensitivity level required are different for each specimen type. It consists in a rapid protocol to lyse the bacterial cells and eliminate the PCR inhibitory effects (see example 11 for urine specimen preparation). For amplification from bacterial or fungal cultures, the samples were added directly to the PCR amplification mixture without any pre-treatment step (see example 10). Primer sequences derived from highly conserved regions of the bacterial 16S ribosomal RNA gene were used to provide an internal control for all PCR reactions. Alternatively, the

internal control was derived from sequences not found in microorganisms or in the human genome. The internal control was integrated into all amplification reactions to verify the efficiency of the PCR assays and to ensure that significant PCR inhibition was absent. The internal control derived from rRNA was also useful to monitor the efficiency of bacterial lysis protocols.

PCR reactions were then subjected to thermal cycling (3 min at 95°C followed by 30 cycles of 1 second at 95°C for the denaturation step and 30 second at 55°C for the annealing-extension step) using a PTC-200 thermal cycler (MJ Research Inc.) and subsequently analyzed by standard ethidium bromide-stained agarose gel electrophoresis. The number of cycles performed for the PCR assays varies according to the sensitivity level required. For example, the sensitivity level required for microbial detection directly from clinical specimens is higher for blood specimens than for urine specimens because the concentration of microorganisms associated with a septicemia can be much lower than that associated with a urinary tract infection. Consequently, more sensitive PCR assays having more thermal cycles are required for direct detection from blood specimens. Similarly, PCR assays performed directly from bacterial or fungal cultures may be less sensitive than PCR assays performed directly from clinical specimens because the number of target organisms is normally much lower in clinical specimens than in microbial cultures.

It is clear that other methods for the detection of specific amplification products, which may be faster and more practical for routine diagnosis, may be used. Such methods may be based on the detection of fluorescence after amplification (e.g. TaqMan™ system from Perkin Elmer or Amplisensor™ from Biotronics). Methods based on the detection of fluorescence are particularly promising for utilization in routine diagnosis as they are very rapid, quantitative and can be automated (Example 14).

Microbial pathogens detection and identification may also be performed by solid support or liquid hybridization using species-specific internal DNA probes hybridizing to an amplification product. Such probes may be generated from any species-specific or genus-specific DNA amplification products which are objects of the present invention. Alternatively, the internal probes for species or genus detection and identification may be derived from the amplicons produced by the universal amplification assay. The oligonucleotide probes may be labeled with biotin or with digoxigenin or with any other reporter molecules.

To assure PCR efficiency, glycerol, dimethyl sulfoxide (DMSO) or other related solvents can be used to increase the sensitivity of the PCR and to overcome problems associated with the amplification of a target DNA having a high GC content or forming strong secondary structures (Dieffenbach and Dveksler, 1995, PCR Primer : A Laboratory Manual, Cold Spring Harbor Laboratory Press, Plainview, New York). The

concentration ranges for glycerol and DMSO are 5-15% (v/v) and 3-10% (v/v), respectively. For the PCR reaction mixture, the concentration ranges for the amplification primers and $MgCl_2$ are 0.1-1.5 μM and 1.5-3.5 mM, respectively. Modifications of the standard PCR protocol using external and nested primers (i.e. nested PCR) or using more than one primer pair (i.e. multiplex PCR) may also be used (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.). For more details about the PCR protocols and amplicon detection methods, see Examples 9 to 14.

The person skilled in the art of DNA amplification knows the existence of other rapid amplification procedures such as ligase chain reaction (LCR), transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bDNA) and cycling probe technology (CPT) (Lee *et al.*, 1997, Nucleic Acid Amplification Technologies: Application to Disease Diagnosis, Eaton Publishing, Boston, MA ; Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.). The scope of this invention is not limited to the use of amplification by PCR, but rather includes the use of any rapid nucleic acid amplification method or any other procedure which may be used to increase rapidity and sensitivity of the tests. Any oligonucleotide suitable for the amplification of nucleic acids by approaches other than PCR and derived from the species-specific, genus-specific and universal DNA fragments as well as from selected antibiotic resistance gene sequences included in this document are also under the scope of this invention.

Hybridization assays with oligonucleotide probes

In hybridization experiments, single-stranded oligonucleotides (size less than 100 nucleotides) have some advantages over DNA fragment probes for the detection of bacteria, such as ease of synthesis in large quantities, consistency in results from batch to batch and chemical stability. Briefly, for the hybridizations, oligonucleotides were 5' end-labeled with the radionucleotide γ-^{32}P(dATP) using T4 polynucleotide kinase (Pharmacia) (Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). The unincorporated radionucleotide was removed by passing the labeled oligonucleotide through a Sephadex G-50™ column. Alternatively, oligonucleotides were labeled with biotin, either enzymatically at their 3' ends or incorporated directly during synthesis at their 5' ends, or with digoxigenin. It will be appreciated by the person skilled in the art that labeling means other than the three above labels may be used.

Each oligonucleotide probe was then tested for its specificity by hybridization to DNAs from a variety of bacterial and fungal species selected from Tables 4, 5 and 6. All of the bacterial or fungal species tested were likely to be pathogens associated

with common infections or potential contaminants which can be isolated from clinical specimens. Each target DNA was released from bacterial cells using standard chemical treatments to lyse the cells (Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Subsequently, the DNA was denatured by conventional methods and then irreversibly fixed onto a solid support (e.g. nylon or nitrocellulose membranes) or free in solution. The fixed single-stranded target DNAs were then hybridized with the oligonucleotide probe cells (Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Pre-hybridization conditions were in 1 M NaCl + 10% dextran sulfate + 1% SDS + 100 μg/mL salmon sperm DNA at 65°C for 15 min. Hybridization was performed in fresh pre-hybridization solution containing the labeled probe at 65°C overnight. Post-hybridization washing conditions were as follows: twice in 3X SSC containing 1% SDS, twice in 2X SSC containing 1% SDS and twice in 1X SSC containing 1% SDS (all of these washes were at 65°C for 15 min), and a final wash in 0.1X SSC containing 1% SDS at 25°C for 15 min. Autoradiography of washed filters allowed the detection of selectively hybridized probes. Hybridization of the probe to a specific target DNA indicated a high degree of similarity between the nucleotide sequence of these two DNAs because of the high stringency of the washes.

An oligonucleotide probe was considered specific only when it hybridized solely to DNA from the species or genus from which it was isolated. Oligonucleotide probes found to be specific were subsequently tested for their ubiquity (i.e. ubiquitous probes recognized most or all isolates of the target species or genus) by hybridization to microbial DNAs from clinical isolates of the species or genus of interest including ATCC strains. The DNAs from strains of the target species or genus were denatured, fixed onto nylon membranes and hybridized as described above. Probes were considered ubiquitous when they hybridized specifically with the DNA from at least 80% of the isolates of the target species or genus.

Specificity and ubiquity tests for oligonucleotide primers and probes

The specificity of oligonucleotide primers and probes, derived either from the DNA fragments sequenced by us or selected from databases, was tested by amplification of DNA or by hybridization with bacterial or fungal species selected from those listed in Tables 4, 5 and 6, as described in the two previous sections. Oligonucleotides found to be specific were subsequently tested for their ubiquity by amplification (for primers) or by hybridization (for probes) with bacterial DNAs from isolates of the target species or genus. Results for specificity and ubiquity tests with the oligonucleotide primers are summarized in Table 7. The specificity and ubiquity of the PCR assays using the selected amplification primer pairs were tested directly from cultures (see Examples 9 and 10) of bacterial or fungal species.

The various species-specific and genus-specific PCR assays which are objects of the present invention are all specific. For the PCR assays specific to bacterial species or genus, this means that DNA isolated from a wide variety of bacterial species, other than that from the target species or genus and selected from Tables 4 and 5, could not be amplified. For the PCR assay specific to *Candida albicans*, it means there was no amplification with genomic DNA from the fungal species listed in Table 6 as well as with a variety of bacterial species selected from Tables 4 and 5.

The various species-specific and genus-specific PCR assays which are objects of the present invention are also all ubiquitous (Table 7). (i) The species-specific PCR assays for *E. faecium*, *L. monocytogenes*, *S. saprophyticus*, *S. agalactiae* and *C. albicans* amplified genomic DNA from all or most strains of the target species tested, which were obtained from various sources and which are representative of the diversity within each target species (Table 7). The species identification of all of these strains was based on classical biochemical methods which are routinely used in clinical microbiology laboratories. (ii) The genus-specific PCR assays specific for *Enterococcus* spp., *Staphylococcus* spp., *Streptococcus* spp. and *Neisseria* spp. amplified genomic DNA from all or most strains of the target genus tested, which represent all clinically important bacterial species for each target genus. These strains were obtained from various sources and are representative of the diversity within each target genus. Again, the species identification of all of these strains was based on classical biochemical methods which are routinely used in clinical microbiology laboratories. More specifically, the four genus-specific PCR assays amplified the following species: (1) The *Enterococcus*-specific assay amplified efficiently DNA from all of the 11 enterococcal species tested including *E. avium*, *E. casseliflavus*, *E. dispar*, *E. durans*, *E. faecalis*, *E. faecium*, *E. flavescens*, *E. gallinarum*, *E. hirae*, *E. mundtii* and *E. raffinosus*. (2) The *Neisseria*-specific assay amplified efficiently DNA from all of the 12 neisserial species tested including *N. canis*, *N. cinerea*, *N. elongata*, *N. flavescens*, *N. gonorrhoeae*, *N. lactamica*, *N. meningitidis*, *N. mucosa*, *N. polysaccharea*, *N. sicca*, *N. subflava* and *N. weaveri*. (3) The *Staphylococcus*-specific assay amplified efficiently DNA from 13 of the 14 staphylococcal species tested including *S. aureus*, *S. auricularis*, *S. capitis*, *S. cohnii*, *S. epidermidis*, *S. haemolyticus*, *S. hominis*, *S. lugdunensis*, *S. saprophyticus*, *S. schleiferi*, *S. simulans*, *S. warneri* and *S. xylosus*. The staphylococcal species which could not be amplified is *S. sciuri*. (4) Finally, the *Streptococcus*-specific assay amplified efficiently DNA from all of the 22 streptococcal species tested including *S. agalactiae*, *S. anginosus*, *S. bovis*, *S. constellatus*, *S. crista*, *S. dysgalactiae*, *S. equi*, *S. gordonii*, *S. intermedius*, *S. mitis*, *S. mutans*, *S. oralis*, *S. parasanguis*, *S. pneumoniae*, *S. pyogenes*, *S. salivarius*, *S. sanguis*, *S. sabrinus*, *S. suis*, *S. uberis*, *S. vestibularis* and *S. viridans*. On the other hand, the *Streptococcus*-specific assay did not amplify 3 out of 9 strains

of *S. mutans* and 1 out of 23 strains of *S. salivarius*, thereby showing a slight lack of ubiquity for these two streptococcal species.

All specific and ubiquitous amplification primers for each target microbial species or genus or antibiotic resistance gene investigated are listed in Annex VI. Divergence in the sequenced DNA fragments can occur, insofar as the divergence of these sequences or a part thereof does not affect the specificity of the probes or amplification primers. Variant bacterial DNA is under the scope of this invention.

The PCR amplification primers listed in Annex VI were all tested for their specificity and ubiquity using reference strains as well as clinical isolates from various geographical locations. The 351 reference strains used to test the amplification and hybridization assays (Tables 4, 5 and 6) were obtained from (i) the American Type Culture Collection (ATCC): 85%, (ii) the Laboratoire de santé publique du Québec (LSPQ): 10%, (iii) the Centers for Disease Control and Prevention (CDC): 3% , (iv) the National Culture Type Collection (NCTC): 1% and (v) several other reference laboratories throughout the world: 1%. These reference strains are representative of (i) 90 gram-negative bacterial species (169 strains; Table 4), (ii) 97 gram-positive bacterial species (154 strains; Table 5) and (iii) 12 fungal species (28 strains; Table 6).

Antibiotic resistance genes

Antimicrobial resistance complicates treatment and often leads to therapeutic failures. Furthermore, overuse of antibiotics inevitably leads to the emergence of bacterial resistance. Our goal is to provide clinicians, in approximately one hour, the needed information to prescribe optimal treatments. Besides the rapid identification of negative clinical specimens with DNA-based tests for universal bacterial detection and the identification of the presence of a specific pathogen in the positive specimens with species- and/or genus-specific DNA-based tests, clinicians also need timely information about the ability of the bacterial pathogen to resist antibiotic treatments. We feel that the most efficient strategy to evaluate rapidly bacterial resistance to antimicrobials is to detect directly from the clinical specimens the most common and clinically important antibiotic resistance genes (i.e. DNA-based tests for the detection of antibiotic resistance genes). Since the sequence from the most important and common bacterial antibiotic resistance genes are available from databases, our strategy was to use the sequence from a portion or from the entire resistance gene to design specific oligonucleotide primers or probes which will be used as a basis for the development of rapid DNA-based tests. The sequence from each of the bacterial antibiotic resistance genes selected on the basis of their clinical relevance (i.e. high incidence and importance) is given in the Sequence Listing. Tables 9 and 10 summarize some characteristics of the selected antibiotic resistance genes. Our approach is unique because the antibiotic resistance genes detection and the bacterial detection and identification are performed simultaneously in multiplex assays under

uniform PCR amplification conditions (Example 13).

Annex VI provides a list of all amplification primers selected from 26 clinically important antibiotic resistance genes which were tested in PCR assays. The various PCR assays for antibiotic resistance genes detection and identification were validated by testing several resistant bacterial isolates known to carry the targeted gene and obtained from various countries. The testing of a large number of strains which do not carry the targeted resistance gene was also performed to ensure that all assays were specific. So far, all PCR assays for antibiotic resistance genes are highly specific and have detected all control resistant bacterial strains known to carry the targeted gene. The results of some clinical studies to validate the array of PCR assays for the detection and identification of antibiotic resistance genes and correlate these DNA-based assays with standard antimicrobials susceptibility testing methods are presented in Tables 11 and 12.

Universal bacterial detection

In the routine microbiology laboratory, a high percentage of clinical specimens sent for bacterial identification are negative by culture (Table 4). Testing clinical samples with universal amplification primers or universal probes to detect the presence of bacteria prior to specific identification and screen out the numerous negative specimens is thus useful as it saves costs and may rapidly orient the clinical management of the patients. Several amplification primers and probes were therefore synthesized from highly conserved portions of bacterial sequences from the *tuf* genes (Table 8). The universal primer selection was based on a multiple sequence alignment constructed with sequences determined by us or selected from available database sequences as described in Example 1 and Annex I.

For the identification of database sequences suitable for the universal detection of bacteria, we took advantage of the fact that the complete genome sequences for two distant microorganisms (i.e. *Mycoplasma genitalium* and *Haemophilus influenzae*) are available. A comparison of the amino acid sequence for all proteins encoded by the genome of these two distant microorganisms led to the identification of highly homologous proteins. An analysis of these homologous proteins allowed to select some promising candidates for the development of universal DNA-based assays for the detection of bacteria. Since the complete nucleotide sequence of several other microbial genomes are presently available in databases, a person skilled in the art could arrive to the same conclusions by comparing genomes sequences other than those of *Mycoplasma genitalium* and *Haemophilus influenzae*. The selected *tuf* gene encodes a protein (EF-Tu) involved in the translation process during protein synthesis. Subsequently, an extensive nucleotide sequence analysis was performed with the *tuf* gene sequences available in databases as well as with novel *tuf* sequences which we have determined as described previously. All computer analysis of amino acid and

nucleotide sequences were performed by using the GCG programs. Subsequently, optimal PCR primers for the universal amplification of bacteria were selected with the help of the Oligo™ program. The selected primers are degenerated at several nucleotide positions and contain several inosines in order to allow the amplification of all clinically relevant bacterial species (Annex I). Inosine is a nucleotide analog able to specifically bind to any of the four nucleotides A, C, G or T. Degenerated oligonucleotides consist of an oligonucleotide mix having two or more of the four nucleotides A, C, G or T at the site of mismatches. The inclusion of inosine and/or of degenerescences in the amplification primers allow mismatch tolerance thereby permitting the amplification of a wider array of target nucleotide sequences (Dieffenbach and Dveksler, 1995 PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Plainview, NY).

The amplification conditions with the universal primers were identical to those used for the species- and genus-specific amplification assays except that the annealing temperature was 50°C instead of 55°C. This universal PCR assay was specific and nearly ubiquitous for the detection of bacteria. The specificity for bacteria was verified by amplifying genomic DNA isolated from the 12 fungal species listed in Table 6 as well as genomic DNA from *Leishmania donovani*, *Saccharomyces cerevisiae* and human lymphocytes. None of the above eukaryotic DNA preparations could be amplified by the universal assay, thereby suggesting that this test is specific for bacteria. The ubiquity of the universal assay was verified by amplifying genomic DNAs from 116 reference strains which represent 95 of the most clinically relevant bacterial species. These species have been selected from the bacterial species listed in Tables 4 and 5. We found that 104 of these 116 strains could be amplified. The bacterial species which could not be amplified belong to the following genera: *Corynebacterium* (11 species) and *Stenotrophomonas* (1 species). Sequencing of the *tuf* genes from these bacterial species has been recently performed. This sequencing data has been used to select new universal primers which may be more ubiquitous. These primers are in the process of being tested. We also observed that for several species the annealing temperature had to be reduced to 45°C in order to get an efficient amplification. These bacterial species include *Gemella morbilbrum*, *Listeria* spp. (3 species) and *Gardnerella vaginalis*. It is important to note that the 95 bacterial species selected from Tables 4 and 5 to test the ubiquity of the universal assay include all of the most clinically relevant bacterial species associated with a variety of human infections acquired in the community or in hospitals (nosocomial infections). The most clinically important bacterial and fungal pathogens are listed in Tables 1 and 2.

EXAMPLES AND ANNEXES

The following examples and annexes are intended to be illustrative of the various methods and compounds of the invention, rather than limiting the scope thereof.

The various annexes show the strategies used for the selection of amplification primers from *tuf* sequences or from the *recA* gene: (i) Annex I illustrates the strategy used for the selection of the universal amplification primers from *tuf* sequences. (ii) Annex II shows the strategy used for the selection of the amplification primers specific for the genus *Enterococcus* from *tuf* sequences. (iii) Annex III illustrates the strategy used for the selection of the amplification primers specific for the genus *Staphylococcus* from *tuf* sequences. (iv) Annex IV shows the strategy used for the selection of the amplification primers specific for the species *Candida albicans* from *tuf* sequences. (v) Annex V illustrates the strategy used for the selection of the amplification primers specific for the genus *Streptococcus* from *recA* sequences. (vi) Annex VI gives a list of all selected primer pairs. As shown in these annexes, the selected amplification primers may contain inosines and/or degenerescences. Inosine is a nucleotide analog able to specifically bind to any of the four nucleotides A, C, G or T. Alternatively, degenerated oligonucleotides which consist of an oligonucleotide mix having two or more of the four nucleotides A, C, G or T at the site of mismatches were used. The inclusion of inosine and/or of degenerescences in the amplification primers allow mismatch tolerance thereby permitting the amplification of a wider array of target nucleotide sequences (Dieffenbach and Dveksler, 1995 PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Plainview, New York).

EXAMPLES

EXAMPLE 1 :

Selection of universal PCR primers from *tuf* sequences. As shown in Annex I, the comparison of *tuf* sequences from a variety of bacterial and eukaryotic species allowed the selection of PCR primers which are universal for the detection of bacteria. The strategy used to design the PCR primers was based on the analysis of a multiple sequence alignment of various *tuf* sequences. This multiple sequence alignment includes *tuf* sequences from 38 bacterial species and 3 eukaryotic species either determined by us or selected from databases (Table 13). A careful analysis of this multiple sequence alignment allowed the selection of primer sequences which are conserved within eubacteria but which discriminate sequences from eukaryotes, thereby permitting the universal detection of bacteria. As shown in Annex I, the selected primers contain several inosines and degenerescences. This was necessary because there is a relatively high polymorphism among bacterial *tuf* sequences despite the fact that this gene is highly conserved. In fact, among the *tuf* sequences that we determined, we found many nucleotide variations as well as some deletions and/or

insertions of amino acids. The selected universal primers were specific and ubiquitous for bacteria (Table 7). Of the 95 most clinically important bacterial species tested, 12 were not amplified. These species belong to the genera *Corynebacterium* (11 species) and *Stenotrophomonas* (1 species). The universal primers did not amplify DNA of non-bacterial origin, including human and other types of eukaryotic DNA.

EXAMPLE 2 :

Selection of genus-specific PCR primers from *tuf* sequences. As shown in Annexes 2 and 3, the comparison of *tuf* sequences from a variety of bacterial species allowed the selection of PCR primers specific for *Enterococcus* spp. or for *Staphylococcus* spp. The strategy used to design the PCR primers was based on the analysis of a multiple sequence alignment of various *tuf* sequences. These multiple sequence alignments include the *tuf* sequences of four representative bacterial species selected from each target genus as well as *tuf* sequences from species of other closely related bacterial genera. A careful analysis of those alignments allowed the selection of oligonucleotide sequences which are conserved within the target genus but which discriminate sequences from other closely related genera, thereby permitting the genus-specific and ubiquitous detection and identification of the target bacterial genus.

For the selection of primers specific for *Enterococcus* spp. (Annex II), we have sequenced a portion of approximately 890 bp of the *tuf* genes for *Enterococcus avium, E. faecalis, E. faecium* and *E. gallinarum*. All other *tuf* sequences used in the alignment were either sequenced by us or selected from databases. The analysis of this sequence alignment led to the selection of a primer pair specific and ubiquitous for *Enterococcus* spp. (Table 7). All of the 11 enterococcal species tested were efficiently amplified and there was no amplification with genomic DNA from bacterial species of other genera.

For the selection of primers specific for *Staphylococcus* spp. (Annex III), we have also sequenced a portion of approximately 890 bp of the *tuf* genes for *Staphylococcus aureus, S. epidermidis, S. saprophyticus* and *S. simulans*. All other *tuf* sequences used in the alignment were either sequenced by us or selected from databases. The analysis of this sequence alignment led to the selection of two primer pairs specific and ubiquitous for *Staphylococcus* spp. (Table 7). Annex III shows the strategy used to select one of these two PCR primer pairs. The same strategy was used to select the other primer pair. Of the 14 staphylococcal species tested, one (*S. sciuri*) could not be amplified by the *Staphylococcus*-specific PCR assays using either one of these two primer pairs. For PCR assays using either one of these two primer pairs, there was no amplification with DNA from species of other bacterial genera.

EXAMPLE 3 :

Selection from *tuf* sequences of PCR primers specific for *Candida albicans*. As shown in Annex IV, the comparison of *tuf* sequences from a variety of bacterial and eukaryotic species allowed the selection of PCR primers specific for *Candida albicans*. The strategy used to design the PCR primers was based on the analysis of a multiple sequence alignment of various *tuf* sequences. This multiple sequence alignment includes *tuf* sequences of five representative fungal species selected from the genus *Candida* which were determined by our group (i.e. *C. albicans, C. glabrata, C. krusei, C. parapsilosis* and *C. tropicalis*) as well as *tuf* sequences from other closely related fungal species. *tuf* sequences from various bacterial species were also included. A careful analysis of this sequence alignment allowed the selection of primers from the *C. albicans tuf* sequence; these primers discriminate sequences from other closely related *Candida* species and other fungal species, thereby permitting the species-specific and ubiquitous detection and identification of *C. albicans* (Table 7). All of 88 *Candida albicans* strains tested were efficiently amplified and there was no amplification with genomic DNA from other fungal or bacterial species.

EXAMPLE 4:

Selection of PCR primers specific for *Streptococcus* from *recA*. As shown in Annex V, the comparison of the various bacterial *recA* gene sequences available from databases (GenBank and EMBL) was used as a basis for the selection of PCR primers which are specific and ubiquitous for the bacterial genus *Streptococcus*. Since sequences of the *recA* gene are available for many bacterial species including five species of streptococci, it was possible to choose sequences well conserved within the genus *Streptococcus* but distinct from the *recA* sequences for other bacterial genera. When there were mismatches between the *recA* gene sequences from the five *Streptococcus* species, an inosine residue was incorporated into the primer (Annex V). The selected primers, each containing one inosine and no degenerescence, were specific and ubiquitous for *Streptococcus* species (Table 7). This PCR assay amplified all of the 22 streptococcal species tested. However, the *Streptococcus*-specific assay did not amplify DNA from 3 out of 9 strains of *S. mutans* and 1 out of 3 strains of *S. salivarius*. There was no amplification with genomic DNA from other bacterial genera (Table 7).

EXAMPLE 5:

Nucleotide sequencing of DNA fragments. The nucleotide sequence of a portion of the *tuf* genes from a variety of bacterial or fungal species was determined by using the dideoxynucleotide chain termination sequencing method (Sanger *et al.*, 1977, Proc. Natl. Acad. Sci. USA. **74**:5463-5467). The sequencing was performed by using an Applied Biosystems automated DNA sequencer (model 373A) with their PRISM™ Sequenase® Terminator Double-stranded DNA Sequencing Kit (Perkin-Elmer Corp.,

Applied Biosystems Division, Foster City, CA). The sequencing strategy does not discriminate *tufA* and *tufB* genes because the sequencing primers hybridize efficiently to both bacterial *tuf* genes. These DNA sequences are shown in the sequence listing (SEQ ID Nos: 118 to 146). The presence of several degenerated nucleotides in the various *tuf* sequences determined by our group (Table 13) corresponds to sequence variations between *tufA* and *tufB*.

Oligonucleotide primers and probes selection. Oligonucleotide probes and amplification primers were selected from the given proprietary DNA fragments or database sequences using the Oligo™ program and were synthesized with an automated ABI DNA synthesizer (Model 391, Perkin-Elmer Corp., Applied Biosystems Division) using phosphoramidite chemistry.

EXAMPLE 6 :

Labeling of oligonucleotides for hybridization assays. Each oligonucleotide was 5' end-labeled with γ-^{32}P (dATP) by the T4 polynucleotide kinase (Pharmacia) as described earlier. The label could also be non-radioactive.

Specificity test for oligonucleotide probes. All labeled oligonucleotide probes were tested for their specificity by hybridization to DNAs from a variety of bacterial and fungal species selected from Tables 4, 5 and 6 as described earlier. Species-specific or genus-specific probes were those hybridizing only to DNA from the microbial species or genus from which it was isolated. Oligonucleotide probes found to be specific were submitted to ubiquity tests as follows.

Ubiquity test for oligonucleotide probes. Specific oligonucleotide probes were then used in ubiquity tests with strains of the target species or genus including reference strains and other strains obtained from various countries and which are representative of the diversity within each target species or genus. Chromosomal DNAs from the isolates were transferred onto nylon membranes and hybridized with labeled oligonucleotide probes as described for specificity tests. The batteries of isolates constructed for each target species or genus contain reference ATCC strains as well as a variety of clinical isolates obtained from various sources. Ubiquitous probes were those hybridizing to at least 80% of DNAs from the battery of clinical isolates of the target species or genus.

EXAMPLE 7:

Same as example 6 except that a pool of specific oligonucleotide probes is used for microbial identification (i) to increase sensitivity and assure 100% ubiquity or (ii) to identify simultaneously more than one microbial species and/or genus. Microbial identification could be performed from microbial cultures or directly from any clinical specimen.

EXAMPLE 8:

Same as example 6 except that bacteria or fungi were detected directly from clinical samples. Any biological sample was loaded directly onto a dot blot apparatus and cells were lysed *in situ* for bacterial or fungal detection and identification. Blood samples should be heparizined in order to avoid coagulation interfering with their convenient loading on a dot blot apparatus.

EXAMPLE 9:

PCR amplification. The technique of PCR was used to increase the sensitivity and the rapidity of the assays. The sets of primers were tested in PCR assays performed directly from bacterial colonies or from a standardized bacterial suspension (see Example 10) to determine their specificity and ubiquity (Table 7). Examples of specific and ubiquitous PCR primer pairs are listed in Annex VI.

Specificity and ubiquity tests for amplification primers. The specificity of all selected PCR primer pairs was tested against DNAs from a variety of bacterial and fungal species selected from Tables 4, 5 and 6 as described earlier. Primer pairs found specific for each species or genus were then tested for their ubiquity to ensure that each set of primers could amplify at least 90% of DNAs from a battery of isolates of the target species or genus. The batteries of isolates constructed for each species contain reference ATCC strains and various clinical isolates from around the world which are representative of the diversity within each species or genus.

Standard precautions to avoid false positive PCR results should be taken (Kwok and Higuchi, 1989, Nature, **239**:237-238). Methods to inactivate PCR amplification products such as the inactivation by uracil-N-glycosylase may be used to control PCR carryover.

EXAMPLE 10:

Amplification directly from bacterial or yeast cultures. PCR assays were performed either directly from a bacterial colony or from a bacterial suspension, the latter being adjusted to a standard McFarland 0.5 (corresponds to approximately 1.5 x 10^8 bacteria/mL). In the case of direct amplification from a colony, a portion of a colony was transferred using a plastic rod directly into a 20 μL PCR reaction mixture containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM $MgCl_2$, 0.4 μM of each primer, 200 μM of each of the four dNTPs and 0.5 unit of *Taq* DNA polymerase (Promega) combined with the TaqStart™ antibody (Clontech Laboratories Inc.). For the bacterial suspension, 1 μL of the cell suspension was added to 19 μL of the same PCR reaction mixture. For the identification from yeast cultures, 1 µL of a standard McFarland 1.0 (corresponds to approximately 3.0 x 10^8 bacteria/mL) concentrated 100 times by centrifugation was added directly to the PCR reaction. This concentration step for yeast cells was performed because a McFarland 0.5 for yeast cells has approximately 200 times fewer cells than a McFarland 0.5 for bacterial cells.

PCR reactions were then subjected to thermal cycling (3 min at 95°C followed by 30 cycles of 1 second at 95°C for the denaturation step and 30 seconds at 55°C for the annealing-extension step) using a PTC-200 thermal cycler. PCR amplification products were then analyzed by standard agarose gel (2%) electrophoresis. Amplification products were visualized in agarose gels containing 0.25 μg/mL of ethidium bromide under UV at 254 nm. The entire PCR assay can be completed in approximately one hour.

Primer sequences derived from highly conserved regions of the bacterial 16S ribosomal RNA gene were used to provide an internal control for all PCR reactions. Alternatively, the internal control was derived from sequences not found in microorganisms or in the human genome. The internal control was integrated into all amplification reactions to verify the efficiency of the PCR assays and to ensure that significant PCR inhibition was absent. The internal control derived from rRNA was also useful to monitor the efficiency of the bacterial lysis protocols. The internal control and the species-specific or genus-specific amplifications were performed simultaneously in multiplex PCR assays.

EXAMPLE 11:

Amplification directly from urine specimens. For PCR amplification performed directly from urine specimens, 1 μL of urine was mixed with 4 μL of a lysis solution containing 500 mM KCl, 100 mM tris-HCl (pH 9.0), 1% triton X-100. After incubation for at least 15 minutes at room temperature, 1 μL of the treated urine specimen was added directly to 19 μL of the PCR reaction mixture. The final concentration of the PCR reagents was 50 mM KCl, 10 mM Tris (pH 9.0), 0.1% Triton X-100, 2.5 mM $MgCl_2$, 0.4 μM of each primer, 200 μM of each of the four dNTPs. In addition, each 20 μL reaction contained 0.5 unit of *Taq* DNA polymerase (Promega) combined with the TaqStart™ antibody (Clontech Laboratories Inc.).

Strategies for the internal control, PCR amplification and agarose gel detection of the amplicons are as previously described in example 10.

EXAMPLE 12:

Detection of antibiotic resistance genes. The presence of specific antibiotic resistance genes which are frequently encountered and clinically relevant is identified using the PCR amplification or hybridization protocols described previously. Specific oligonucleotides used as a basis for the DNA-based tests are selected from the antibiotic resistance gene sequences. These tests, which allow the rapid evaluation of bacterial resistance to antimicrobial agents, can be performed either directly from clinical specimens, from a standardized bacterial suspension or from a bacterial colony and should complement diagnostic tests for the universal detection of bacteria as well as for the species-specific and genus-specific microbial detection and identification.

EXAMPLE 13:

Same as examples 10 and 11 except that assays were performed by multiplex PCR (i.e. using several pairs of primers in a single PCR reaction) to reach an ubiquity of 100% for the specific targeted pathogen(s). For more heterogeneous microbial species or genus, a combination of PCR primer pairs may be required to detect and identify all representatives of the target species or genus.

Multiplex PCR assays could also be used to (i) detect simultaneously several microbial species and/or genera or, alternatively, (ii) to simultaneously detect and identify bacterial and/or fungal pathogens and detect specific antibiotic resistance genes either directly from a clinical specimen or from bacterial cultures.

For these applications, amplicon detection methods should be adapted to differentiate the various amplicons produced. Standard agarose gel electrophoresis could be used because it discriminates the amplicons based on their sizes. Another useful strategy for this purpose would be detection using a variety of fluorescent dyes emitting at different wavelengths. The fluorescent dyes can be each coupled with a specific oligonucleotide linked to a fluorescence quencher which is degraded during amplification to release the fluorescent dyes (e.g. TaqMan™, Perkin Elmer).

EXAMPLE 14:

Detection of amplification products. The person skilled in the art will appreciate that alternatives other than standard agarose gel electrophoresis (Example 10) may be used for the revelation of amplification products. Such methods may be based on fluorescence polarization or on the detection of fluorescence after amplification (e.g. Amplisensor™, Biotronics; TaqMan™, Perkin-Elmer Corp.) or other labels such as biotin (SHARP Signal™ system, Digene Diagnostics). These methods are quantitative and may be automated. One of the amplification primers or an internal oligonucleotide probe specific to the amplicon(s) derived from the species-specific, genus-specific or universal DNA fragments is coupled with the fluorescent dyes or with any other label. Methods based on the detection of fluorescence are particularly suitable for diagnostic tests since they are rapid and flexible as fluorescent dyes emitting at different wavelengths are available.

EXAMPLE 15:

Species-specific, genus-specific, universal and antibiotic resistance gene amplification primers can be used in other rapid amplification procedures such as the ligase chain reaction (LCR), transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), cycling probe technology (CPT) and branched DNA (bDNA) or any other methods to increase the sensitivity of the test. Amplifications can be performed from isolated bacterial cultures or directly from any clinical specimen. The scope of this invention is therefore not limited to the use of the

DNA sequences from the enclosed Sequence Listing for PCR only but rather includes the use of any procedures to specifically detect bacterial DNA and which may be used to increase rapidity and sensitivity of the tests.

EXAMPLE 16:

A test kit would contain sets of probes specific for each microbial species or genus as well as a set of universal probes. The kit is provided in the form of test components, consisting of the set of universal probes labeled with non-radioactive labels as well as labeled species- or genus-specific probes for the detection of each pathogen of interest in specific types of clinical samples. The kit will also include test reagents necessary to perform the pre-hybridization, hybridization, washing steps and hybrid detection. Finally, test components for the detection of known antibiotic resistance genes (or derivatives therefrom) will be included. Of course, the kit will include standard samples to be used as negative and positive controls for each hybridization test.

Components to be included in the kits will be adapted to each specimen type and to detect pathogens commonly encountered in that type of specimen. Reagents for the universal detection of bacteria will also be included. Based on the sites of infection, the following kits for the specific detection of pathogens may be developed:

- A kit for the universal detection of bacterial or fungal pathogens from all clinical specimens which contains sets of probes specific for highly conserved regions of the microbial genomes.

- A kit for the detection of microbial pathogens retrieved from urine samples, which contains 5 specific test components (sets of probes for the detection of *Enterococcus faecium, Enteroccus* species, *Staphylococcus saprophyticus, Staphylococcus* species and *Candida albicans)*.

- A kit for the detection of respiratory pathogens which contains 3 specific test components (sets of probes for the detection of *Staphylococcus* species, *Enterococcus* species and *Candida albicans*).

- A kit for the detection of pathogens retrieved from blood samples, which contains 10 specific test components (sets of probes for the detection of *Streptococcus* species, *Streptococcus agalactiae*, *Staphylococcus* species, *Staphylococcus saprophyticus*, *Enterococcus* species, *Enterococcus faecium*, *Neisseria* species, *Neisseria meningitidis*, *Listeria monocytogenes* and *Candida albicans)*. This kit can also be applied for direct detection and identification from blood cultures.

- A kit for the detection of pathogens causing meningitis, which contains 5 specific test components (sets of probes for the detection of *Streptococcus* species, *Listeria monocytogenes, Neisseria meningitidis, Neisseria* species and *Staphylococcus* species).

- A kit for the detection of clinically important antibiotic resistance genes which contains sets of probes for the specific detection of at least one of the 26 following genes associated with antibiotic resistance: *bla*$_{tem}$, *bla*$_{rob}$, *bla*$_{shv}$, *bla*$_{oxa}$, *blaZ*, *aadB*, *aacC1*, *aacC2*, *aacC3*, *aacA4*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *mecA*, *vanA*, *vanB*, *vanC*, *satA*, *aac(6')-aph(2'')*, *aad(6')*, *vat*, *vga*, *msrA*, *sul* and *int*.

- Other kits adapted for the detection of pathogens from skin, abdominal wound or any other clinically relevant infections may also be developed.

EXAMPLE 17:

Same as example 16 except that the test kits contain all reagents and controls to perform DNA amplification assays. Diagnostic kits will be adapted for amplification by PCR (or other amplification methods) performed directly either from clinical specimens or from microbial cultures. Components required for (i) universal bacterial detection, (ii) species-specific and genus-specific bacterial and/or fungal detection and identification and (iii) detection of antibiotic resistance genes will be included.

Amplification assays could be performed either in tubes or in microtitration plates having multiple wells. For assays in plates, the wells will contain the specific amplification primers and control DNAs and the detection of amplification products will be automated. Reagents and amplification primers for universal bacterial detection will be included in kits for tests performed directly from clinical specimens. Components required for species-specific and genus-specific bacterial and/or fungal detection and identification as well as for the simultaneous antibiotic resistance genes detection will be included in kits for testing directly from bacterial or fungal cultures as well as in kits for testing directly from any type of clinical specimen.

The kits will be adapted for use with each type of specimen as described in example 16 for hybridization-based diagnostic kits.

EXAMPLE 18:

It is understood that the use of the probes and amplification primers described in this invention for bacterial and/or fungal detection and identification is not limited to clinical microbiology applications. In fact, we feel that other sectors could also benefit from these new technologies. For example, these tests could be used by industries for quality control of food, water, air, pharmaceutical products or other products requiring microbiological control. These tests could also be applied to detect and identify bacteria or fungi in biological samples from organisms other than humans (e.g. other primates, birds, plants, mammals, farm animals, livestock and others). These diagnostic tools could also be very useful for research purposes including clinical trials and epidemiological studies.

This invention has been described herein above, and it is readily apparent that modifications can be made thereto without departing from the spirit of this invention. These modifications are under the scope of this invention, as defined in the appended claims.

Table 1. Distribution (%) of nosocomial pathogens for various human infections in USA (1990-1992)[1].

Pathogen	UTI[2]	SSI[3]	BSI[4]	Pneumonia	CSF[5]
Escherichia coli	27	9	5	4	2
Staphylococcus aureus	2	21	17	21	2
Staphylococcus epidermidis	2	6	20	0	1
Enterococcus faecalis	16	12	9	2	0
Enterococcus faecium	1	1	0	0	0
Pseudomonas aeruginosa	12	9	3	18	0
Klebsiella pneumoniae	7	3	4	9	0
Proteus mirabilis	5	3	1	2	0
Streptococcus pneumoniae	0	0	3	1	18
Group B *Streptococci*	1	1	2	1	6
Other *Streptococci*	3	5	2	1	3
Haemophilus influenzae	0	0	0	6	45
Neisseria meningitidis	0	0	0	0	14
Listeria monocytogenes	0	0	0	0	3
Other *Enterococci*	1	1	0	0	0
Other *Staphylococci*	2		8	13	20
Candida albicans	9	3	5	5	0
Other *Candida*	2		1	3	10
Enterobacter spp.	5	7	4	12	2
Acinetobacter spp.	1	1	2	4	2
Citrobacter spp.	2	1	1	1	0
Serratia marcescens	1	1	1	3	1
Other *Klebsiella*	1	1	1	2	1
Others	0	6	4	5	0

[1] Data recorded by the National Nosocomial Infections Surveillance (NNIS) from 80 hospitals (Emori and Gaynes, 1993, Clin. Microbiol. Rev., **6**:428-442).

[2] Urinary tract infection.

[3] Surgical site infection.

[4] Bloodstream infection.

[5] Cerebrospinal fluid.

Table 2. **Distribution (%) of bloodstream infection pathogens in Quebec (1995), Canada (1992), UK (1969-1988) and USA (1990-1992).**

Organism	Quebec[1]	Canada[2]	UK[3]		USA[4]
			Community-acquired	Hospital-acquired	Hospital-acquired
E. coli	15.6	53.8	24.8	20.3	5.0
S. epidermidis and other CoNS[5]	25.8	NI[6]	0.5	7.2	31.0
S. aureus	9.6	NI	9.7	19.4	16.0
S. pneumoniae	6.3	NI	22.5	2.2	NR[7]
E. faecalis	3.0	NI	1.0	4.2	NR
E. faecium	2.6	NI	0.2	0.5	NR
Enterococcus spp.	NR	NI	NR	NR	9.0
H. influenzae	1.5	NR	3.4	0.4	NR
P. aeruginosa	1.5	8.2	1.0	8.2	3.0
K. pneumoniae	3.0	11.2	3.0	9.2	4.0
P. mirabilis	NR	3.9	2.8	5.3	1.0
S. pyogenes	NR	NI	1.9	0.9	NR
Enterobacter spp.	4.1	5.5	0.5	2.3	4.0
Candida spp.	8.5	NI	NR	1.0	8.0
Others	18.5	17.4[8]	28.7	18.9	19.0

[1] Data obtained for 270 isolates collected at the Centre Hospitalier de l'Université Laval (CHUL) during a 5 month period (May to October 1995).

[2] Data from 10 hospitals throughout Canada representing 941 gram-negative bacterial isolates. (Chamberland *et al.*, 1992, Clin. Infect. Dis., **15**:615-628).

[3] Data from a 20-year study (1969-1988) for nearly 4000 isolates (Eykyn *et al.*, 1990, J. Antimicrob. Chemother., Suppl. C, **25**:41-58).

[4] Data recorded by the National Nosocomial Infections Surveillance (NNIS) from 80 hospitals (Emori and Gaynes, 1993, Clin. Microbiol. Rev., **6**:428-442).

[5] Coagulase-negative staphylococci.

[6] NI, not included. This survey included only gram-negative species.

[7] NR, incidence not reported for these species or genera.

[8] In this case, 17.4 stands for other gram-negative bacterial species.

Table 3. Distribution of positive and negative clinical specimens tested at the microbiology laboratory of the CHUL (February 1994 – January 1995).

Clinical specimens and/or sites	No. of samples tested (%)	% of positive specimens	% of negative specimens
Urine	17,981 (54.5)	19.4	80.6
Blood culture/marrow	10,010 (30.4)	6.9	93.1
Sputum	1,266 (3.8)	68.4	31.6
Superficial pus	1,136 (3.5)	72.3	27.7
Cerebrospinal fluid	553 (1.7)	1.0	99.0
Synovial fluid	523 (1.6)	2.7	97.3
Respiratory tract	502 (1.5)	56.6	43.4
Deep pus	473 (1.4)	56.8	43.2
Ears	289 (0.9)	47.1	52.9
Pleural and pericardial fluid	132 (0.4)	1.0	99.0
Peritoneal fluid	101(0.3)	28.6	71.4
Total:	**32,966 (100.0)**	**20.0**	**80.0**

Table 4. Gram-negative bacterial species (90) used to test the specificity of PCR primers and DNA probes (continues on next page).

Bacterial species	Number of reference strains tested[a]	Bacterial species	Number of reference strains tested[a]
Acinetobacter baumannii	1	*Moraxella phenylpyruvica*	1
Acinetobacter lwoffii	3	*Morganella morganii*	1
Actinobacillus lignieresii	1	*Neisseria animalis*	1
Alcaligenes faecalis	1	*Neisseria canis*	1
Alcaligenes odorans	1	*Neisseria caviae*	1
Alcaligenes xylosoxydans subsp. *denitrificans*	1	*Neisseria cinerea*	1
Bacteroides distasonis	1	*Neisseria cuniculi*	1
Bacteroides fragilis	1	*Neisseria elongata* subsp. *elongata*	1
Bacteroides ovatus	1	*Neisseria elongata* subsp. *glycoytica*	1
Bacteroides thetaiotaomicron	1	*Neisseria flavescens*	1
Bacteroides vulgatus	1	*Neisseria flavescens* Branham	1
Bordetella bronchiseptica	1	*Neisseria gonorrhoeae*	18
Bordetella parapertussis	1	*Neisseria lactamica*	1
Bordetella pertussis	2	*Neisseria meningitidis*	4
Burkholderia cepacia	1	*Neisseria mucosa*	2
Citrobacter amalonaticus	1	*Neisseria polysaccharea*	1
Citrobacter diversus subsp. *koseri*	2	*Neisseria sicca*	3
Citrobacter freundii	1	*Neisseria subflava*	3
Comamonas acidovorans	1	*Neisseria weaveri*	1
Enterobacter aerogenes	1	*Ochrobactrum antropi*	1
Enterobacter agglomerans	1	*Pasteurella aerogenes*	1
Enterobacter cloacae	1	*Pasteurella multocida*	1
Escherichia coli	9	*Prevotella melaninogenica*	1
Escherichia fergusonii	1	*Proteus mirabilis*	3
		Proteus vulgaris	1

Bacterial species	Number of reference strains tested[a]	Bacterial species	Number of reference strains tested[a]
Escherichia hermannii	1	*Providencia alcalifaciens*	1
Escherichia vulneris	1	*Providencia rettgeri*	1
Flavobacterium meningosepticum	1	*Providencia rustigianii*	1
Flavobacterium indologenes	1	*Providencia stuartii*	1
Flavobacterium odoratum	1	*Pseudomonas aeruginosa*	14
Fusobacterium necrophorum	2	*Pseudomonas fluorescens*	2
Gardnerella vaginalis	1	*Pseudomonas stutzeri*	1
Haemophilus haemolyticus	1	*Salmonella arizonae*	1
Haemophilus influenzae	12	*Salmonella choleraesuis*	1
Haemophilus parahaemolyticus	1	*Salmonella gallinarum*	1
Haemophilus parainfluenzae	2	*Salmonella typhimurium*	3
Hafnia alvei	1	*Serratia liquefaciens*	1
Kingella indologenes subsp. *suttonella*	1	*Serratia marcescens*	1
Kingella kingae	1	*Shewanella putida*	1
Klebsiella ornithinolytica	1	*Shigella boydii*	1
Klebsiella oxytoca	1	*Shigella dysenteriae*	1
Klebsiella pneumoniae	8	*Shigella flexneri*	1
Moraxella atlantae	1	*Shigella sonnei*	1
Moraxella catarrhalis	5	*Stenotrophomonas maltophilia*	1
Moraxella lacunata	1	*Yersinia enterocolitica*	1
Moraxella osloensis	1		

[a] Most reference strains were obtained from the American Type Culture Collection (ATCC). The other reference strains were obtained from (i) the Laboratoire de Santé Publique du Québec (LSPQ), (ii) the Center for Disease Control and Prevention (CDC) and (iii) the National Culture Type Collection (NCTC).

Table 5. Gram-positive bacterial species (97) used to test the specificity of PCR primers and DNA probes (continues on next page).

Bacterial species	Number of reference strains tested[a]	Bacterial species	Number of reference strains tested[a]
Abiotrophia adiacens	1	*Micrococcus kristinae*	1
Abiotrophia defectiva	1	*Micrococcus luteus*	1
Actinomyces israelii	1	*Micrococcus lylae*	1
Clostridium perfringens	1	*Micrococcus roseus*	1
Corynebacterium accolens	1	*Micrococcus varians*	1
Corynebacterium aquaticum	1	*Peptococcus niger*	1
Corynebacterium bovis	1	*Peptostreptococcus anaerobius*	1
Corynebacterium cervicis	1	*Peptostreptococcus asaccharolyticus*	1
Corynebacterium diphteriae	6	*Staphylococcus aureus*	10
Corynebacterium flavescens	1	*Staphylococcus auricularis*	1
Corynebacterium genitalium	6	*Staphylococcus capitis* subsp. *urealyticus*	1
Corynebacterium jeikeium	1	*Staphylococcus cohnii*	1
Corynebacterium kutcheri	1	*Staphylococcus epidermidis*	2
Corynebacterium matruchotii	1	*Staphylococcus haemolyticus*	2
Corynebacterium minutissimum	1	*Staphylococcus hominis*	2
Corynebacterium mycetoides	1	*Staphylococcus lugdunensis*	1
Corynebacterium pseudodiphtheriticum	1	*Staphylococcus saprophyticus*	3
Corynebacterium pseudogenitalium	6	*Staphylococcus schleiferi*	1
Corynebacterium renale	1	*Staphylococcus sciuri*	1
Corynebacterium striatum	1	*Staphylococcus simulans*	1
Corynebacterium ulcerans	1	*Staphylococcus warneri*	1

Bacterial species	Number of reference strains tested[a]	Bacterial species	Number of reference strains tested[a]
Corynebacterium urealyticum	1	*Staphylococcus xylosus*	1
Corynebacterium xerosis	1	*Streptococcus agalactiae*	6
Enterococcus avium	1	*Streptococcus anginosus*	2
Enterococcus casseliflavus	1	*Streptococcus bovis*	2
Enterococcus cecorum	1	*Streptococcus constellatus*	1
Enterococcus dispar	1	*Streptococcus crista*	1
Enterococcus durans	1	*Streptococcus dysgalactiae*	1
Enterococcus faecalis	6	*Streptococcus equi*	1
Enterococcus faecium	3	*Streptococcus gordonii*	1
Enterococcus flavescens	1	*Group C Streptococci*	1
Enterococcus gallinarum	3	*Group D Streptococci*	1
Enterococcus hirae	1	*Group E Streptococci*	1
Enterococcus mundtii	1	*Group F Streptococci*	1
Enterococcus pseudoavium	1	*Group G Streptococci*	1
Enterococcus raffinosus	1	*Streptococcus intermedius*	1
Enterococcus saccharolyticus	1	*Streptococcus mitis*	2
Enterococcus solitarius	1	*Streptococcus mutans*	1
Eubacterium lentum	1	*Streptococcus oralis*	1
Gemella haemolysans	1	*Streptococcus parasanguis*	1
Gemella morbillorum	1	*Streptococcus pneumoniae*	6
Lactobacillus acidophilus	1	*Streptococcus pyogenes*	3
Listeria innocua	1	*Streptococcus salivarius*	2
Listeria ivanovii	1	*Streptococcus sanguis*	2
Listeria grayi	1	*Streptococcus sobrinus*	1
Listeria monocytogenes	3	*Streptococcus suis*	1
Listeria murrayi	1	*Streptococcus uberis*	1
Listeria seeligeri	1	*Streptococcus vestibularis*	1
Listeria welshimeri	1		

[a] Most reference strains were obtained from the American Type Culture Collection (ATCC). The other reference strains were obtained from (i) the Laboratoire de Santé Publique du Québec (LSPQ), (ii) the Center for Disease Control and Prevention (CDC) and (iii) the National Culture Type Collection (NCTC).

Table 6. Fungal species (12) used to test the specificity of PCR primers and DNA probes.

Fungal species	Number of reference strains tested[a]
Candida albicans	12
Candida glabrata	1
Candida guilliermondii	1
Candida kefyr	3
Candida krusei	2
Candida lusitaniae	1
Candida parapsilosis	2
Candida tropicalis	3
Rhodotorula glutinis	1
Rhodotorula minuta	1
Rhodotorula rubra	1
Saccharomyces cerevisiae	1

[a] Most reference strains were obtained from (i) the American Type Culture Collection (ATCC) and (ii) the Laboratoire de Santé Publique du Québec (LSPQ).

Table 7. PCR assays developed for several clinically important bacterial and fungal pathogens (continues on next page).

Organism	Primer Pair[a] SEQ ID NO	Amplicon size (bp)	Ubiquity[b]	DNA amplification from culture[c]	DNA amplification from specimens[d]
Enterococcus faecium	1-2	216	79/80	+	+
Listeria monocytogenes	3-4	130	164/168[e]	+	+
Neisseria meningitidis	5-6	177	258/258	+	+
Staphylococcus saprophyticus	7-8	149	245/260	+	NT
Streptococcus agalactiae	9-10	154	29/29	+	+
Candida albicans	11-12	149	88/88	+	NT
Enterococcus spp. (11 species)[f]	13-14	112	87/87	+	NT
Neisseria spp. (12 species)[f]	15-16	103	321/321	+	+
Staphylococcus spp. (14 species)	17-18	192	13/14	+	NT
	19-20	221	13/14	+	NT
Streptococcus spp. (22 species)[f]	21-22	153	210/214[g]	+	+
Universal detection[h] (95 species)[i]	23-24	309	104/ 116[i]	+	+

[a] All primer pairs are specific in PCR assays since no amplification was observed with DNA from the bacterial and fungal species other than the species of interest listed in Tables 4, 5 and 6.

[b] Ubiquity was tested by using reference strains as well as strains from throughout the world, which are representatite of the diversity within each target species or genus.

[c] For all primer pairs, PCR amplifications performed directly from a standardized microbial suspension (MacFarland) or from a colony were all specific and ubiquitous.

[d] PCR assays performed directly from blood cultures, urine specimens or

cerebrospinal fluid. NT, not tested.

[e] The four *L. monocytogenes* strains undetected are not clinical isolates. These strains were isolated from food and are not associated with a human infection.

[f] The bacterial species tested include all those clinically relevant for each genus (Tables 4 and 5). All of these species were efficiently amplified by their respective genus-specific PCR assay, except for the *Staphylococcus*-specific assay, which does not amplify *S. sciuri*.

[g] The *Streptococcus*-specific PCR assay did not amplify 3 out of 9 strains of *S. mutans* and 1 out of 3 strains of *S. salivarius*.

[h] The primers selected for universal bacterial detection do not amplify DNA of non-bacterial origin, including human and other types of eukaryotic genomic DNA.

[i] For the universal amplification, the 95 bacterial species tested represent the most clinically important bacterial species listed in Tables 4 and 5. The 12 strains not amplified are representatives of genera *Corynebacterium* (11 species) and *Stenotrophomonas* (1 species).

Table 8. Target genes for the various genus-specific, species-specific and universal amplification assays.

Microorganisms	Gene	Protein encoded
Candida albicans	*tuf*	translation elongation factor EF-Tu
Enterococcus faecium	*ddl*	D-alanine:D-alanine ligase
Listeria monocytogenes	*actA*	actin-assembly inducing protein
Neisseria meningitidis	*omp*	outer membrane protein
Streptococcus agalactiae	*cAMP*	cAMP factor
Staphylococcus saprophyticus	unknown	unknown
Enterococcus spp.	*tuf*	translation elongation factor EF-Tu
Neisseria spp.	*asd*	ASA-dehydrogenase
Staphylococcus spp.	*tuf*	translation elongation factor EF-Tu
Streptococcus spp.	*recA*	RecA protein
Universal detection	*tuf*	translation elongation factor EF-Tu

Table 9. Antibiotic resistance genes selected for diagnostic purposes.

Genes	SEQ ID NOs		Antibiotics	Bacteria[a]
	selected primers	originating fragment		
bla_{oxa}	49-50	110	β-lactams	*Enterobacteriaceae*, *Pseudomonadaceae*
blaZ	51-52	111	β-lactams	*Enterococcus* spp.
aac6'-IIa	61-64	112	Aminoglycosides	*Pseudomonadaceae*
ermA	91-92	113	Macrolides	*Staphylococcus* spp.
ermB	93-94	114	Macrolides	*Staphylococcus* spp.
ermC	95-96	115	Macrolides	*Staphylococcus* spp.
vanB	71-74	116	Vancomycin	*Enterococcus* spp.
vanC	75-76	117	Vancomycin	*Enterococcus* spp.
aad(6')	173-174	-	Streptomycin	*Enterococcus* spp.

[a] Bacteria having high incidence for the specified antibiotic resistance genes. The presence of these antibiotic resistance genes in other bacteria is not excluded.

Table 10. Antibiotic resistance genes from our co-pending US (N.S. 08/526840) and PCT (PCT/CA/95/00528) patent applications for which we have selected PCR primer pairs.

Genes	SEQ ID NOs of selected primers	Antibiotics	Bacteria[a]
bla$_{tem}$	37-40	β-lactams	*Enterobacteriaceae*, *Pseudomonadaceae*, *Haemophilus* spp., *Neisseria* spp.
bla$_{rob}$	45-48	β-lactams	*Haemophilus* spp., *Pasteurella* spp.
bla$_{shv}$	41-44	β-lactams	*Klebsiella* spp. and other *Enterobacteriaceae*
*aad*B	53-54	Aminoglycosides	*Enterobacteriaceae*, *Pseudomonadaceae*
*aac*C1	55-56		
*aac*C2	57-58		
*aac*C3	59-60		
*aac*A4	65-66		
*mec*A	97-98	β-lactams	*Staphylococcus* spp.
*van*A	67-70	Vancomycin	*Enterococcus* spp.
*sat*A	81-82	Macrolides	*Enterococcus* spp.
aac(6')-*aph*(2")	83-86	Aminoglycosides	*Enterococcus* spp., *Staphylococcus* spp.
vat	87-88	Macrolides	*Staphylococcus* spp.
vga	89-90	Macrolides	*Staphylococcus* spp.
*msr*A	77-80	Erythromycin	*Staphylococcus* spp.
int	99-102	β-lactams, trimethoprim, aminoglycosides, antiseptic, chloramphenicol	*Enterobacteriaceae*, *Pseudomonadaceae*
sul	103-106		

[a] Bacteria having high incidence for the specified antibiotic resistance genes. The presence of these antibiotic resistance genes in other bacteria is not excluded.

Table 11. Correlation between disk diffusion and PCR amplification of antibiotic resistance genes in *Staphylococcus* species[a].

				Disk diffusion (Kirby-Bauer)[b]		
Antibiotic	Phenotype		PCR	Resistant	Intermediate	Sensitive
Penicillin	*blaZ*		+	165	0	0
			-	0	0	31
Oxacillin	*mecA*		+	51	11	4
			-	2	0	128
Gentamycin	*aac*(6')*aph*(2")		+	24	18	6
			-	0	0	148
Erythromycin	*ermA*		+	15	0	0
	ermB		+	0	0	0
	ermC		+	43	0	0
	msrA		+	4	0	0
			-	0	1	136

[a] The *Staphylococcus* strains studied include *S. aureus* (82 strains), *S. epidermidis* (83 strains), *S. hominis* (2 strains), *S. capitis* (3 strains), *S. haemolyticus* (9 strains), *S. simulans* (12 strains) and *S. warneri* (5 strains), for a total of 196 strains.

[b] Susceptibility testing was performed by the method of Kirby-Bauer according to the protocol reccommended by the National Committee of Clinical Laboratory Standards (NCCLS).

Table 12. Correlation between disk diffusion profiles and PCR amplification of antibiotic resistance genes in *Enterococcus* species[a].

Antibiotic	Phenotype	PCR	Disk diffusion (Kirby-Bauer)[b]	
			Resistant	Sensitive
Ampicillin	*blaZ*	+	0	2
		-	1	30
Gentamycin	*aac*(6')*aph*(2'')	+	51	1
		-	3	38
Streptomycin	*aad*(6')	+	26	15
		-	6	27
Vancomycin	*vanA*	+	36	0
	vanB	+	26	0
		-	0	40

[a] The *Enterococcus* strains studied include *E. faecalis* (33 strains) and *E. faecium* (69 strains), for a total of 102 strains.

[b] Susceptibility testing was performed by the method of Kirby-Bauer according to the protocol reccommended by the National Committee of Clinical Laboratory Standards (NCCLS).

Table 13. Origin of *tuf* sequences in the Sequence Listing (continues on next page).

SEQ ID NO	Bacterial or fungal species	Source
118	*Abiotrophia adiacens*	This patent
119	*Abiotrophia defectiva*	This patent
120	*Candida albicans*	This patent
121	*Candida glabrata*	This patent
122	*Candida krusei*	This patent
123	*Candida parapsilosis*	This patent
124	*Candida tropicalis*	This patent
125	*Corynebacterium accolens*	This patent
126	*Corynebacterium diphteriae*	This patent
127	*Corynebacterium genitalium*	This patent
128	*Corynebacterium jeikeium*	This patent
129	*Corynebacterium pseudotuberculosis*	This patent
130	*Corynebacterium striatum*	This patent
131	*Enterococcus avium*	This patent
132	*Enterococcus faecalis*	This patent
133	*Enterococcus faecium*	This patent
134	*Enterococcus gallinarum*	This patent
135	*Gardnerella vaginalis*	This patent
136	*Listeria innocua*	This patent
137	*Listeria ivanovii*	This patent
138	*Listeria monocytogenes*	This patent
139	*Listeria seeligeri*	This patent
140	*Staphylococcus aureus*	This patent
141	*Staphylococcus epidermidis*	This patent
142	*Staphylococcus saprophyticus*	This patent
143	*Staphylococcus simulans*	This patent
144	*Streptococcus agalactiae*	This patent
145	*Streptococcus pneumoniae*	This patent

SEQ ID NO	Bacterial or fungal species	Source
146	*Streptococcus salivarius*	This patent
147	*Agrobacterium tumefaciens*	Database
148	*Bacillus subtilis*	Database
149	*Bacteroides fragilis*	Database
150	*Borrelia burgdorferi*	Database
151	*Brevibacterium linens*	Database
152	*Burkholderia cepacia*	Database
153	*Chlamydia trachomatis*	Database
154	*Escherichia coli*	Database
155	*Fibrobacter succinogenes*	Database
156	*Flavobacterium ferrugineum*	Database
157	*Haemophilus influenzae*	Database
158	*Helicobacter pylori*	Database
159	*Micrococcus luteus*	Database
160	*Mycobacterium tuberculosis*	Database
161	*Mycoplasma genitalium*	Database
162	*Neisseria gonorrhoeae*	Database
163	*Rickettsia prowazekii*	Database
164	*Salmonella typhimurium*	Database
165	*Shewanella putida*	Database
166	*Stigmatella aurantiaca*	Database
167	*Streptococcus pyogenes*	Database
168	*Thiobacillus cuprinus*	Database
169	*Treponema pallidum*	Database
170	*Ureaplasma urealyticum*	Database
171	*Wolinella succinogenes*	Database

Annex I: **Strategy for the selection from *tuf* sequences of the universal amplification primers (continues on pages 49 to 51).**

		491	517...776	802	SEQ ID NO
5	*Abiotrophia adiacens*	CAACTGTAAC	TGGTGTTGAA ATGTTCC...AAATGGT	AATGCCTGGT GATAACGTAA	118
	Abiotrophia defectiva	CTACCGTTAC	CGGTGTTGAA ATGTTCC...AAATGGT	TATGCCAGGC GACAACGTAC	119
	Agrobacterium tumefaciens	CGACTGTTAC	CGGCGTTGAA ATGTTCC...AAATGGT	TATGCCTGGC GACAACGTCA	147
10	*Bacillus subtilis*	CAACTGTTAC	AGGTGTTGAA ATGTTCC...AAATGGT	TATGCCTGGA GATAACACTG	148
	Bacteroides fragilis	CAGTTGTAAC	AGGTGTTGAA ATGTTCC...AAATGGT	AATGCCGGGT GATAACGTAA	149
15	*Borrelia burgdorferi*	CTACTGTTAC	TGGTGTTGAA ATGTTCC...AAATGGT	TATGCCTGGT GATAATGTTG	150
	Brevibacterium linens	CGACTGTCAC	CGCTATCGAG ATGTTCC...AGATGGT	CATGCCCGGC GACACCACCG	151
	Burkholderia cepacia	CGACCTGCAC	GGGCGTTGAA ATGTTCC...AAATGGT	CATGCCGGGC GACAACGTGT	152
20	*Chlamydia trachomatis*	CGATTGTTAC	TGGGGTTGAA ATGTTCA...AGATGGT	CATGCCTGGG GATAACGTTG	153
	Corynebacterium diphteriae	CCACCGTTAC	CGGTATCGAG ATGTTCC...AGATGGT	CATGCCTGGC GACAACGTCG	126

	Corynebacterium genitalium	CCACCGTTAC CTCCATCGAG ATGTTCA...AGATGGT TATGCCGGGC GACAACGTTG	127
	Corynebacterium jeikeium	CCACCGTTAC CTCCATCGAG ATGTTCA...AGATGGT TATGCCGGGC GACAACGTTG	128
5	*Enterococcus faecalis*	CAACYGTTAC AGGTGTTGAA ATGTTCC...AAATGGT AATGCCTGGT GATAACGTTG	132
	Enterococcus faecium	CAACAGTTAC TGGTGTTGAA ATGTTCC...AAATGGT CATGCCCGGT GACAACGT..	133
	Escherichia	CTACCTGTAC TGGCGTTGAA ATGTTCC...AGATGGT AATGCCGGGC GACAACATCA	154
10	*coli*		
	Fibrobacter succinogenes	ACGTCATCAC CGGTGTTGAA ATGTTCC...AAATGGT TACTCCGGGT GACACGGTCA	155
	Flavobacterium ferrugineum	CTACCGTTAC AGGTGTTGAG ATGTTCC...AAATGGT TATGCCTGGT GATAACACCA	156
15	*Gardnerella vaginalis*	CCACCGTCAC CTCTATCGAG ACCTTCC...AAATGGT TCAGCCAGGC GATCACGCAA	135
	Haemophilus influenzae	CTACTGTAAC GGGTGTTGAA ATGTTCC...AAATGGT AATGCCAGGC GATAACATCA	157
	Helicobacter	CGACTGTAAC CGGTGTAGAA ATGTTTA...AAATGGT TATGCCTGGC GATAATGTGA	158
20	*pylori*		
	Listeria monocytogenes	TAGTAGTAAC TGGAGTAGAA ATGTTCC...AAATGGT AAYGCCTGGT GATAACATTG	138
	Micrococcus luteus	CCACTGTCAC CGGCATCGAG ATGTTCC...AGATGGT CATGCCCGGC GACAACACCG	159
25	*Mycobacterium tuberculosis*	CCACCGTCAC CGGTGTGGAG ATGTTCC...AGATGGT GATGCCCGGT GACAACACCA	160

	Mycoplasma genitalium	CAGTTGTTAC TGGAATTGAA ATGTTCA...AAATGGT TCTACCTGGT GATAATGCTT	161
	Neisseria gonorrhoeae	CCACCTGTAC CGGCGTTGAA ATGTTCC...AAATGGT AATGCCGGGT GAGAACGTAA	162
5	*Rickettsia prowazekii*	CGACTTGTAC AGGTGTAGAA ATGTTCA...AGATGGT TATGCCTGGA GATAATGCTA	163
	Salmonella typhimurium	CTACCTGTAC TGGCGTTGAA ATGTTCC...AGATGGT AATGCCGGGC GACAACATCA	164
	Shewanella putida	CAACGTGTAC TGGTGTAGAA ATGTTCC...AGATGGT AATGCCAGGC GATAACATCA	165
10	*Stigmatella aurantiaca*	CGGTCATCAC GGGGGTGGAG ATGTTCC...AGATGGT GATGCCGGGA GACAACATCG	166
	Staphylococcus aureus	CAACTGTTAC AGGTGTTGAA ATGTTCC...AAATGGT AATGCCTGGT GATAACGTTG	140
15	*Staphylococcus epidermidis*	CAACTGTTAC TGGTGTAGAA ATGTTCC...AAATGGT TATGCCTGGC GACAACGTTG	141
	Streptococcus agalactiae	CAGTTGTTAC TGGTGTTGAA ATGTTCC...AAATGGT TATGCCTGGT GATAACGTTA	144
	Streptococcus pneumoniae	CAGTTGTTAC TGGTGTTGAA ATGTTCC...AAATGGT AATGCCTGGT GATAACGTGA	145
20	*Streptococcus pyogenes*	CTGTTGTTAC TGGTGTTGAA ATGTTCC...AAATGGT TATGCCTGGT GATAACGTGA	167
	Thiobacillus cuprinus	CCACCTGCAC CGGCGTGGAA ATGTTCA...AAATGGT CATGCCCGGC GATAATGTGA	168
25	*Treponema pallidum*	CAGTGGTTAC TGGCATTGAG ATGTTTA...ACATGGT GAAGCCGGGG GATAACACCA	169

	Ureaplasma urealyticum	CTGTTGTTAC AGGAATTGAA ATGTTTA...ATTTGGT TATGCCAGGT GATGACGTTG	170
	Wolinella succinogenes	CAACCGTAAC TGGCGTTGAG ATGTTCC...AGATGGT TATGCCTGGT GACAACGTTA	171
5	*Candida albicans*	GTGTTACCAC TGAAGTCAAR TCCGTTG...AGRAATT GGAAGAAAAT CCAAAATTCG	120
	Schizo-saccharomyces pombe	GTGTCACTAC CGAAGTCAAG TCTGTTG...AGAAGAT TGAGGAGTCC CCTAAGTTTG	
	Human	TGACAGGCAT TGAGATGTTC CACAAGA...AGAAGGAGCTTGCCATG CCCGGGGAGG	
10	Selected[a] equences[a]	ACIKKIAC IGGIGTIGAR ATGTT ATGGT IATGCCIGGI GAIAAYRT	
	Selected universal	SEQ ID NO:23	SEQ ID NO: 24[b]
15	primer sequences[a]:	ACIKKIAC IGGIGTIGAR ATGTT AYRTT ITCICCIGGC ATIACCAT	

The sequence numbering refers to the *E. coli tuf* gene fragment. Underlined nucleotides are identical to the selected sequence or match that sequence.

20 [a] "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T. "K", "R" and "Y" designate nucleotide positions which are degenerated. "K" stands for T or G; "R" stands for A or G; "Y" stands for C or T.

[b] This sequence is the reverse complement of the above *tuf* sequence.

Annex II: **Strategy for the selection from *tuf* sequences of the amplification primers specific for the genus *Enterococcus* (continues on pages 53 and 54).**

	314	348	401	435	SEQ ID NO
Bacillus subtilis	CGCGACACTG	AAAAACCATT	CATGATGCCA GTTGA...	CGCGG ACAAGTTAAA GTCGGTGACG AAGTTGAAAT	148
Bacteroides fragilis	CGCGATGTTG	ATAAACCTTT	CTTGATGCCG GTAGA...	ACTGG TGTTATCCAT GTAGGTGATG AAATCGAAAT	149
Burkholderia cepacia	CGTGCAGTTG	ACGGCGCGTT	CCTGATGCCG GTGGA...	CGCGG CATCGTGAAG GTCGGCGAAG AAATCGAAAT	152
Chlamydia trachomatis	AGAGAAATTG	ACAAGCCTTT	CTTAATGCCT ATTGA...	CGTGG AATTGTTAAA GTTTCCGATA AAGTTCAGTT	153
Corynebacterium diphteriae	CGTGAGACCG	ACAAGCCATT	CCTCATGCCT ATCGA...	CGTGG CTCCCTGAAG GTCAACGAGG ACGTCGAGAT	126
Enterococcus avium	CGTGATACTG	ACAAACCATT	CATGATGCCA GTCGA...	CGTGG ACAAGTTCGC GTTGGTGACG AAGTTGAAAT	131
Enterococcus faecalis	CGTGATACTG	ACAAACCATT	CATGATGCCA GTCGA...	CGTGG TGAAGTTCGC GTTGGTGACG AAGTTGAAAT	132
Enterococcus faecium	CGTGACAACG	ACAAACCATT	CATGATGCCA GTTGA...	CGTGG ACAAGTTCGC GTTGGTGACG AAGTTGAAGT	133
Enterococcus gallinarum	CGTGATACTG	ACAAACCATT	CATGATGCCA GTCGA...	CGTGG ACAAGTTCGC GTTGGTGATG AAGTAGAAAT	134
Escherichia coli	CGTGCGATTG	ACAAGCCGTT	CCTGCTGCCG ATCGA...	CGCGG TATCATCAAA GTTGGTGAAG AAGTTGAAAT	154

	Gardnerella vaginalis	CACGATCTTG ACAAGCCATT CTTGATGCCA ATCGA...CGTGG TAAGCTCCCA ATCAACACCC CAGTTGAGAT	135
	Haemophilus influenzae	CGTGCGATTG ACCAACCGTT CCTTCTTCCA ATCGA...CGAGG TATTATCCGT ACAGGTGATG AAGTAGAAAT	157
5	*Helicobacter pylori*	AGAGACACTG AAAAAACTTT CTTGATGCCG GTTGA...AGAGG CGTGGTGAAA GTAGGCGATG AAGTGGAAAT	158
	Listeria monocytogenes	CGTGATACTG ACAAACCATT CATGATGCCA GTTGA...CGTGG ACAAGTTAAA GTTGGTGACG AAGTAGAAGT	138
	Micrococcus	CGCGACAAGG ACAAGCCGTT CCTGATGCCG ATCGA...CGCGG CACCCTGAAG ATCAACTCCG AGGTCGAGAT	159
10	*luteus*		
	Mycobacterium tuberculosis	CGCGAGACCG ACAAGCCGTT CCTGATGCCG GTCGA...CGCGG CGTGATCAAC GTGAACGAGG AAGTTGAGAT	160
	Mycoplasma genitalium	CGTGAAGTAG ATAAACCTTT CTTATTAGCA ATTGA...AGAGG TGAACTCAAA GTAGGTCAAG AAGTTGAAAT	161
15	*Neisseria gonorrhoeae*	CGTGCCGTGG ACAAACCATT CCTGCTGCCT ATCGA...CGAGG TATCATCCAC GTTGGTGACG AGATTGAAAT	162
	Salmonella typhimurium	CGTGCGATTG ACAAGCCGTT CCTGCTGCCG ATCGA...CGCGG TATCATCAAA GTGGGCGAAG AAGTTGAAAT	164
	Shewanella	CGTGACATCG ATAAGCCGTT CCTACTGCCA ATCGA...CGTGG TATTGTACGC GTAGGCGACG AAGTTGAAAT	165
20	*putida*		
	Staphylococcus aureus	CGTGATTCTG ACAAACCATT CATGATGCCA GTTGA...CGTGG TCAAATCAAA GTTGGTGAAG AAGTTGAAAT	140
	Staphylococcus epidermidis	CGTGATTCTG ACAAACCATT CATGATGCCA GTTGA...CGTGG TCAAATCAAA GTWGGTGAAG AAGTTGAAAT	141
25	*Staphylococcus saprophyticus*	CGTGATTCTG ACAAACCATT CATGATGCCA GTTGA...CGTGG TCAAATCAAA GTCGGTGAAG AAATCGARAT	142

Streptococcus agalactiae	CGTGA**TACTG** **ACAAACCTTT** AC**T**TC**T**TCCA GTTGA...CGTGG TACT**GTTCGT** **GT**CAAC**GACG** **AAGTT**GAAAT	144
Streptococcus pneumoniae	CGTGAC**ACTG** **ACAAACCATT** GC**T**TC**T**TCCA GTCGA...CGTGG TATC**GTTAAA** **GT**CAAC**GACG** **AAA**TCGAAAT	145
Streptococcus pyogenes	CGCGAC**ACTG** **ACAAACCATT** GC**T**TC**T**TCCA GTCGA...CGTGG TACT**GTTCGT** **GT**CAAC**GACG** **AAA**TCGAAAT	167
Ureaplasma urealyticum	CGTAG**TACTG** **ACAAACCATT** **C**TTAT**T**AGCA ATTGA...CGTGG TGTAT**T**AAAA **GTTAATGATG** **AGGTT**GAAAT	170
Selected sequences	**TACTG** **ACAAACCATT** **CATGATG** **GTTCGC** **GTTGGTGACG** **AAGTT**	
Selected genus-specific primer sequences:	SEQ ID NO: 13 **TACTG ACAAACCATT CATGATG**	SEQ ID NO: 14[a] **AACTTC GTCACCAACG CGAAC**

The sequence numbering refers to the *E. faecalis tuf* gene fragment. Underlined nucleotides are identical to the selected sequence or match that sequence.

[a] This sequence is the reverse complement of the above *tuf* sequence.

NOTE: The above primers also amplify *tuf* sequences from *Abiotrophia* species; this genus has recently been related to the *Enterococcus* genus by 16S rRNA analysis.

PCT/CA97/00829

Annex III: **Strategy for the selection from *tuf* sequences of the amplification primers specific for the genus *Staphylococcus* (continues on pages 56 and 57).**

	385	420.....579	611	SEQ ID NO
Bacillus subtilis	TGGCCGTGTA GAACGCGGAC AAGTTAAAGT	CGG.....TTG	CTAAACCAGG TACAATCACT CCACACAGCA	148
Bacteroides fragilis	AGGTCGTATC GAAACTGGTG TTATCCATGT	AGG.....TTT	GTAAACCGGG TCAGATTAAA CCTCACTCTA	149
Burkholderia cepacia	GGGTCGTGTC GAGCGCGGCA TCGTGAAGGT	CGG.....TGG	CGAAGCCGGG TTCGATCACG CCGCACACGC	152
Chlamydia trachomatis	TGGACGTATT GAGCGTGGAA TTGTTAAAGT	TTC.....TTT	GCTTGCCAAA CAGTGTTAAA CCTCATACAC	153
Corynebacterium diphteriae	CGGCCGTGTT GAGCGTGGCT CCCTGAAGGT	CAA.....TTG	TTAAGCCAGG CGCTTACACC CCTCACACCG	126
Enterococcus faecalis	AGGACGTGTT GAACGTGGTG AAGTTCGCGT	TGG.....TAG	CTAAACCAGC TACAATCACT CCACACACAA	132
Enterococcus faecium	AGGTCGTGTT GAACGTGGAC AAGTTCGCGT	TGG.....TAG	CTAAACCAGG TACAATCACA CCTCRTACAA	133
Escherichia coli	CGGTCGTGTA GAACGCGGTA TCATCAAAGT	TGG.....TGG	CTAAGCCGGG CACCATCAAG CCGCACACCA	154
Gardnerella vaginalis	CGGTCGTGTT GAGCGTGGTA AGCTCCCAAT	CAA.....TGG	CTGCTCCAGG TTCTGTGACT CCACACACCA	135

Haemophilus influenzae	AGGTCGTGTA GAACGAGGTA TTATCCGTAC AGG.....TAG CGAAACCAGG TTCAATCACA CCACACACTG	157
Helicobacter pylori	AGGTAGGATT GAAAGAGGCG TGGTGAAAGT AGG.....TAT GCAAACCAGG TTCTATCACT CCGCACAAGA	158
Listeria monocytogenes	TGGACGTGTT GAACGTGGAC AAGTTAAAGT TGG.....TAG CTAAACCAGG TTCGATTACT CCACACACTA	138
Micrococcus luteus	CGGTCGCGCC GAGCGCGGCA CCCTGAAGAT CAA.....TGG TGGAGCCGGG CTCCATCACC CCGCACACCA	159
Mycobacterium tuberculosis	CGGACGTGTG GAGCGCGGCG TGATCAACGT GAA.....TCA CCAAGCCCGG CACCACCACG CCGCACACCG	160
Mycoplasma genitalium	AGGAAGAGTT GAAAGAGGTG AACTCAAAGT AGG.....TAG CAAAACCAGG CTCTATTAAA CCGCACAAGA	161
Neisseria gonorrhoeae	CGGCCGTGTA GAGCGAGGTA TCATCCACGT TGG.....TGG CCAAACGGGG TACTATCACT CCTCACACCA	162
Salmonella typhimurium	CGGTCGTGTA GAGCGCGGTA TCATCAAAGT GGG.....TGG CTAAGCCGGG CACCATCAAG CCGCACACCA	164
Shewanella putida	AGGTCGTGTT GAGCGTGGTA TTGTACGCGT AGG.....TAG CGAAGCCAGG TTCAATCAAC CCACACACTA	165
Staphylococcus aureus	AGGCCGTGTT GAACGTGGTC AAATCAAAGT TGG.....TAG CTGCTCCTGG TTCAATTACA CCACATACTG	140
Staphylococcus epidermidis	AGGCCGTGTT GAACGTGGTC AAATCAAAGT WGG.....TAG CTGCTCCTGG TTCTATTACA CCACACACAA	141
Staphylococcus saprophyticus	AGGCCGTGTT GAACGTGGTC AAATCAAAGT CGG.....TAG CTGCTCCTGG TACTATCACA CCACATACAA	142
Staphylococcus simulans	AGGCCGTGTT GAACGTGGTC AAATCAAAGT CGG.....TAG CAGCTCCTGG CTCTATTACT CCACACACAA	143

Streptococcus agalactiae	AGGACGTATC GACCGTGGTA CTGTTCGTGT CAA.....TTG CTAAACCAGG TTCAATCAAC CCACACACTA	144
Streptococcus pneumoniae	AGGACGTATC GACCGTGGTA TCGTTAAAGT CAA.....TCG CTAAACCAGG TTCAATCAAC CCACACACTA	145
Ureaplasma urealyticum	TGGACGTGTT GAACGTGGTG TATTAAAAGT TAA.....TTG TAAAACCAGG ATCAATTAAA CCTCACCGTA	170
Selected sequences[a]	CCGTGTT GAACGTGGTC AAATCAAA GCTCCTGG YWCWATYACA CCACAYA	
Selected genus-specific primer sequences[a]:	SEQ ID NO: 17 CCGTGTT GAACGTGGTC AAATCAAA	SEQ ID NO: 18[b] TRTGTGGT GTRATWGWRC CAGGAGC

The sequence numbering refers to the *S.aureus tuf* gene fragment. Underlined nucleotides are identical to the selected sequence or match that sequence.

[a] "R", "W" and "Y" designate nucleotide positions which are degenerated. "R" stands for A or G; "W", for A or T; "Y", for C or T.

[b] This sequence is the reverse complement of the above *tuf* sequence.

Annex IV: **Strategy for the selection from *tuf* sequences of the amplification primers specific for the species *Candida albicans* (continues on pages 59 and 60).**

	58	90	181	213	SEQ ID NO
Candida albicans	CGTCAAGAAG GTTGGTTACA ACCCAAAGAC	TGT...	CAA ATCCGGTAAA GTTACTGGTA AGACCTTGTT		120
Candida glabrata	CATCAAGAAG GTCGGTTACA ACCCAAAGAC	TGT...	CAA GGCTGGTGTC GTCAAGGGTA AGAYCTTGTT		121
Candida krusei	CATCAAGAAG GTTGGTTACA ACCCAAAGAC	TGT...	CAA GGCAGGTGTT GTTAAGGGTA AGACCTTATT		122
Candida parapsilosis	CGTCAAGAAG GTTGGTTACA ACCCTAAAGC	TGT...	TAA AGCTGGTAAG GTTACCGGTA AGACCTTGTT		123
Candida tropicalis	CGTCAAGAAG GTTGGTTACA ACCCTAAGGC	TGT...	CAA GGCTGGTAAG GTTACCGGTA AGACTTTGTT		124
Schizo-saccharomyces pombe	CATCAAGAAG GTCGGTTTCA ACCCCAAGAC	CGT...	CAA GGCTGGTGTC GTCAAGGGTA AGACTCTTTT		
Human	GGAGATCCGG GAGCTGCTCA CCGAGTTTGG	CTA...	GTT AGGCCTGAAG TCTGTGCAGA AGCTACTGGA		
Chlamydia trachomatis	GGAGCTGCGC GAGCTGCTCA GCAAGTACGG	CTT...	CAA ATG..... ..TATTCTGG AGCTGATGAA		153
Corynebacterium diphteriae	GGAGATCCRT GAGCTGCTCG CTGAGCAGGA	TTA...	GAA GTGGACCCAG TCCATCATCG ACCTCATGCA		126
Enterococcus faecalis	GGAAGTTCGT GACTTATTAT CAGAATACGA	TTT.....	...TGAAGAA AAAATCTTAG AATTAATGGC		132
Escherichia coli	GGAAGTTCGT GAACTTCTGT CTCAGTACGA	CTT.....	..GGGAAGCG AAAATCCTGG AACTGGCTGG		154

	Flavobacterium ferrugineum	CGAGGTTCGC GAAGAACTGA CTAAACGCGG TTT..... ..GGGTTAAA GAAATTGAAA ACCTGATGGA	156
	Gardnerella vaginalis	AGAGGTCCGT GACCTCCTCG AAGAAAACGG CTT...CAA GTGGGTAGAG ACCGTCAAGG AACTCATGAA	135
5	*Haemophilus influenzae*	GGAAGTTCGT GAACTTCTAT CTCAATATGA CTT..... ..GGGAAGAA AAAATCCTTG AGTTAGCAAA	157
	Listeria monocytogenes	GGAAATTCGT GATCTATTAA CTGAATATGA ATT..... ..GGGAAGCT AAAATTGACG AGTTAATGGA	138
	Micrococcus luteus	GGAAGTCCGT GAGTTGCTGG CTGCCCAGGA ATT...CAA GTGGGTCGAG TCTGTCACAC AGTTGATGGA	159
10	*Neisseria gonorrhoeae*	GGAAATCCGC GACCTGCTGT CCAGCTACGA CTT..... ..ACGAAGAA AAAATCTTCG AACTGGCTAC	162
	Salmonella typhimurium	GGAAGTTCGC GAACTGCTGT CTCAGTACGA CTT..... ..GGGAAGCG AAAATCATCG AACTGGCTGG	164
15	*Staphylococcus aureus*	GGAAGTTCGT GACTTATTAA GCGAATATGA CTT..... ...CGAAGAA AAAATCTTAG AATTAATGGA	140
	Streptococcus pneumoniae	GGAAATCCGT GACCTATTGT CAGAATACGA CTT..... ...CGAAGAC ATCGTTATGG AATTGATGAA	145
	Treponema	AGAGGTGCGT GATGCGCTTG CTGGATATGG GTT...GGA GGATGCAGCT TGTATTGAGG AACTGCTTGC	169
20	*pallidum*		

Selected sequences	<u>CAAGAAG</u> <u>GTTGGTTACA</u> <u>ACCCAAAGA</u>	<u>ATCCGGTAAA</u> <u>GTTACTGGTA</u> <u>AGACCT</u>
Selected species-specific primer sequences:	SEQ ID NO: 11 **CAAGAAG GTTGGTTACA ACCCAAAGA**	SEQ ID NO: 12[a] **AGGTCTTACC AGTAACTTTAC CGGAT**

The sequence numbering refers to the *Candida albicans tuf* gene fragment. Underlined nucleotides are identical to the selected sequence or match that sequence.

[a] This sequence is the reverse-complement of the above *tuf* sequence.

Annex V: **Strategy for the selection from the *recA* gene of the amplification primers specific for the genus *Streptococcus* (continues on pages 62 and 63).**

	415	449...540	574 SEQ ID NO
Bordetella pertussis	CTCGAGATCA CCGACGCGCT GGTGCGCTCG	GGCTC...GGCCC GCCTGATGAG CCAGGCGCTG CGCAAGCTGA	
Burkholderia cepacia	CTCGAAATCA CCGATGCGCT GGTGCGCTCG	GGCTC...GGCCC GCCTGATGTC GCAGGCGCTG CGCAAGCTGA	
Campylobacter jejuni	TTAGAAATTG TAGAAACTAT AGCAAGAAGT	GGCGC...AGCAA GACTTATGTC TCAAGCTCTA AGAAAACTTA	
Chlamydia trachomatis	TTGAGTATTG CAGAGCTCTT AGCGCGTTCT	GGAGC...AGCTC GCATGATGTC GCAGGCTCTA CGCAAATTAA	
Clostridium perfringens	TTAGAAATAA CAGAAGCTTT AGTTAGATCA	GGAGC...AGCTA GATTAATGTC ACAAGCCTTA AGAAAGTTAA	
Corynebacterium pseudotuberculosis	CTGGAGATTG CAGATATGCT TGTTCGCTCT	GGAGC...AGCGC GTTTGATGAG TCAGGCGCTG CGTAAGATGA	
Enterobacter agglomerans	CTGGAAATCT GTGATGCGCT GACCCGTTCA	GGCGC...AGCTC GTATGATGAG CCAGGCGATG CGTAAGCTTG	
Enterococcus faecium	TTAGAGATTG CCGATGCCTT AGTTTCAAGT	GGTGC...AGCTC GACTAATGTC TCAAGCACTA CGTAAATTAT	
Escherichia coli	CTGGAAATCT GTGACGCCCT GGCGCGTTCT	GGCGC...GGCAC GTATGATGAG CCAGGCGATG CGTAAGCTGG	

	Haemophilus influenzae	GCGAACAGAA GAATAGAATT TTAATGCATT ACCGC...GACCT GTGAGTTTAC GCAAAGCTTG AGACATTAAA	
	Helicobacter pylori	TTAGAAATTT TAGAAACGAT CACCAGAAGC GGAGG...AGCAA GGCTTATGAG CCATGCGTTA AGAAAAATCA	
5	*Lactococcus lactis*	CTTCAAATTG CTGAAAAATT GATTACTTCT GGAGC...AGCAC GTATGATGTC ACAAGCCATG CGTAAACTTG	
	Legionella pneumophila	CTGGAAATTA CTGATATGCT GGTGCGTTCT GCAGC...GGCAA GATTGATGTC GCAAGCCCTG CGTAAATTGA	
	Mycoplasma genitalium	TTTGCTCTTA TCGAATCATT AATTAAAACA AACAA...TGCAA GAATGATGTC AAAAGGTTTG CGAAGAATAC	
10	*Neisseria gonorrhoeae*	TTGGAAATCT GCGACACGCT CGTCCGTTCG GGCGG...GGCGC GCCTGATGAG TCAGGCTTTG CGCAAACTGA	
	Proteus mirabilis	CTGGAAATTT GTGATGCATT ATCTCGCTCT GGTGC...CGCAC GTATGATGAG CCAAGCTATG CGTAAACTAG	
15	*Pseudomonas aeruginosa*	CTGGAAATCA CCGACATGCT GGTGCGCTCC AACGC...GGCAC GCCTGATGTC CCAGGCGCTG CGCAAGATCA	
	Serratia marcescens	CTGGAAATCT GTGATGCGCT GACCCGCTCC GGCGC...GGCGC GCATGATGAG CCAGGCGATG CGTAAGCTGG	
	Shigella flexneri	CTGGAAATCT GTGACGCCCT GGCGCGTTCT GGCGC...GGCAC GTATGATGAG CCAGGCGATG CGTAAGCTGG	
20	*Staphylococcus aureus*	CTTGAAATCG CCGAAGCATT TGTTAGAAGT GGTGC...AGCTC GTTTAATGTC ACAAGCGTTA CGTAAACTTT	
	Streptococcus gordonii	TTAGAAATTG CAGGAAAATT GATTGACTCT GGGGC.....	32
25	*Streptococcus mutans*	CTTGAAATTG CAGGGAAATT GATTGATTCT GGCGC...AGCAC GCATGATGAG TCAAGCGATG CGTAAATTAT	33

Streptococcus pneumoniae	CTTGAGATTG CGGGAAAATT GATTGACTCA GGTGC...GGCTC GTATGATGAG CCAGGCCATG CGTAAACTTG	34
Streptococcus pyogenes	CTTGAAATTG CAGGTAAATT GATTGATTCT GGTGC...AGCAC GTATGATGAG TCAGGCCATG CGTAAATTAT	35
Streptococcus salivarius	CTCGAAATTG CAGGTAAGCT GATTGACTCT GGTGC...AGCGC GTATGATGAG TCAAGCCATG CGTAAACTTT	36
Vibrio cholerae	CTGGAAATTT GTGATGCACT GGCTCGCTCT GGTGC...AGCGC GTATGTTGTC GCAAGCAATG CGTAAACTGA	
Yersinia pestis	CTGGAAATTT GTGATGCGCT GACTCGCTCT GGTGC...CGCGC GTATGATGAG CCAGGCTATG CGTAAGCTGG	
Selected sequences[a]	GAAATTG CAGGIAAATT GATTGA ATGATGAG TCAIGCCATG CGTAA	
Selected genus-specific primer sequences[a]:	SEQ ID NO: 21 GAAATTG CAGGIAAATT GATTGA	SEQ ID NO: 22[b] TTACGCAT GGCITGACTC ATCAT

The sequence numbering refers to the *S.pneumoniae recA* sequence. Underlined nucleotides are identical to the selected sequence or match that sequence.

[a] "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

[b] This sequence is the reverse complement of the above *rec*A sequence.

Annex VI: Specific and ubiquitous primers for DNA amplification

SEQ ID NO	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO	Nucleotide position
Bacterial species: ***Enterococcus faecium***			
1	5'-TGC TTT AGC AAC AGC CTA TCA G	26[a]	273-294
2[b]	5'-TAA ACT TCT TCC GGC ACT TCG	26[a]	468-488
Bacterial species: ***Listeria monocytogenes***			
3	5'-TGC GGC TAT AAA TGA AGA GGC	27[a]	339-359
4[b]	5'-ATC CGA TGA TGC TAT GGC TTT	27[a]	448-468
Bacterial species: ***Neisseria meningitidis***			
5	5'-CCA GCG GTA TTG TTT GGT GGT	28[a]	56-76
6[b]	5'-CAG GCG GCC TTT AAT AAT TTC	28[a]	212-232
Bacterial species: ***Staphylococcus saprophyticus***			
7	5'- AGA TCG AAT TCC ACA TGA AGG TTA TTA TGA	29[c]	290-319
8[b]	5'- TCG CTT CTC CCT CAA CAA TCA AAC TAT CCT	29[c]	409-438
Bacterial species: ***Streptococcus agalactiae***			
9	5'-TTT CAC CAG CTG TAT TAG AAG TA	30[a]	59-81
10[b]	5'-GTT CCC TGA ACA TTA TCT TTG AT	30[a]	190-212
Fungal species: ***Candida albicans***			
11	5'-CAA GAA GGT TGG TTA CAA CCC AAA GA	120[c]	61-86
12[b]	5'-AGG TCT TAC CAG TAA CTT TAC CGG AT	120[c]	184-209

[a] Sequences from databases.

[b] These sequences are from the opposite DNA strand of the sequence of the originating fragment given in the Sequence Listing.

[c] Sequences determined by our group.

Annex VI: Specific and ubiquitous primers for DNA amplification
(continues on next page)

SEQ ID NO	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO	Nucleotide position
Bacterial genus: ***Enterococcus***			
13	5'-TAC TGA CAA ACC ATT CAT GAT G	131-134[a,b]	319-340[c]
14[d]	5'-AAC TTC GTC ACC AAC GCG AAC	131-134[a,b]	410-430[c]
Bacterial genus: ***Neisseria***			
15	5'-CTG GCG CGG TAT GGT CGG TT	31[e]	21-40[f]
16[d]	5'-GCC GAC GTT GGA AGT GGT AAA G	31[e]	102-123[f]
Bacterial genus: ***Staphylococcus***			
17	5'-CCG TGT TGA ACG TGG TCA AAT CAA A	140-143[a,b]	391-415[g]
18[d]	5'-TRT GTG GTG TRA TWG WRC CAG GAG C	140-143[a,b]	584-608[g]
19	5'-ACA ACG TGG WCA AGT WTT AGC WGC T	140-143[a,b]	562-583[g]
20[d]	5'-ACC ATT TCW GTA CCT TCT GGT AAG T	140-143[a,b]	729-753[g]
Bacterial genus: ***Streptococcus***			
21	5'-GAA ATT GCA GGI AAA TTG ATT GA	32-36[e]	418-440[h]
22[d]	5'-TTA CGC ATG GCI TGA CTC ATC AT	32-36[e]	547-569[h]
Universal primers			
23	5'-ACI KKI ACI GGI GTI GAR ARG TT	118-146[a,b] 147-171[a,e]	493-515[i]
24[d]	5'-AYR TTI TCI CCI GGC ATI ACC AT	118-146[a,b] 147-171[a,e]	778-800[i]

[a] These sequences were aligned to derive the corresponding primer.

[b] *tuf* sequences determined by our group.

[c] The nucleotide positions refer to the *E. faecalis tuf* gene fragment (SEQ ID NO: 132).

[d] These sequences are from the opposite DNA strand of the sequence of the originating fragment given in the Sequence Listing.

[e] Sequences from databases.

[f] The nucleotide positions refer to the *N. meningitidis asd* gene fragment (SEQ ID NO: 31).

[g] The nucleotide positions refer to the *S. aureus tuf* gene fragment (SEQ ID NO: 140).

[h] The nucleotide positions refer to the *S. pneumoniae recA* gene (SEQ ID NO: 34).

[i] The nucleotide positions refer to the *E. coli tuf* gene fragment (SEQ ID NO: 154).

Annex VI: Specific and ubiquitous primers for DNA amplification

SEQ ID NO	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO	Nucleotide position
Antibiotic resistance gene: *bla*$_{tem}$			
37	5'-CTA TGT GGC GCG GTA TTA TC	-	-
38	5'-CGC AGT GTT ATC ACT CAT GG	-	-
39	5'-CTG AAT GAA GCC ATA CCA AA	-	-
40	5'-ATC AGC AAT AAA CCA GCC AG	-	-
Antibiotic resistance gene: *bla*$_{shv}$			
41	5'-TTA CCA TGA GCG ATA ACA GC	-	-
42	5'-CTC ATT CAG TTC CGT TTC CC	-	-
43	5'-CAG CTG CTG CAG TGG ATG GT	-	-
44	5'-CGC TCT GCT TTG TTA TTC GG	-	-
Antibiotic resistance gene: *bla*$_{rob}$			
45	5'-TAC GCC AAC ATC GTG GAA AG	-	-
46	5'-TTG AAT TTG GCT TCT TCG GT	-	-
47	5'-GGG ATA CAG AAA CGG GAC AT	-	-
48	5'-TAA ATC TTT TTC AGG CAG CG	-	-
Antibiotic resistance gene: *bla*$_{oxa}$			
49	5'-GAT GGT TTG AAG GGT TTA TTA TAA G	110[a]	686-710
50[b]	5'-AAT TTA GTG TGT TTA GAA TGG TGA T	110[a]	802-826
Antibiotic resistance gene: *blaZ*			
51	5'-ACT TCA ACA CCT GCT GCT TTC	111[a]	511-531
52[b]	5'-TGA CCA CTT TTA TCA GCA ACC	111[a]	663-683
Antibiotic resistance gene: *aadB*			
53	5'-GGC AAT AGT TGA AAT GCT CG	-	-
54	5'-CAG CTG TTA CAA CGG ACT GG	-	-
Antibiotic resistance gene: *aacC1*			
55	5'-TCT ATG ATC TCG CAG TCT CC	-	-
56	5'-ATC GTC ACC GTA ATC TGC TT	-	-

[a] Sequences from databases.

[b] These sequences are from the opposite DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex VI: Specific and ubiquitous primers for DNA amplification

SEQ ID NO	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO	Nucleotide position
Antibiotic resistance gene: ***aacC2***			
57	5'-CAT TCT CGA TTG CTT TGC TA	-	-
58	5'-CCG AAA TGC TTC TCA AGA TA	-	-
Antibiotic resistance gene: ***aacC3***			
59	5'-CTG GAT TAT GGC TAC GGA GT	-	-
60	5'-AGC AGT GTG ATG GTA TCC AG	-	-
Antibiotic resistance gene: ***aac6'-IIa***			
61	5'-GAC TCT TGA TGA AGT GCT GG	112[a]	123-142
62[b]	5'-CTG GTC TAT TCC TCG CAC TC	112[a]	284-303
63	5'-TAT GAG AAG GCA GGA TTC GT	112[a]	445-464
64[b]	5'-GCT TTC TCT CGA AGG CTT GT	112[a]	522-541
Antibiotic resistance gene: ***aacA4***			
65	5'-GAG TTG CTG TTC AAT GAT CC	-	-
66	5'-GTG TTT GAA CCA TGT ACA CG	-	-
Antibiotic resistance gene: ***aad(6')***			
173	5'-TCT TTA GCA GAA CAG GAT GAA	-	-
174	5'-GAA TAA TTC ATA TCC TCC G	-	-
Antibiotic resistance gene: ***vanA***			
67	5'-TGT AGA GGT CTA GCC CGT GT	-	-
68	5'-ACG GGG ATA ACG ACT GTA TG	-	-
69	5'-ATA AAG ATG ATA GGC CGG TG	-	-
70	5'-TGC TGT CAT ATT GTC TTG CC	-	-
Antibiotic resistance gene: ***vanB***			
71	5'-ATT ATC TTC GGC GGT TGC TC	116[a]	22-41
72[b]	5'-GAC TAT CGG CTT CCC ATT CC	116[a]	171-190
73	5'-CGA TAG AAG CAG CAG GAC AA	116[a]	575-594
74[b]	5'-CTG ATG GAT GCG GAA GAT AC	116[a]	713-732

[a] Sequences from databases.

[b] These sequences are from the opposite DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex VI: Specific and ubiquitous primers for DNA amplification

SEQ ID NO	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO	Nucleotide position
Antibiotic resistance gene: ***vanC***			
75	5'-GCC TTA TGT ATG AAC AAA TGG	117[a]	373-393
76[b]	5'-GTG ACT TTW GTG ATC CCT TTT GA	117[a]	541-563
Antibiotic resistance gene: ***msrA***			
77	5'-TCC AAT CAT TGC ACA AAA TC	-	-
78	5'-AAT TCC CTC TAT TTG GTG GT	-	-
79	5'-TCC CAA GCC AGT AAA GCT AA	-	-
80	5'-TGG TTT TTC AAC TTC TTC CA	-	-
Antibiotic resistance gene: ***satA***			
81	5'-TCA TAG AAT GGA TGG CTC AA	-	-
82	5'-AGC TAC TAT TGC ACC ATC CC	-	-
Antibiotic resistance gene: ***aac(6')-aph(2")***			
83	5'-CAA TAA GGG CAT ACC AAA AAT C	-	-
84	5'-CCT TAA CAT TTG TGG CAT TAT C	-	-
85	5'-TTG GGA AGA TGA AGT TTT TAG A	-	-
86	5'-CCT TTA CTC CAA TAA TTT GGC T	-	-
Antibiotic resistance gene: ***vat***			
87	5'-TTT CAT CTA TTC AGG ATG GG	-	-
88	5'-GGA GCA ACA TTC TTT GTG AC	-	-
Antibiotic resistance gene: ***vga***			
89	5'-TGT GCC TGA AGA AGG TAT TG	-	-
90	5'-CGT GTT ACT TCA CCA CCA CT	-	-
Antibiotic resistance gene: ***ermA***			
91	5'-TAT CTT ATC GTT GAG AAG GGA TT	113[a]	370-392
92[b]	5'-CTA CAC TTG GCT TAG GAT GAA A	113[a]	487-508

[a] Sequences from databases.

[b] These sequences are from the opposite DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex VI: Specific and ubiquitous primers for DNA amplification

SEQ ID NO	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO	Nucleotide position
Antibiotic resistance gene: *ermB*			
93	5'-CTA TCT GAT TGT TGA AGA AGG ATT	114[a]	366-389
94[b]	5'-GTT TAC TCT TGG TTT AGG ATG AAA	114[a]	484-507
Antibiotic resistance gene: *ermC*			
95	5'-CTT GTT GAT CAC GAT AAT TTC C	115[a]	214-235
96[b]	5'-ATC TTT TAG CAA ACC CGT ATT C	115[a]	382-403
Antibiotic resistance gene: *mecA*			
97	5'-AAC AGG TGA ATT ATT AGC ACT TGT AAG	-	-
98	5'-ATT GCT GTT AAT ATT TTT TGA GTT GAA	-	-
Antibiotic resistance gene: *int*			
99	5'-GTG ATC GAA ATC CAG ATC C	-	-
100	5'-ATC CTC GGT TTT CTG GAA G	-	-
101	5'-CTG GTC ATA CAT GTG ATG G	-	-
102	5'-GAT GTT ACC CGA GAG CTT G	-	-
Antibiotic resistance gene: *sul*			
103	5'-TTA AGC GTG CAT AAT AAG CC	-	-
104	5'-TTG CGA TTA CTT CGC CAA CT	-	-
105	5'-TTT ACT AAG CTT GCC CCT TC	-	-
106	5'-AAA AGG CAG CAA TTA TGA GC	-	-

[a] Sequences from databases.

[b] These sequences are from the opposite DNA strand of the sequence of the originating fragment given in the Sequence Listing.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) NAME: INFECTIO DIAGNOSTIC (I.D.I.) INC.
(B) STREET: 2050, BOULEVARD RENE LEVESQUE OUEST, 4E ETAGE
(C) CITY: STE-FOY
(D) STATE: QUEBEC
(E) COUNTRY: CANADA
(F) POSTAL CODE (ZIP): G1V 2K8
(G) TELEPHONE: (418) 681-4343
(H) TELEFAX: (418) 681-5254

(A) NAME: BERGERON, MICHEL G.
(B) STREET: 2069 RUE BRULARD
(C) CITY: SILLERY
(D) STATE: QUEBEC
(E) COUNTRY: CANADA
(F) POSTAL CODE (ZIP): G1T 1G2

(A) NAME: PICARD, FRANCOIS J.
(B) STREET: 1245, RUE DE LA SAPINIERE
(C) CITY: CAP-ROUGE
(D) STATE: QUEBEC
(E) COUNTRY: CANADA
(F) POSTAL CODE (ZIP): G1Y 1A1

(A) NAME: OUELLETTE, MARC
(B) STREET: 1035 DE PLOERMEL
(C) CITY: SILLERY
(D) STATE: QUEBEC
(E) COUNTRY: CANADA
(F) POSTAL CODE (ZIP): G1S 3S1

(A) NAME: ROY, PAUL H.
(B) STREET: 28, RUE CHARLES GARNIER
(C) CITY: LORETTEVILLE
(D) STATE: QUEBEC
(E) COUNTRY: CANADA
(F) POSTAL CODE (ZIP): G2A 3S1

(ii) TITLE OF INVENTION: SPECIES-SPECIFIC, GENIUS-SPECIFIC AND UNIVERSAL DNA PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL AND FUNGAL PATHOGENS AND ASSOCIATED ANTIBIOTIC RESISTANCE GENES ...

(iii) NUMBER OF SEQUENCES: 174

(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/743,637
(B) FILING DATE: 04-NOV-1996

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Enterococcus faecium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TGCTTTAGCA ACAGCCTATC AG 22

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Enterococcus faecium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TAAACTTCTT CCGGCACTTC G 21

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Listeria monocytogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TGCGGCTATA AATGAAGAGG C 21

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Listeria monocytogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

ATCCGATGAT GCTATGGCTT T 21

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Neisseria meningitidis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CCAGCGGTAT TGTTTGGTGG T 21

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Neisseria meningitidis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CAGGCGGCCT TTAATAATTT C 21

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Staphylococcus saprophyticus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AGATCGAATT CCACATGAAG GTTATTATGA 30

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Staphylococcus saprophyticus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

TCGCTTCTCC CTCAACAATC AAACTATCCT 30

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus agalactiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TTTCACCAGC TGTATTAGAA GTA 23

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus agalactiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTTCCCTGAA CATTATCTTT GAT 23

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Candida albicans*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CAAGAAGGTT GGTTACAACC CAAAGA 26

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Candida albicans*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AGGTCTTACC AGTAACTTTA CCGGAT 26

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TACTGACAAA CCATTCATGA TG 22

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AACTTCGTCA CCAACGCGAA C 21

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CTGGCGCGGT ATGGTCGGTT 20

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GCCGACGTTG GAAGTGGTAA AG 22

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CCGTGTTGAA CGTGGTCAAA TCAAA 25

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

TRTGTGGTGT RATWGWRCCA GGAGC 25

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ACAACGTGGW CAAGTWTTAG CWGCT 25

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

ACCATTTCWG TACCTTCTGG TAAGT 25

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GAAATTGCAG GNAAATTGAT TGA 23

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

TTACGCATGG CNTGACTCAT CAT 23

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:3
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:9
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:15
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

ACNKKNACNG GNGTNGARAT GTT 23

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:9
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:18
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

AYRTTNTCNC CNGGCATNAC CAT 23

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

TCGCTTCTCC 10

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 600 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Enterococcus faecium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

TTCTTAGAGA CATTGAATAT GCCTTATGTC GGCGCAGGCG TATTGACCAG TGCATGTGCC 60

ATGGATAAAA TCATGACCAA GTATATTTTA CAAGCTGCTG GTGTGCCGCA AGTTCCTTAT 120

GTACCAGTAC TTAAGAATCA ATGGAAAGAA AATCCTAAAA AAGTATTTGA TCAATGTGAA 180

GGTTCTTTGC TTTATCCGAT GTTTGTCAAA CCTGCGAATA TGGGTTCTAG TGTCGGCATT 240

ACAAAGGCAG AAAACCGAGA AGAGCTGCAA AATGCTTTAG CAACAGCCTA TCAGTATGAT 300

TCTCGAGCAA TCGTTGAACA AGGAATTGAA GCGCGCGAAA TCGAAGTTGC TGTATTAGGA 360

AATGAAGATG TTCGGACGAC TTTGCCTGGC GAAGTCGTAA AAGACGTAGC ATTCTATGAT 420

TATGAAGCCA AATATATCAA TAATAAAATC GAAATGCAGA TTCCAGCCGA AGTGCCGGAA 480

GAAGTTTATC AAAAAGCGCA AGAGTACGCG AAGTTAGCTT ACACGATGTT AGGTGGAAGC 540

GGATTGAGCC GGTGCGATTT CTTTTTGACA AATAAAAATG AATTATTCCT GAATGAATTA 600

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1920 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Listeria monocytogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GTGGGATTAA ACAGATTTAT GCGTGCGATG ATGGTGGTTT TCATTACTGC CAATTGCATT 60

ACGATTAACC CCGACATAAT ATTTGCAGCG ACAGATAGCG AAGATTCTAG TCTAAACACA 120

GATGAATGGG AAGAAGAAAA AACAGAAGAG CAACCAAGCG AGGTAAATAC GGGACCAAGA 180

TACGAAACTG CACGTGAAGT AAGTTCACGT GATATTAAAG AACTAGAAAA ATCGAATAAA 240

GTGAGAAATA CGAACAAAGC AGACCTAATA GCAATGTTGA AAGAAAAAGC AGAAAAAGGT 300

CCAAATATCA ATAATAACAA CAGTGAACAA ACTGAGAATG CGGCTATAAA TGAAGAGGCT 360

TCAGGAGCCG ACCGACCAGC TATACAAGTG GAGCGTCGTC ATCCAGGATT GCCATCGGAT 420

AGCGCAGCGG AAATTAAAAA AAGAAGGAAA GCCATAGCAT CATCGGATAG TGAGCTTGAA 480

AGCCTTACTT ATCCGGATAA ACCAACAAAA GTAAATAAGA AAAAAGTGGC GAAAGAGTCA 540

GTTGCGGATG CTTCTGAAAG TGACTTAGAT TCTAGCATGC AGTCAGCAGA TGAGTCTTCA 600

CCACAACCTT TAAAAGCAAA CCAACAACCA TTTTTCCCTA AAGTATTTAA AAAAATAAAA 660

GATGCGGGGA AATGGGTACG TGATAAAATC GACGAAAATC CTGAAGTAAA GAAAGCGATT 720

GTTGATAAAA GTGCAGGGTT AATTGACCAA TTATTAACCA AAAAGAAAAG TGAAGAGGTA 780

AATGCTTCGG ACTTCCCGCC ACCACCTACG GATGAAGAGT TAAGACTTGC TTTGCCAGAG 840

ACACCAATGC TTCTTGGTTT TAATGCTCCT GCTACATCAG AACCGAGCTC ATTCGAATTT 900

CCACCACCAC CTACGGATGA AGAGTTAAGA CTTGCTTTGC CAGAGACGCC AATGCTTCTT 960

GGTTTTAATG CTCCTGCTAC ATCGGAACCG AGCTCGTTCG AATTTCCACC GCCTCCAACA 1020

GAAGATGAAC TAGAAATCAT CCGGGAAACA GCATCCTCGC TAGATTCTAG TTTTACAAGA 1080

GGGGATTTAG CTAGTTTGAG AAATGCTATT AATCGCCATA GTCAAAATTT CTCTGATTTC 1140

CCACCAATCC CAACAGAAGA AGAGTTGAAC GGGAGAGGCG GTAGACCAAC ATCTGAAGAA 1200

TTTAGTTCGC TGAATAGTGG TGATTTTACA GATGACGAAA ACAGCGAGAC AACAGAAGAA 1260

GAAATTGATC GCCTAGCTGA TTTAAGAGAT AGAGGAACAG GAAAACACTC AAGAAATGCG 1320

GGTTTTTTAC CATTAAATCC GTTTGCTAGC AGCCCGGTTC CTTCGTTAAG TCCAAAGGTA 1380

TCGAAAATAA GCGACCGGGC TCTGATAAGT GACATAACTA AAAAAACGCC ATTTAAGAAT 1440

CCATCACAGC CATTAAATGT GTTTAATAAA AAAACTACAA CGAAAACAGT GACTAAAAAA 1500

CCAACCCCTG TAAAGACCGC ACCAAAGCTA GCAGAACTTC CTGCCACAAA ACCACAAGAA 1560

ACCGTACTTA GGGAAAATAA AACACCCTTT ATAGAAAAAC AAGCAGAAAC AAACAAGCAG 1620

TCAATTAATA TGCCGAGCCT ACCAGTAATC CAAAAAGAAG CTACAGAGAG CGATAAAGAG 1680

GAAATGAAAC CACAAACCGA GGAAAAAATG GTAGAGGAAA GCGAATCAGC TAATAACGCA 1740

AACGGAAAAA ATCGTTCTGC TGGCATTGAA GAAGGAAAAC TAATTGCTAA AAGTGCAGAA 1800

GACGAAAAAG CGAAGGAAGA ACCAGGGAAC CATACGACGT TAATTCTTGC AATGTTAGCT 1860

ATTGGCGTGT TCTCTTTAGG GGCGTTTATC AAAATTATTC AATTAAGAAA AAATAATTAA 1920

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 415 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Neisseria meningitidis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

TACCGGTACG CTAAATATTG GTGATGTATT GGATATTATG ATTTGGGAAG CGCCGCCAGC 60

GGTATTGTTT GGTGGTGGCC TTTCTTCGAT GGGCTCGGGT AGTGCGCAAC AAACCAAGTT 120

GCCGGAGCAA CTGGTGACGG CACGTGGTAC GGTTTCTGTG CCGTTTGTTG GCGATATTTC 180

GGTGGTCGGT AAAACGCCTG GTCAGGTTCA GGAAATTATT AAAGGCCGCC TGAAAAAAAT 240

GGCCAATCAG CCGCAAGTGA TGGTGCGCTT GGTGCAGAAT AATGCGGCAA ATGTATCGGT 300

GATTCGCGCA GGCAATAGTG TGCGTATGCC GTTGACGGCA GCCGGTGAGC GTGTGTTGGA 360

TGCGGTGGCT GCGGTAGGTG GTTCAACGGC AAATGTGCAG GATACGAATG TGCAG 415

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 438 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Staphylococcus saprophyticus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

TCGCTTCTCC AGAAGAAATT TTAGAAACAT ATCTAGAAAA TCCCAAATTA GATAAACCGT 60

TTATATTATG TGAATACGCA CATGCAATGG GAAATTCACC AGGAGATCTT AATGCATATC 120

AAACATTAAT TGAAAAATAT GATAGTTTTA TTGGCGGTTT TGTTTGGGAA TGGTGTGATC 180

ATAGCATTCA GGTTGGGATA AAGGAAGGTA AACCAATTTT TAGATATGGT GGAGATTTTG 240

GTGAGGCCTT ACATGACGGT AATTTTTGTG TTGATGGTAT TGTTTCGCCA GATCGAATTC 300

CACATGAAGG TTATTATGAG TTTAAACATG AACATAGACC TTTGAGATTG GTTAACGAAG 360

AGGATTATCG GTTTACATTG AAGAATCAAT TTGATTTTAC AAATGCGGAG GATAGTTTGA 420

TTGTTGAGGG AGAAGCGA 438

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 768 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus agalactiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

ATGAACGTTA CACATATGAT GTATCTATCT GGAACTCTAG TGGCTGGTGC ATTGTTATTT 60

TCACCAGCTG TATTAGAAGT ACATGCTGAT CAAGTGACAA CTCCACAAGT GGTAAATCAT 120

GTAAATAGTA ATAATCAAGC CCAGCAAATG GCTCAAAAGC TTGATCAAGA TAGCATTCAG 180

TTGAGAAATA TCAAAGATAA TGTTCAGGGA ACAGATTATG AAAAACCGGT TAATGAGGCT 240

ATTACTAGCG TGGAAAAATT AAAGACTTCA TTGCGTGCCA ACCCTGAGAC AGTTTATGAT 300

TTGAATTCTA TTGGTAGTCG TGTAGAAGCC TTAACAGATG TGATTGAAGC AATCACTTTT 360

TCAACTCAAC ATTTAACAAA TAAGGTTAGT CAAGCAAATA TTGATATGGG ATTTGGGATA 420

ACTAAGCTAG TTATTCGCAT TTTAGATCCA TTTGCTTCAG TTGATTCAAT TAAAGCTCAA 480

GTTAACGATG TAAAGGCATT AGAACAAAAA GTTTTAACTT ATCCTGATTT AAAACCAACT 540

GATAGAGCTA CCATCTATAC AAAATCAAAA CTTGATAAGG AAATCTGGAA TACACGCTTT 600

ACTAGAGATA AAAAAGTACT TAACGTCAAA GAATTTAAAG TTTACAATAC TTTAAATAAA 660

GCAATCACAC ATGCTGTTGG AGTTCAGTTG AATCCAAATG TTACGGTACA ACAAGTTGAT 720

CAAGAGATTG TAACATTACA AGCAGCACTT CAAACAGCAT TAAAATAA 768

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 421 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Neisseria meningitidis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

ATGAAAGTAG GTTTCGTCGG CTGGCGCGGT ATGGTCGGTT CGGTTTTGAT GCAGCGTATG 60

AAAGAAGAAA ACGACTTCGC CCACATTCCC GAAGCGTTTT TCTTTACCAC TTCCAACGTC 120

GGCGGCGCAC GCCCTGATTT CGGTCAGGCG GCTAAAACAT TATTGGACGC GAACAACGTT 180

GCCGAGCTGG CAAAAATGGA CATCATCGTT ACCTGCCAAG GCGGCGACTA CACCAAATCC 240

GTCTTCCAAG CCCTGCGCGA CAGCGGCTGG AACGGCTACT GGATTGACGC GGCATCCTCG 300

CTGCGTATGA AAGACGACGC GATTATCGTC CTCGACCCCG TCAACCGCAA CGTCATCGAC 360

AACGGCCTCA AAAACGGCGT GAAAAACTAC ATCGGCGGCA ACTGTACCGT TCCCTGATG 420

C 421

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 213 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus gordonii*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

TTCATAGACG CTGAGCACGC TTTGGATCCA TCTTACGCGG CTGCTCTAGG TGTAAATATT 60

GATGAGCTGT TGCTATCTCA ACCAGATTCT GGTGAGCAAG GTTTAGAAAT TGCAGGAAAA 120

TTGATTGACT CTGGGGCAGT TGATTTAGTT GTCATCGACT CTGTTGCAGC TCTTGTACCA 180

CGTGCGGAAA TCGATGGAGA TATCGGTGAT AGC 213

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 692 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus mutans*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

GGGCCGGAAT CTTCTGGTAA GACAACTGTC GCTCTTCATG CTGCTGCTCA GGCGCAAAAA 60

GATGGCGGTA TTGCCGCTTT CATTGATGCA GAACATGCCC TTGATCCAGC CTATGCTGCT 120

GCTCTTGGCG TTAATATTGA TGAGCTTTTG CTTTCACAAC CAGATTCAGG AGAACAGGGT 180

CTTGAAATTG CAGGGAAATT GATTGATTCT GGCGCTGTTG ATTTAGTTGT TGTTGACTCA 240

GTGGCAGCTT TAGTACCACG TGCGGAGATT GACGGAGATA TTGGTAATAG TCATGTTGGC 300

TTACAAGCAC GCATGATGAG TCAAGCGATG CGTAAATTAT CAGCTTCAAT CAATAAAACA 360

AAAACCATTG CTATTTTTAT TAATCAATTG CGGGAAAAAG TTGGTATTAT GTTTGGTAAT 420

CCAGAAACAA CCCCTGGCGG GCGTGCCTTG AAGTTTTATT CTTCTGTGCG TCTTGATGTC 480

CGCGGCAATA CTCAAATTAA AGGAACCGGG GAACAAAAAG ACAGCAATAT TGGTAAAGAG 540

ACCAAAATTA AAGTTGTTAA AAATAAAGTT GCTCCACCAT TTAAGGAAGC TTTTGTAGAA 600

ATTATATATG GTGAAGGCAT TTCTCGTACA GGTGAATTAG TTAAGATTGC CAGTGATTTG 660

GGAATTATCC AAAAAGCTGG AGCTTGGTAC TC 692

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1204 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus pneumoniae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

ATGGCGAAAA AACCAAAAAA ATTAGAAGAA ATTTCAAAAA AATTTGGGGC AGAACGTGAA 60

AAGGCCTTGA ATGACGCTCT TAAATTGATT GAGAAAGACT TTGGTAAAGG ATCAATCATG 120

CGTTTGGGTG AACGTGCGGA GCAAAAGGTG CAAGTGATGA GCTCAGGTTC TTTAGCTCTT 180

GACATTGCCC TTGGCTCAGG TGGTTATCCT AAGGGACGTA TCATCGAAAT CTATGGCCCA 240

GAGTCATCTG GTAAGACAAC GGTTGCCCTT CATGCAGTTG CACAAGCGCA AAAAGAAGGT 300

GGGATTGCTG CCTTTATCGA TGCGGAACAT GCCCTTGATC CAGCTTATGC TGCGGCCCTT 360

GGTGTCAATA TTGACGAATT GCTCTTGTCT CAACCAGACT CAGGAGAGCA AGGTCTTGAG 420

ATTGCGGGAA AATTGATTGA CTCAGGTGCA GTTGATCTTG TCGTAGTCGA CTCAGTTGCT 480

GCCCTTGTTC CTCGTGCGGA AATTGATGGA GATATCGGAG ATAGCCATGT TGGTTTGCAG 540

GCTCGTATGA TGAGCCAGGC CATGCGTAAA CTTGGCGCCT CTATCAATAA AACCAAAACA 600

ATTGCCATTT TTATCAACCA ATTGCGTGAA AAAGTTGGAG TGATGTTTGG AAATCCAGAA 660

ACAACACCGG GCGGACGTGC TTTGAAATTC TATGCTTCAG TCCGCTTGGA TGTTCGTGGT 720

AATACACAAA TTAAGGGAAC TGGTGATCAA AAAGAAACCA ATGTCGGTAA AGAAACTAAG 780

ATTAAGGTTG TAAAAAATAA GGTAGCTCCA CCGTTTAAGG AAGCCGTAGT TGAAATTATG 840

TACGGAGAAG GAATTTCTAA GACTGGTGAG CTTTTGAAGA TTGCAAGCGA TTTGGATATT 900

ATCAAAAAAG CAGGGGCTTG GTATTCTTAC AAAGATGAAA AAATTGGGCA AGGTTCTGAG 960

AATGCTAAGA AATACTTGGC AGAGCACCCA GAAATCTTTG ATGAAATTGA TAAGCAAGTC 1020

CGTTCTAAAT TTGGCTTGAT TGATGGAGAA GAAGTTTCAG AACAAGATAC TGAAAACAAA 1080

AAAGATGAGC CAAAGAAAGA AGAAGCAGTG AATGAAGAAG TTCCGCTTGA CTTAGGCGAT 1140

GAACTTGAAA TCGAAATTGA AGAATAAGCT GTTAAAGCAG TGGAGAAATC CGCTACTTTT 1200

TCGA 1204

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 981 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus pyogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

ATGCGTTCAG GAAGTCTAGC TCTTGATATT GCTTGGATAG CTGGTGGTTA TCCTAAAGGA 60

CGTATCATCG AAATCTATGG TCCAGAGTCT TCCGGTAAAA CGACTGTGGC TTTACATGCT 120

GTAGCACAAG CTCAAAAAGA AGGTGGAATC GCAGCCTTTA TCGATGCCGA GCATGCGCTT 180

GATCCAGCTT ATGCTGCTGC GCTTGGGGTT AATATTGATG AACTTCTCTT GTCTCAACCA 240

GATTCTGGAG AACAAGGACT TGAAATTGCA GGTAAATTGA TTGATTCTGG TGCGGTTGAC 300

CTGGTTGTTG TCGATTCAGT AGCAGCTTTA GTGCCACGTG CTGAAATTGA TGGTGATATT 360

GGCGATAGCC ATGTCGGATT GCAAGCACGT ATGATGAGTC AGGCCATGCG TAAATTATCA 420

GCTTCTATTA ATAAAACAAA AACTATCGCA ATCTTTATCA ACCAATTGCG TGAAAAAGTT 480

GGTGTGATGT TTGGAAATCC TGAAACAACA CCAGGTGGTC GAGCTTTGAA ATTCTATGCT 540

TCTGTTCGGC TGGATGTGCG TGGAAACAAC CAAATTAAAG GAACTGGTGA CCAAAAGATA 600

GCCAGCATTG GTAAGGAGAC CAAAATCAAG GTTGTTAAAA ACAAGGTCGC TCCGCCATTT 660

AAGGTAGCAG AAGTTGAAAT CATGTATGGG GAAGGTATTT CTCGTACAGG GGAGCTTGTG 720

AAAATTGCTT CTGATTTGGA CATTATCCAA AAAGCAGGTG CTTGGTTCTC TTATAATGGT 780

GAGAAGATTG GCCAAGGTTC TGAAAATGCT AAGCGTTATT TGGCCGATCA TCCACAATTG 840

TTTGATGAAA TCGACCGTAA AGTACGTGTT AAATTTGGTT TGCTTGAAGA AAGCGAAGAA 900

GAATCTGCTA TGGCAGTAGC ATCAGAAGAA ACCGATGATC TTGCTTTAGA TTTAGATAAT 960

GGTATTGAAA TTGAAGATTA A 981

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 312 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus salivarius*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GCGTATGCAC GAGCTCTAGG TGTTAATATC GATGAGCTTC TTTTGTCGCA GCCTGATTCT 60

GGTGAGCAAG GTCTCGAAAT TGCAGGTAAG CTGATTGACT CTGGTGCAGT GGATTTAGTT 120

GTTGTTGACT CAGTTGCGGC CTTCGTACCA CGTGCAGAAA TTGATGGAGA TAGTGGTGAC 180

AGTCATGTAG GACTTCAAGC GCGTATGATG AGTCAAGCCA TGCGTAAACT TCTGCATCT 240

ATTAATAAAA CAAAAACGAT TGCTATCTTT ATTAACCAGT TGCGTGAAAA AGTTGGTATC 300

ATGTTTGGTA AC 312

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

CTATGTGGCG CGGTATTATC 20

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

CGCAGTGTTA TCACTCATGG 20

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

CTGAATGAAG CCATACCAAA 20

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

ATCAGCAATA AACCAGCCAG 20

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

TTACCATGAG CGATAACAGC 20

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

CTCATTCAGT TCCGTTTCCC 20

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

CAGCTGCTGC AGTGGATGGT 20

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

CGCTCTGCTT TGTTATTCGG 20

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

TACGCCAACA TCGTGGAAAG 20

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

TTGAATTTGG CTTCTTCGGT 20

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

GGGATACAGA AACGGGACAT 20

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

TAAATCTTTT TCAGGCAGCG 20

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

GATGGTTTGA AGGGTTTATT ATAAG 25

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

AATTTAGTGT GTTTAGAATG GTGAT 25

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

ACTTCAACAC CTGCTGCTTT C 21

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

TGACCACTTT TATCAGCAAC C 21

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

GGCAATAGTT GAAATGCTCG 20

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

CAGCTGTTAC AACGGACTGG 20

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

TCTATGATCT CGCAGTCTCC 20

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

ATCGTCACCG TAATCTGCTT 20

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

CATTCTCGAT TGCTTTGCTA 20

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

CCGAAATGCT TCTCAAGATA 20

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

CTGGATTATG GCTACGGAGT 20

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

AGCAGTGTGA TGGTATCCAG 20

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

GACTCTTGAT GAAGTGCTGG 20

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

CTGGTCTATT CCTCGCACTC 20

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

TATGAGAAGG CAGGATTCGT 20

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

GCTTTCTCTC GAAGGCTTGT 20

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

GAGTTGCTGT TCAATGATCC 20

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

GTGTTTGAAC CATGTACACG 20

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

TGTAGAGGTC TAGCCCGTGT 20

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

ACGGGGATAA CGACTGTATG 20

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

ATAAAGATGA TAGGCCGGTG 20

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

TGCTGTCATA TTGTCTTGCC 20

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

ATTATCTTCG GCGGTTGCTC 20

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

GACTATCGGC TTCCCATTCC 20

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

CGATAGAAGC AGCAGGACAA 20

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

CTGATGGATG CGGAAGATAC 20

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

GCCTTATGTA TGAACAAATG G 21

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

GTGACTTTWG TGATCCCTTT TGA 23

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

TCCAATCATT GCACAAAATC 20

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

AATTCCCTCT ATTTGGTGGT 20

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

TCCCAAGCCA GTAAAGCTAA 20

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

TGGTTTTTCA ACTTCTTCCA 20

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

TCATAGAATG GATGGCTCAA 20

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

AGCTACTATT GCACCATCCC 20

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

CAATAAGGGC ATACCAAAAA TC 22

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

CCTTAACATT TGTGGCATTA TC 22

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

TTGGGAAGAT GAAGTTTTTA GA 22

(2) INFORMATION FOR SEQ ID NO: 86:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

CCTTTACTCC AATAATTTGG CT 22

(2) INFORMATION FOR SEQ ID NO: 87:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

TTTCATCTAT TCAGGATGGG 20

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

GGAGCAACAT TCTTTGTGAC 20

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

TGTGCCTGAA GAAGGTATTG 20

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

CGTGTTACTT CACCACCACT 20

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

TATCTTATCG TTGAGAAGGG ATT 23

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

CTACACTTGG CTTAGGATGA AA 22

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

CTATCTGATT GTTGAAGAAG GATT 24

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

GTTTACTCTT GGTTTAGGAT GAAA 24

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

CTTGTTGATC ACGATAATTT CC 22

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

ATCTTTTAGC AAACCCGTAT TC 22

(2) INFORMATION FOR SEQ ID NO: 97:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

AACAGGTGAA TTATTAGCAC TTGTAAG 27

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

ATTGCTGTTA ATATTTTTTG AGTTGAA 27

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

GTGATCGAAA TCCAGATCC 19

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

ATCCTCGGTT TTCTGGAAG 19

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

CTGGTCATAC ATGTGATGG 19

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

GATGTTACCC GAGAGCTTG 19

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

TTAAGCGTGC ATAATAAGCC 20

(2) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

TTGCGATTAC TTCGCCAACT 20

(2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

TTTACTAAGC TTGCCCCTTC 20

(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

AAAAGGCAGC AATTATGAGC 20

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:9
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:15
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:18
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:21
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

AAYATGATNA CNGGNGCNGC NCARATGGA 29

(2) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:3
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:9
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

CCNACNGTNC KNCCRCCYTC RCG 23

(2) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:15
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature

(B) LOCATION:18
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

CARYTNATHG TNGCNGTNAA YAARATGGA 29

(2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 831 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:

ATGAAAAACA CAATACATAT CAACTTCGCT ATTTTTTTAA TAATTGCAAA TATTATCTAC 60

AGCAGCGCCA GTGCATCAAC AGATATCTCT ACTGTTGCAT CTCCATTATT TGAAGGAACT 120

GAAGGTTGTT TTTTACTTTA CGATGCATCC ACAAACGCTG AAATTGCTCA ATTCAATAAA 180

GCAAAGTGTG CAACGCAAAT GGCACCAGAT TCAACTTTCA AGATCGCATT ATCACTTATG 240

GCATTTGATG CGGAAATAAT AGATCAGAAA ACCATATTCA AATGGGATAA AACCCCCAAA 300

GGAATGGAGA TCTGGAACAG CAATCATACA CCAAAGACGT GGATGCAATT TTCTGTTGTT 360

TGGGTTTCGC AAGAAATAAC CCAAAAAATT AGATTAAATA AAATCAAGAA TTATCTCAAA 420

GATTTTGATT ATGGAAATCA AGACTTCTCT GGAGATAAAG AAAGAAACAA CGGATTAACA 480

GAAGCATGGC TCGAAAGTAG CTTAAAAATT TCACCAGAAG AACAAATTCA ATTCCTGCGT 540

AAAATTATTA ATCACAATCT CCCAGTTAAA AACTCAGCCA TAGAAAACAC CATAGAGAAC 600

ATGTATCTAC AAGATCTGGA TAATAGTACA AAACTGTATG GGAAAACTGG TGCAGGATTC 660

ACAGCAAATA GAACCTTACA AAACGGATGG TTTGAAGGGT TTATTATAAG CAAATCAGGA 720

CATAAATATG TTTTTGTGTC CGCACTTACA GGAAACTTGG GGTCGAATTT AACATCAAGC 780

ATAAAAGCCA AGAAAAATGC GATCACCATT CTAAACACAC TAAATTTATA A 831

(2) INFORMATION FOR SEQ ID NO: 111:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 846 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:

TTGAAAAAGT TAATATTTTT AATTGTAATT GCTTTAGTTT TAAGTGCATG TAATTCAAAC 60

AGTTCACATG CCAAAGAGTT AAATGATTTA GAAAAAAAAT ATAATGCTCA TATTGGTGTT 120

TATGCTTTAG ATACTAAAAG TGGTAAGGAA GTAAAATTTA ATTCAGATAA GAGATTTGCC 180

TATGCTTCAA CTTCAAAAGC GATAAATAGT GCTATTTTGT TAGAACAAGT ACCTTATAAT 240

AAGTTAAATA AAAAAGTACA TATTAACAAA GATGATATAG TTGCTTATTC TCCTATTTTA 300

GAAAAATATG TAGGAAAAGA TATCACTTTA AAAGCACTTA TTGAGGCTTC AATGACATAT 360

AGTGATAATA CAGCAAACAA TAAAATTATA AAAGAAATCG GTGGAATCAA AAAAGTTAAA 420

CAACGTCTAA AAGAACTAGG AGATAAAGTA ACAAATCCAG TTAGATATGA GATAGAATTA 480

AATTACTATT CACCAAAGAG CAAAAAAGAT ACTTCAACAC CTGCTGCTTT CGGTAAGACT 540

TTAAATAAAC TTATCGCAAA TGGAAAATTA AGCAAAGAAA ACAAAAAATT CTTACTTGAT 600

TTAATGTTAA ATAATAAAAG CGGAGATACT TTAATTAAAG ACGGTGTTCC AAAAGACTAT 660

AAGGTTGCTG ATAAAAGTGG TCAAGCAATA ACATATGCTT CTAGAAATGA TGTTGCTTTT 720

GTTTATCCTA AGGGCCAATC TGAACCTATT GTTTTAGTCA TTTTTACGAA TAAAGACAAT 780

AAAAGTGATA AGCCAAATGA TAAGTTGATA AGTGAAACCG CCAAGAGTGT AATGAAGGAA 840

TTTTAA 846

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 555 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

ATGTCCGCGA GCACCCCCCC CATAACTCTT CGCCTCATGA CCGAGCGCGA CCTGCCGATG 60

CTCCATGACT GGCTCAACCG GCCGCACATC GTTGAGTGGT GGGGTGGCGA CGAAGAGCGA 120

CCGACTCTTG ATGAAGTGCT GGAACACTAC CTGCCCAGAG CGATGGCGGA AGAGTCCGTA 180

ACACCGTACA TCGCAATGCT GGGCGAGGAA CCGATCGGCT ATGCTCAGTC GTACGTCGCG 240

CTCGGAAGCG GTGATGGCTG GTGGGAAGAT GAAACTGATC CAGGAGTGCG AGGAATAGAC 300

CAGTCTCTGG CTGACCCGAC ACAGTTGAAC AAAGGCCTAG GAACAAGGCT TGTCCGCGCT 360

CTCGTTGAAC TACTGTTCTC GGACCCCACC GTGACGAAGA TTCAGACCGA CCCGACTCCG 420

AACAACCATC GAGCCATACG CTGCTATGAG AAGGCAGGAT TCGTGCGGGA GAAGATCATC 480

ACCACGCCTG ACGGGCCGGC GGTTTACATG GTTCAAACAC GACAAGCCTT CGAGAGAAAG 540

CGCGGTGTTG CCTAA 555

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 732 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

ATGAACCAGA AAAACCCTAA AGACACGCAA AATTTTATTA CTTCTAAAAA GCATGTAAAA 60

GAAATATTGA ATCACACGAA TATCAGTAAA CAAGACAACG TAATAGAAAT CGGATCAGGA 120

AAAGGACATT TTACCAAAGA GCTAGTCAAA ATGAGTCGAT CAGTTACTGC TATAGAAATT 180

GATGGAGGCT TATGTCAAGT GACTAAAGAA GCGGTAAACC CCTCTGAGAA TATAAAAGTG 240

ATTCAAACGG ATATTCTAAA ATTTTCCTTC CCAAAACATA TAAACTATAA GATATATGGT 300

AATATTCCTT ATAACATCAG TACGGATATT GTCAAAAGAA TTACCTTTGA AAGTCAGGCT 360

AAATATAGCT ATCTTATCGT TGAGAAGGGA TTTGCGAAAA GATTGCAAAA TCTGCAACGA 420

GCTTTGGGTT TACTATTAAT GGTGGAGATG GATATAAAAA TGCTCAAAAA AGTACCACCA 480

CTATATTTTC ATCCTAAGCC AAGTGTAGAC TCTGTATTGA TTGTTCTTGA ACGACATCAA 540

CCATTGATTT CAAAGAAGGA CTACAAAAAG TATCGATCTT TTGTTTATAA GTGGGTAAAC 600

CGTGAATATC GTGTTCTTTT CACTAAAAAC CAATTCCGAC AGGCTTTGAA GCATGCAAAT 660

GTCACTAATA TTAATAAACT ATCGAAGGAA CAATTTCTTT CTATTTTCAA TAGTTACAAA 720

TTGTTTCACT AA 732

(2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 738 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:

ATGAACAAAA ATATAAAATA TTCTCAAAAC TTTTTAACGA GTGAAAAAGT ACTCAACCAA 60

ATAATAAAAC AATTGAATTT AAAAGAAACC GATACCGTTT ACGAAATTGG AACAGGTAAA 120

GGGCATTTAA CGACGAAACT GGCTAAAATA AGTAAACAGG TAACGTCTAT TGAATTAGAC 180

AGTCATCTAT TCAACTTATC GTCAGAAAAA TTAAAATCGA ATACTCGTGT CACTTTAATT 240

CACCAAGATA TTCTACAGTT TCAATTCCCT AACAAACAGA GGTATAAAAT TGTTGGGAAT 300

ATTCCTTACC ATTTAAGCAC ACAAATTATT AAAAAAGTGG TTTTTGAAAG CCATGCGTCT 360

GACATCTATC TGATTGTTGA AGAAGGATTC TACAAGCGTA CCTTGGATAT TCACCGAACA 420

CTAGGGTTGC TCTTGCACAC TCAAGTCTCG ATTCAGCAAT TGCTTAAGCT GCCAGCGGAA 480

TGCTTTCATC CTAAACCAAG AGTAAACAGT GTCTTAATAA AACTTACCCG CCATACCACA 540

GATGTTCCAG ATAAATATTG GAAGCTATAT ACGTACTTTG TTTCAAAATG GGTCAATCGA 600

GAATATCGTC AACTGTTTAC TAAAAATCAG TTTCATCAAG CAATGAAACA CGCCAAAGTA 660

AACAATTTAA GTACCGTTAC TTATGAGCAA GTATTGTCTA TTTTTAATAG TTATCTATTA 720

TTTAACGGGA GGAAATAA 738

(2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 735 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:

ATGAACGAGA AAAATATAAA ACACAGTCAA AACTTTATTA CTTCAAAACA TAATATAGAT 60

AAAATAATGA CAAATATAAG ATTAAATGAA CATGATAATA TCTTTGAAAT CGGCTCAGGA 120

AAAGGGCATT TTACCCTTGA ATTAGTACAG AGGTGTAATT TCGTAACTGC CATTGAAATA 180

GACCATAAAT TATGCAAAAC TACAGAAAAT AAACTTGTTG ATCACGATAA TTTCCAAGTT 240

TTAAACAAGG ATATATTGCA GTTTAAATTT CCTAAAAACC AATCCTATAA AATATTTGGT 300

AATATACCTT ATAACATAAG TACGGATATA ATACGCAAAA TTGTTTTTGA TAGTATAGCT 360

GATGAGATTT ATTTAATCGT GGAATACGGG TTTGCTAAAA GATTATTAAA TACAAAACGC 420

TCATTGGCAT TATTTTTAAT GGCAGAAGTT GATATTTCTA TATTAAGTAT GGTTCCAAGA 480

GAATATTTTC ATCCTAAACC TAGAGTGAAT AGCTCACTTA TCAGATTAAA TAGAAAAAAA 540

TCAAGAATAT CACACAAAGA TAAACAGAAG TATAATTATT TCGTTATGAA ATGGGTTAAC 600

AAAGAATACA AGAAAATATT TACAAAAAAT CAATTTAACA ATTCCTTAAA ACATGCAGGA 660

ATTGACGATT TAAACAATAT TAGCTTTGAA CAATTCTTAT CTCTTTTCAA TAGCTATAAA 720

TTATTTAATA AGTAA 735

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1029 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

ATGAATAAAA TAAAAGTCGC AATTATCTTC GGCGGTTGCT CGGAGGAACA TGATGTGTCG 60

GTAAAATCCG CAATAGAAAT TGCTGCGAAC ATTAATACTG AAAAATTCGA TCCGCACTAC 120

ATCGGAATTA CAAAAAACGG CGTATGGAAG CTATGCAAGA AGCCATGTAC GGAATGGGAA 180

GCCGATAGTC TCCCCGCCAT ATTCTCCCCG GATAGGAAAA CGCATGGTCT GCTTGTCATG 240

AAAGAAAGAG AATACGAAAC TCGGCGTATT GACGTGGCTT TCCCGGTTTT GCATGGCAAA 300

TGCGGGGAGG ATGGTGCGAT ACAGGGTCTG TTTGAATTGT CTGGTATCCC CTATGTAGGC 360

TGCGATATTC AAAGCTCCGC AGCTTGCATG GACAAATCAC TGGCCTACAT TCTTACAAAA 420

AATGCGGGCA TCGCCGTCCC CGAATTTCAA ATGATTGAAA AAGGTGACAA ACCGGAGGCG 480

AGGACGCTTA CCTACCCTGT CTTTGTGAAG CCGGCACGGT CAGGTTCGTC CTTTGGCGTA 540

ACCAAAGTAA ACAGTACGGA AGAACTAAAC GCTGCGATAG AAGCAGCAGG ACAATATGAT 600

GGAAAAATCT TAATTGAGCA AGCGATTTCG GGCTGTGAGG TCGGCTGCGC GGTCATGGGA 660

AACGAGGATG ATTTGATTGT CGGCGAAGTG GATCAAATCC GGTTGAGCCA CGGTATCTTC 720

CGCATCCATC AGGAAAACGA GCCGGAAAAA GGCTCAGAGA ATGCGATGAT TATCGTTCCA 780

GCAGACATTC CGGTCGAGGA ACGAAATCGG GTGCAAGAAA CGGCAAAGAA AGTATATCGG 840

GTGCTTGGAT GCAGAGGGCT TGCTCGTGTT GATCTTTTTT TGCAGGAGGA TGGCGGCATC 900

GTTCTAAACG AGGTCAATAC CCTGCCCGGT TTTACATCGT ACAGCCGCTA TCCACGCATG 960

GCGGCTGCCG CAGGAATCAC GCTTCCCGCA CTAATTGACA GCCTGATTAC ATTGGCGATA 1020

GAGAGGTGA 1029

(2) INFORMATION FOR SEQ ID NO: 117:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1031 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

ATGAAAAAAA TTGCCGTTTT ATTTGGAGGG AATTCTCCAG AATACTCAGT GTCACTAACC 60

TCAGCAGCAA GTGTGATCCA AGCTATTGAC CCGCTGAAAT ATGAAGTAAT GACCATTGGC 120

ATCGCACCAA CAATGGATTG GTATTGGTAT CAAGGAAACC TCGCGAATGT TCGCAATGAT 180

ACTTGGCTAG AAGATCACAA AAACTGTCAC CAGCTGACTT TTTCTAGCCA AGGATTTATA 240

TTAGGAGAAA AACGAATCGT CCCTGATGTC CTCTTTCCAG TCTTGCATGG GAAGTATGGC 300

GAGGATGGCT GTATCCAAGG ACTGCTTGAA CTAATGAACC TGCCTTATGT TGGTTGCCAT 360

GTCGCTGCCT CCGCATTATG TATGAACAAA TGGCTCTTGC ATCAACTTGC TGATACCATG 420

GGAATCGCTA GTGCTCCCAC TTTGCTTTTA TCCCGCTATG AAAACGATCC TGCCACAATC 480

GATCGTTTTA TTCAAGACCA TGGATTCCCG ATCTTTATCA AGCCGAATGA AGCCGGTTCT 540

TCAAAAGGGA TCACAAAAGT AACTGACAAA ACAGCGCTCC AATCTGCATT AACGACTGCT 600

TTTGCTTACG GTTCTACTGT GTTGATCCAA AAGGCGATAG CGGGTATTGA AATTGGCTGC 660

GGCATCTTAG GAAATGAGCA ATTGACGATT GGTGCTTGTG ATGCGATTTC TCTTGTCGAC 720

GGTTTTTTTG ATTTTGAAGA GAAATACCAA TTAATCAGCG CCACGATCAC TGTCCCAGCA 780

CCATTGCCTC TCGCGCTTGA ATCACAGATC AAGGAGCAGG CACAGCTGCT TTATCGAAAC 840

TTGGGATTGA CGGGTCTGGC TCGAATCGAT TTTTTCGTCA CCAATCAAGG AGCGATTTAT 900

TTAAACGAAA TCAACACCAT GCCGGGATTT ACTGGGCACT CCCGCTACCC AGCTATGATG 960

GCGGAAGTCG GGTTATCCTA CGAAATATTA GTAGAGCAAT TGATTGCACT GGCAGAGGAG 1020

GACAAACGAT G 1031

(2) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 809 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Abiotrophia adiacens*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

TGGTGCTATC TTAGTAGTAT CTGCAGCTGA TGGTCCAATG CCTCAAACAC GTGAACACAT 60

CTTATTATCA CGTCAAGTAG GTGTTCCTTA CATCGTTGTA TTCTTAAACA AAGTTGACAT 120

GGTTGACGAT GAAGAATTAT TAGAATTAGT AGAAATGGAA GTTCGTGACT TATTATCAGA 180

ATACGATTTC CCAGGCGATG ACACTCCAGT TGTTGCAGGT TCTGCTTTAC GCGCTTTAGA 240

AGGCGACGCT TCATACRAAG AAAAAATCTT AGAATTAATG GCTGCTGTTG ACGAATACAT 300

TCCAACTCCA GAACGYGACG TTGACAAACC ATTCATGATG CCAGTTGAAG ACGTGTTCTC 360

AATCACAGGT CGTGGTACTG TTGCTACAGG TCGTGTTGAA CGTGGACAAG TTCGTGTTGG 420

TGACGAAGTT GAAATCGTTG GTATTTCAGA AGAAACTTCA AAAACAACTG TAACTGGTGT 480

TGAAATGTTC CGTAAATTGT TAGACTACGC TGAAGCAGGG GATAACATTG GTACATTATT 540

ACGTGGTGTT ACACGTGACA ACATCGAACG TGGACAAGTT CTTGCTAAAC CAGGAACAAT 600

CACTCCACAT ACTAAATTCA AAGCTGAAGT TTACGTATTA ACTAAAGAAG AAGGTGGACG 660

TCATACTCCA TTCTTCTCTA ACTACCGTCC TCAATTCTAC TTCCGTACAA CAGACATCAC 720

TGGTGTTTGT GTGTTACCAG AAGGCGTTGA AATGGTAATG CCTGGTGATA ACGTAACTAT 780

GGAAGTTGAA TTAATTCACC CAGTAGCGA 809

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Abiotrophia defectiva*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

CGGCGCGATC CTCGTTGTAT CTGCTGCTGA CGGCCCAATG CCACAAACTC GTGAACACAT 60

CCTCTTGTCT CGTCAAGTTG GTGTTCCTTA CATCGTAGTA TTCTTGAACA AAGTTGACAT 120

GGTTGACGAC GAAGAATTGC TCGAATTAGT TGAAATGGAA GTTCGTGACC TCTTGTCTGA 180

ATACGACTTC CCAGGCGACG ACACTCCAGT TATCGCTGGT TCAGCTTTGA AAGCTTTAGA 240

AGGCGACGCT AACTACGAAG CTAAAGTTTT AGAATTGATG GAACAAGTTG ATGCTTACAT 300

TCCAGAACCA GAACGTGACA CTGACAAGCC ATTCATGATG CCAGTCGAAG ACGTATTCTC 360

TATCACTGGT CGTGGTACTG TTGCAACTGG TCGTGTTGAA CGTGGTCAAG TTCGCGTTGG 420

TGACGAAGTT GAAATCGTTG GTATCGAAGA AGAAACTTCT AAGACTACCG TTACCGGTGT 480

TGAAATGTTC CGTAAGTTAT TGGATTACGC TGAAGCTGGG GACAACGTTG GTACCTTGTT 540

ACGTGGTGTA ACTCGTGACC AAATCCAACG TGGTCAAGTA TTATCTAAAC CAGGTTCAAT 600

CACTCCGYAC ACTAAGTTCG AAGCTGAAGT GTACGTATTG TCTAAAGAAG AAGGTGGTCG 660

TCACACTCCA TTCTTCTCTA ACTACCGTCC ACAATTCTAC TTCCGTACAA CTGACGTAAC 720

TGGTGTTGTT ACTTTACCAG AAGGTACTGA AATGGTTATG CCAGGCGACA ACGTACAAAT 780

GGTTGTTGAA TTGATCCACC CAATCGCGAT CGAAGAA 817

(2) INFORMATION FOR SEQ ID NO: 120:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Candida albicans*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

CTCTGTCAAA TGGGACAAAA ACAGATTTGA AGAAATCATC AAGGAAACCT CCAACTTCGT 60

CAAGAAGGTT GGTTACAACC CAAAGACTGT TCCATTCGTT CCAATCTCTG GTTGGAATGG 120

TGACAACWTG ATTGAASCAT CCACCAACTG TCCATGGTAC AAGGGTTGGG AAAAGGAAAC 180

CAAATCCGGT AAAGTTACTG GTAAGACCTT GTTAGAAGCT ATTGACGCTA TTGAACCACC 240

AACCAGACCA ACCGACAAAC CATTGAGATT GCCATTRCAA GATGTTTACA AGATCGGTGG 300

TATTGGTACT GTGCCAGTCG GTAGAGTTGA AACTGGTATC ATCAAAGCCG GTATGGTWGT 360

TACTTTCGCC CCAGCTGGTG TTACCACTGA AGTCAARTCC GTTGAAATGC ATCACGAACA 420

ATTGGCTGAA GGTGTTCCAG GTGACAATGT TRGTTTCAAC GTTAAGAACR TTTCCGTTAA 480

AGAAATTAGA AGAGGTAACG TTTGTGGTGA CTCCAAGAAC GATCCACCAA AGGGTTGTGA 540

CTCTTTCAAT GCCCAAGTCA TTGTTTTGAA CCATCCAGGT CAAATCTCTG CTGGTTACTC 600

TCCAGTCTTG GATTGTCACR CTGCCCACAT TGCTTGTAAA TTCGACRCTT TGGTTGAAAA 660

GATTGACAGA AGAACTGGTA AGRAATTGGA AGAAAATCCA AAATTCGTCA AATCCGGTGA 720

TGCTGCTATC GTCAAGATGG TCCCAACCAA ACCA 754

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 753 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Candida glabrata*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121:

TCTGTCAAGT GGGATGAATC CAGATTCGCT GAAATCGTTA AGGAAACCTC CAACTTCATC 60

AAGAAGGTCG GTTACAACCC AAAGACTGTT CCATTCGTCC CAATCTCTGG TTGGAACGGT 120

GACAACATGA TTGAAGCCAC CACCAACGCT TCCTGGTACA AGGGTTGGGA AAAGGAAACC 180

AAGGCTGGTG TCGTCAAGGG TAAGACCTTG TTGGAAGCCA TTGACGCTAT CGAACCACCA 240

ACCAGACCAA CTGACAAGCC ATTGAGATTG CCATTGCAAG ATGTCTACAA GATCGGTGGT 300

ATCGGTACGG TGCCAGTCGG TAGAGTCGAA ACCGGTGTCA TCAAGCCAGG TATGGTTGTT 360

ACCTTCGCCC CAGCTGGTGT TACCACTGAA GTCAAGTCCG TTGAAATGCA CCACGAACAA 420

TTGACTGAAG GTTTGCCAGG TGACAACGTT GGTTTCAACG TTAAGAACGT TCCGTTAAG 480

GAAATCAGAA GAGGTAATGT CTGTGGTGAC TCCAAGAACG ACCCACCAAA GGCTGCTGCT 540

TCTTTCAACG CTACCGTCAT TGTCTTGAAC CACCCAGGTC AAATCTCTGC TGGTTACTCT 600

CCAGTTTTGG ACTGTCACAC CGCCCACATT GCTTGTAAGT TCGAAGAATT GTTGGAAAAG 660

AACGACAGAA GATCCGGTAA GAAGTTGGAA GACTCTCCAA AGTTCTTGAA GTCCGGTGAC 720

GCTGCTTTGG TTAAGTTCGT TCCATCCAAG CCA 753

(2) INFORMATION FOR SEQ ID NO: 122:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 752 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Candida krusei*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

CCGTTAAGTG GGATGAAAAC AGATTTGAAG AAATTGTCAA GGAAACCCAA AACTTCATCA 60

AGAAGGTTGG TTACAACCCA AAGACTGTTC CATTCGTTCC AATCTCTGGT TGGAATGGTG 120

ACAACATGAT TGAAGCATCC ACCAACTGTC CATGGTACAA GGGTTGGACT AAGGAAACCA 180

AGGCAGGTGT TGTTAAGGGT AAGACCTTAT TAGAAGCAAT CGATGCTATT GAACCACCTG 240

TCAGACCAAC CGAAAAGCCA TTAAGATTAC CATTACAAGA TGTTTACAAG ATTGGTGGTA 300

TTGGTACTGT GCCAGTCGGT AGAGTCGAAA CCGGTGTCAT TAAGCCAGGT ATGGTTGTCA 360

CTTTTGCTCC AGCAGGTGTC ACCACCGAAG TCAAATCCGT TGAAATGCAC CATGAACAAT 420

TAGAACAAGG TGTTCCAGGT GATAACGTTG GTTTCAACGT TAAGAACGTY TCTGTCAAGG 480

ATATCAAGAG AGGTAACGTT TGTGGTGACT CCAAGAACGA CCCACCAATG GGTGCAGCTT 540

CTTTCAATGC TCAAGTCATT GTCTTGAACC ACCCTGGTCA AATTTCCGCT GGTTACTCTC 600

CAGTCTTGGA TTGTCACACT GCCCACATTG CATGTAAGTT CGACGAATTA ATCGAAAAGA 660

TTGACAGAAG AACTGGTAAG TCTGTTGAAG ACCATCCAAA GTCYGTCAAG TCTGGTGATG 720

CAGCTATCGT CAAGATGGTC CCAACCAAGC CA 752

(2) INFORMATION FOR SEQ ID NO: 123:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Candida parapsilosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123:

CTCAGTCAAA TGGGACAAGA RCAGATACGA AGAAATTGTC AAGGAAACTT CCAACTTCGT 60

CAAGAAGGTT GGTTACAACC CTAAAGCTGT CCCATTCGTC CCAATCTCTG GTTGGAACGG 120

TGACAATATG ATTGAACCAT CAACCAACTG TCCATGGTAC AAGGGTTGGG AAAAGGAAAC 180

TAAAGCTGGT AAGGTTACCG GTAAGACCTT GTTGGAAGCT ATCGATGCTA TCGARCCACC 240

AACCAGACCA ACTGACAAGC CATTGAGATT GCCATTGCAA GATGTCTACA AGATTGGTGG 300

TATTGGAACT GTGCCAGTTG GTAGAGTTGA AACCGGTATC ATCAAGGCTG GTATGGTTGT 360

TACTTTTGCC CCAGCTGGTG TTACCACTGA AGTCAAGTCC GTTGAAATGC ACCACGAACA 420

ATTGACTGAA GGTGTCCCAG GTGACAATGT TGGTTTCAAC GTCAAGAACG TTTCAGTTAA 480

GGAAATCAGA AGAGGTAACG TYTGTGGTGA CTCCAAGAAC GATCCACCAA AGGGATGTGA 540

YTCCTTCAAT GCTCAAGTTA TTGTCTTGAA CCACCCAGGT CAAATCTCTG CTGGTTACTC 600

ACCAGTCTTG GATTGTCACA CTGCCCACAT TGCTTGTAAA TTCGACACTT TGATTGAAAA 660

GATTGACAGA AGAACCGGTA AGAAATTGGA AGWTGAACCA AAATTCATCA AGTCCGGTGA 720

TGCTGCYATC GTCAAGATGG TCCCAACCAA GCCA 754

(2) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 753 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Candida tropicalis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:

TCTGTTAAAT GGGACAARAA CAGATTTGAA GAAATTATCA AGGAAACYTC TAACTTCGTC 60

AAGAAGGTTG GTTACAACCC TAAGGCTGTT CCATTCGTTC CAATCTCWGG TTGGAATGGT 120

GACAACATGA TTGAAGCTTC TACCAACTGT CCATGGTACA AGGGTTGGGA AAAAGAAACC 180

AAGGCTGGTA AGGTTACCGG TAAGACTTTG TTGGAAGCCA TTGATGCTAT TGAACCACCT 240

TCAAGACCAA CTGACAAGCC ATTGAGATTG CCATTGCAAG ATGTTTACAA GATTGGTGGT 300

ATTGGTACTG TGCCAGTCGG TAGAGTTGAA ACTGGTGTCA TCAAAGCCGG TATGGTTGTT 360

ACTTTYGCCC CAGCTGGTGT TACCACTGAA GTCAAATCCG TYGAAATGCA CCACGAACAA 420

TTGGCTGAAG GTGTCCCAGG TGACAATGTT GGTTTCAACG TTAAGAACGT TTCTGTTAAA 480

GAAATTAGAA GAGGTAACGT TTGTGGTGAC TCCAAGAACG ATCCACCAAA GGGTTGTGAC 540

TCTTTCAACG CTCAAGTTAT TGTCTTGAAC CACCCAGGTC AAATYTCTGC TGGTTACTCT 600

CCAGTCTTGG ATTGTCACAC TGCTCATATT GCTTGTAAAT TCGACACCTT GGTTGAAAAG 660

ATTGACAGAA GAACTGGTAA GAAATTGGAA GAAAATCCAA AATTCGTCAA ATCCGGTGAT 720

GCTGCTATTG TCAAGATGGT TCCAACCAAA CCA 753

(2) INFORMATION FOR SEQ ID NO: 125:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Corynebacterium accolens*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125:

CGGCGCTATC CTGGTTGTTG CTGCAACCGA TGGCCCGATG CCGCAGACCC GCGAGCACGT 60

TCTGCTTGCT CGCCAGGTTG GCGTTCCTTA CATCCTCGTT GCACTGAACA AGTGCGACAT 120

GGTTGATGAT GAGGAAATCA TCGAGCTCGT GGAGATGGAG ATCTCCGAGC TGCTCGCAGA 180

GCAGGACTAC GATGAGGAAG CTCCTATCGT TCACATCTCC GCTCTGAAGG CACTCGAGGG 240

TGACGAGAAG TGGGTACAGT CCATCGTTGA CCTGATGGAT GCCTGCGACA ACTCCATCCC 300

TGATCCGGAG CGCGCTACCG ATCAGCCGTT CTTGATGCCT ATCGAGGACA TCTTCACCAT 360

TACCGGCCGC GGTACCGTTG TTACCGGCCG TGTTGAGCGT GGTCGTCTGA ACGTCAACGA 420

GGACGTTGAG ATCATCGGTA TCCAGGAGAA GTCCCAGAAC ACCACCGTTA CCGGTATCGA 480

GATGTTCCGC AAGATGATGG ACTACACCGA GGCTGGCGAC AACTGTGGTC TGCTTCTGCG 540

TGGTACCAAG CGTGAGGACG TTGAGCGTGG CCAGGTTGTT ATCAAGCCGG GCGCTTACAC 600

CCCTCACACC AAGTTCGAGG GTTCCGTCTA CGTCCTGAAG AAGGAAGAGG GCGGCCGCCA 660

CACCCCGYTC ATGAACAACT ACCGTCCTCA GTTCTACTTC CGCACCACCG ACGTTACCGG 720

TGTTGTGAAC CTGCCTGAGG GCACCGAGAT GGTTATGCCT GGCGACAACG TTGAGATGTC 780

TGTTGAGCTC ATCCAGCCTG TTGCTATGGA CGAG 814

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Corynebacterium diphteriae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:

CGGCGCAATC CTCGTTGTTG CTGCCACCGA CGGCCCAATG CCTCAGACCC GTGAGCACGT 60

TCTGCTCGCT CGCCAGGTCG GCGTTCCTTA CATCCTCGTT GCTCTGAACA AGTGCGACAT 120

GGTTGATGAT GAGGAAATCA TCGAGCTCGT CGAGATGGAG ATCCRTGAGC TGCTCGCTGA 180

GCAGGATTAC GACGAAGAGG CTCCAATCAT CCACATCTCC GCACTGAAGG CTCTTGAGGG 240

CGACGAGAAG TGGACCCAGT CCATCATCGA CCTCATGCAG GCTTGCKATG ATTCCATCCC 300

AGACCCAGAG CGTGAGACCG ACAAGCCATT CCTCATGCCT ATCGAGGACA TCTTCACCAT 360

CACCGGCCGC GGTACCGTTG TTACCGGCCG TGTTGAGCGT GGCTCCCTGA AGGTCAACGA 420

GGACGTCGAG ATCATCGGTA TCCGCGAGAA KGCTACCACC ACCACCGTTA CCGGTATCGA 480

GATGTTCCGT AAGCTTCTCG ACTACACCGA GGCTGGCGAC AACTGTGGTC TGCTTCTCCG 540

TGGCGTTAAG CGCGAAGACG TTGAGCGTGG CCAGGTTGTT GTTAAGCCAG GCGCTTACAC 600

CCCTCACACC GAGTTCGAGG GCTCTGTCTA CGTTCTGTCC AAGGACGAGG GTGGCCGCCA 660

CACCCCATTC TTCGACAACT ACCGCCCACA GTTCTACTTC CGCACCACCG ACGTTACCGG 720

TGTTGTGAAG CTTCCTGAGG GCACCGAGAT GGTCATGCCT GGCGACAACG TCGACATGTC 780

CGTCACCCTG ATCCAGCCTG TCGCTATGGA TGAG 814

(2) INFORMATION FOR SEQ ID NO: 127:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Corynebacterium genitalium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

CGGCGCCATC CTGGTTGTTG CTGCAACCGA TGGCCCGATG CCGCAGACCC GTGAGCACGT 60

TCTGCTGGCT CGCCAGGTTG GCGTTCCGTA CATCCTAGTT GCACTGAACA AGTGCGACAT 120

GGTTGATGAT GAGGAGCTGC TGGAGCTCGT CGAGATGGAG GTCCGCGAGC TGCTGGCTGA 180

GCAGGACTTC GACGAGGAAG CACCTGTTGT TCACATCTCC GCACTGAAGG CCCTGGAGGG 240

CGACGAGAAG TGGGCTAAGC AGATCCTGGA GCTCATGGAG GCTTGCGACA ACTCCATCCC 300

GGATCCGGAG CGCGAGACCG ACAAGCCGTT CCTGATGCCG GTTGRGGACA TCTTCACCAT 360

TACCGGCCGC GGTACCGTTG TTACCGGCCG TGTTGAGCGT GGCGTCCTGA ACCTGAACGA 420

CGAGGTCGAG ATCCTGGGCA TCCGCGAGAA GTCCACCAAG ACCACCGTTA CCTCCATCGA 480

GATGTTCAAC AAGCTGCTGG ACACCGCAGA GGCTGGCGAC AACGCCGCAC TGCTGCTGCG 540

TGGCCTGAAG CGCGAAGATG TTGAGCGTGG TCAGATCGTT GCTAAGCCGG GCGAGTACAC 600

CCCGCACACC GAGTTCGAGG GCTCCGTCTA CGTTCTGTCC AAGGACGAGG GTGGCCGCCA 660

CACCCCGTTC TTCGACAACT ACCGTCCGCA GTTCTATTTC CGCACCACCG ACGTTACCGG 720

TGTTGTGAAG CTGCCGGAGG GCACCGAGAT GGTTATGCCG GGCGACAACG TTGACATGTC 780

CGTCACCCTG ATCCAGCCGG TTGCTATGGA CGAG 814

(2) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Corynebacterium jeikeium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

CGGCGCCATC CTGGTTGTTG CCGCAACCGA TGGCCCGATG CCGCAGACCC GCGAGCACGT 60

TCTGCTGGCY CGCCAGGTTG GCGTTCCGTA CATCCTGGTT GCACTGAACA AGTGTGACAT 120

GGTTGACGAT GAGGAGCTGC TGGAGCTCGT CGAGATGGAG GTCCGCGAGC TGCTGGCTGA 180

GCAGGACTTC GACGAGGAAG CTCCGGTTGT TCACATCTCC GCACTGAAGG CCCTGGAGGG 240

CGACGAGAAG TGGGCTAACC AGATTCTCGA GCTGATGCAG GCTTGCGACG AGTCTATCCC 300

GGATCCGGAG CGCGAGACCG ACAAGCCGTT CCTGATGCCG GTTGWGGACA TCTTCACCAT 360

TACCGGTCGC GGTACCGTTG TTACCGGCCG TGTTGAGCGT GGCATCCTGA ACCTGAACGA 420

CGAGGTTGAG ATCCTGGGTA TCCGCGAGAA GTCCCAGAAG ACCACCGTTA CCTCCATCGA 480

GATGTTCAAC AAGCTGCTGG ACACCGCAGA GGCTGGCRAC AACGCTGCAC TGCTGCTGCG 540

TGGTCTGAAG CGCGAGGACG TTGAGCGTGG CCAGATCATC GCTAAGCCGG GCGAGTACAC 600

CCCGCACACC GAGTTCGAGG GCTCCGTCTA CGTTCTGTCC AAGGACGAGG GCGGCCGCCA 660

CACCCCGTTC TTCGACAACT ACCGTCCGCA GTTCTACTTC CGCACCACCG ACGTTACCGG 720

TGTTGTGAAG CTGCCTGAGG GCACCGAGAT GGTTATGCCG GGCGACAACG TYGACATGTC 780

CGTCACCCTG ATCCAGCCGG TTGCTATGGA CGAG 814

(2) INFORMATION FOR SEQ ID NO: 129:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 748 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Corynebacterium pseudodiphteriticum*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129:

CGGCGCTATC TTGGTTGTTG CAGCTACCGA CGGCCCAATG CCACAGACTC GCGAGCACGT 60

TCTGCTGGCT CGCCAGGTTG GCGTTCCTTA CATCCTGGTT GCACTAAACA AGTGCGACAT 120

GGTTGACGAC GAGGAAATCC TCGAGCTCGT CGAGATGGAG ATCCGCGAAT TGCTGGCTGA 180

CCAGGAATTC GACGAAGAAG CTCCAATCGT TCACATCTCC GCAGTCGGCG CCTTGGAAGG 240

CGAAGAGAGG TGGGTTAACG CCATCGTTGA ACTGATGGAT GCTTGTGACG AGTCGATCCC 300

TGATCCAGAC CGTGCTACCG ACAAGCCATT CCTGATGCCT ATCGAGGACA TCTTCACCAT 360

TACCGGTCGT GGCACCGTTG TTACGGGTCG TGTTGAGCGT GGTTCCCTGA AGGTCAACGA 420

AGAAGTCGAG ATCATCGGCA TCAAGGAAAA GTCCCAGAAG ACCACCATCA CCGGTATCGA 480

AATGTTCCGC AAGATGCTGG ACTACACCGA GGCCGGCGAC AACGCTGGTC TGCTGCTTCG 540

CGGTACCAAG CGTGAAGACG TTGAGCGTGG ACAGGTTATC GTTGCTCCAG GTGCTTACAG 600

CACCCACAAG AAGTTCGAAG GTTCCGTCTA CGTTCTTTCC AAGGACGAGG GCGGCCGCCA 660

CACCCCGTTC TTCGACAACT ACCGTCCTCA GTTCTACTTC CGCACCACCG ACGTTACCGG 720

TGTTGTTACC CTGCCTGAGG GCACCGAG 748

(2) INFORMATION FOR SEQ ID NO: 130:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 813 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Corynebacterium striatum*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130:

GGCGCTATCT TGGTTGTTGC TGCAACCGAT GGCCCGRTGC CGCAGACCCG CGAGCACGTT 60

CTTCTGGCTC GCCAGGTTGG CGTTCCTTAC ATCCTCGTTG CACTGAACAA GTGCGACATG 120

GTTGACGACG AGGAAATTAT CGAGCTCGTC GAGATGGAGA TCCGCGAACT GCTCGCAGAG 180

CAGGACTACG ATGAGGAAGC TCCGATCGTT CACATCTCTG CTCTGAAGGC TCTTGAGGGC 240

GRCGAGAAGT GGGTACAGGC TATCGTTGAC CTGATGCAGG CTTGCGATGA CTCCATCCCG 300

GATCCGGAGC GCGAGCTGGA CAAGCCGTTC CTGATGCCAA TCGAGGACAT CTTCACCATC 360

ACCGGCCGCG GTACCGTTGT TACTGGCCGT GTTGAGCGTG GCTCCCTGAA CGTCAACGAG 420

GACGTTGAGA TCATCGGTAT CCAGGACARG TCCATCTCCA CCACCGTTAC CGGTATCGAG 480

ATGYTCCGCA AGATGATGGA CTACACCGAG GCTGGCGACA ACTGTGGTCT GCTTCTGCGT 540

GGTACCAAGC GTGAAGAGGT TGAGCGCGGC CAGGTTGTTA TTAAGCCGGG CGCTTACACC 600

CCTCACACCC AGTTCGAGGG TTCCGTCTAC GTCCTGAAGA AGGAAGAGGG CGGCCGCCAC 660

ACCCCGTTCA TGGACAACTA CCGTCCGCAG TTCTACTTCC GCACCACCGA CGTTACCGGC 720

GTCATCAAGC TGCCTGAGGG CACCGAGATG GTTATGCCTG GCGACAACGT CGAGATGTCY 780

GTCGAGCTGA TCCAGCCGGT CGCTATGGAC GAG 813

(2) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Enterococcus avium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131:

CGGAGCTATC TTAGTAGTAT CTGCTGCTGA TGGCCCTATG CCTCAAACTC GTGAACACAT 60

CTTGTTATCT CGTAACGTTG GTGTTCCTTA CATCGTTGTA TTCTTAAACA AAATGGATAT 120

GGTTGACGAT GAAGAATTAC TTGAATTAGT TGAAATGGAA GTTCGTGACT TATTAACTGA 180

ATACGACTTC CCAGGCGACG ACACTCCAGT TATCGCAGGT TCAGCGTTGA AAGCTTTAGA 240

AGGCGACGCT TCATACGAAG AAAAAATCTT AGAATTAATG GCTGCTGTTG ACGAATATAT 300

CCCAACACCA GTTCGTGATA CTGACAAACC ATTCATGATG CCAGTCGAAG ACGTATTCTC 360

AATCACTGGT CGTGGTACTG TTGCAACTGG TCGTGTTGAA CGTGGACAAG TTCGCGTTGG 420

TGACGAAGTT GAAATCGTAG GTATCGCTGA CGAAACTGCT AAAACAACTG TTACAGGTGT 480

TGAAATGTTC CGTAAATTGT TAGACTACGC TGAAGCAGGT GACAACATCG GTGCTTTGTT 540

ACGTGGTGTT GCACGTGAAG ATATCCAACG TGGACAAGTA TTGGCTAAAC CAGCTTCAAT 600

CACTCCACAT ACAAAATTCT CTGCAGAAGT TTATGTTCTA ACTAAAGAAG AAGGTGGACG 660

TCATACTCCA TTCTTCACTA ACTACCGTCC TCAGTTCTAC TTCCGTACAA CTGACGTAAC 720

TGGTGTAGTT GATCTACCAG AAGGTACTGA AATGGTWATG CCTGGGGATA ACGTAACTAT 780

GGAAGTTGAA TTGATYCACC CAATYGCGGT AGAAGAC 817

(2) INFORMATION FOR SEQ ID NO: 132:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Enterococcus faecalis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132:

CGGAGCTATC TTAGTAGTTT CTGCTGCTGA TGGTCCTATG CCTCAAACAC GTGAACATAT 60

CTTATTATCA CGTAACGTTG GTGTACCATA CATCGTTGTA TTCTTAAACA AAATGGATAT 120

GGTTGATGAC GAAGAATTAT TAGAATTAGT AGAAATGGAA GTTCGTGACT TATTATCAGA 180

ATACGATTTC CCAGGCGATG ATGTTCCAGT TATCGCAGGT TCTGCTTTGA AAGCTTTAGA 240

AGGCGACGAG TCTTATGAAG AAAAAATCTT AGAATTAATG GCTGCAGTTG ACGAATATAT 300

CCCAACTCCA GAACGTGATA CTGACAAACC ATTCATGATG CCAGTCGAAG ACGTATTCTC 360

AATCACTGGA CGTGGTACTG TTGCTACAGG ACGTGTTGAA CGTGGTGAAG TTCGCGTTGG 420

TGACGAAGTT GAAATCGTTG GTATTAAAGA CGAAACATCT AAAACAACYG TTACAGGTGT 480

TGAAATGTTC CGTAAATTAT TAGACTACGC TGAAGCAGGC GACAACMTCG GTGCTTTATT 540

ACGTGGTGTA GCACGTGAAG ATATCGAACG TGGACAAGTA TTAGCTAAAC CAGCTACAAT 600

CACTCCACAC ACAAAATTCA AAGCTGAAGT ATACGTATTA TCAAAAGAAG AAGGCGGACG 660

TCACACTCCA TTCTTCACTA ACTACCGTCC TCAATTCTAC TTCCGTACAA CAGACGTTAC 720

TGGTGTTGTA GAATTGCCAG AAGGTACTGA AATGGTAATG CCTGGTGATA ACGTTGCTAT 780

GGACGTTGAA TTAATTCACC CAATCGCTAT CGAAGAC 817

(2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 774 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Enterococcus faecium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133:

CGGAGCTATC TTGGTAGTTT CTGCTGCTGA CGGCCCAATG CCTCAAACTC GTGAACACAT 60

CCTATTGTCT CGTCAAGTTG GTGTTCCTTA CATCGTTGTA TTCTTGAACA AAGTAGACAT 120

GGTTGATGAC GAAGAATTAC TAGAATTAGT TGAAATGGAA GTTCGTGACC TATTAACAGA 180

ATACRAATTC CCTGGTGRCG ATGTTCCTGT AGTTGCTGGA TCAGCTTTGA AAGCTCTAGA 240

AGGCGACGCT TCATACGAAG AAAAAATTCT TGAATTAATG GCTGCAGTTG ACGAATACAT 300

CCCAACTCCA GAACGTGACA ACGACAAACC ATTCATGATG CCAGTTGAAG ACGTGTTCTC 360

AATTACTGGA CGTGGTACTG TTGCTACAGG TCGTGTTGAA CGTGGACAAG TTCGCGTTGG 420

TGACGAAGTT GAAGTTGTTG GTATTGCTGA AGAAACTTCA AAAACAACAG TTACTGGTGT 480

TGAAATGTTC CGTAAATTGT TAGACYACGC TGAAGCTGGA GACRACATTG GTGCTTTACT 540

ACGTGGTGTT GCACGTGAAG ACATCCAACG TGGACAAGTT TTAGCTAAAC CAGGTACAAT 600

CACACCTCRT ACAAAATTCT CTGCAGAAGT ATACGTGTTG ACAAAAGAAG AAGGTGGACG 660

TCATACTCCA TTCTTCACTA ACTACCGTCC ACAATTCTAC TTCCGTACAA CTGACGTAAC 720

AGGTGTTGTT GAATTACCAG AAGGAACTGA AATGGTCATG CCCGGTGACA ACGT 774

(2) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 809 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Enterococcus gallinarum*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:

CGGTGCGATC TTAGTAGTAT CTGCTGCTGA CGGTCCTATG CCTCAAACTC GTGAACACAT 60

CTTGTTATCA CGTAACGTTG GCGTACCATA CATCGTTGTT TTCTTGAACA AAATGGATAT 120

GGTTGAYGAC GAAGAATTGC TAGAATTAGT TGAAATGGAA GTTCGTGACC TATTGTCTGA 180

ATATGACTTC CCAGGCGACG ATGTTCCTGT AATCGCCGGT TCTGCTTTGA AAGCTCTTGA 240

AGGAGATCCT TCATACGAAG AAAAAATCAT GGAATTGATG GCTGCAGTTG ACGAATACGT 300

TCCAACTCCA GAACGTGATA CTGACAAACC ATTCATGATG CCAGTCGAAG ACGTATTCTC 360

AATCACTGGA CGTGGTACTG TTGCTACAGG CCGTGTTGAA CGTGGACAAG TTCGCGTTGG 420

TGATGAAGTA GAAATCGTTG GTATTGCTGA CGAAACTGCT AAAACAACTG TAACAGGTGT 480

TGAAATGTTC CGTAAATTGT TAGACTATGC TGAAGCAGGG GATAACATTG GTGCATTGCT 540

ACGTGGGGTT GCTCGTGAAG ACATCCAACG TGGACAAGTA TTGGCTAAAG CTGGTACAAT 600

CACACCTCAT ACAAAATTCA AAGCTGAAGT TTATGTTTTG ACAAAAGAAG AAGGTGGACG 660

TCACACTCCA TTCTTCACTA ACTACCGTCC TCAGTTCTAC TTCCGTACAA CTGACGTAAC 720

TGGTGTTGTT GAATTACCAG AAGGAACTGA AATGGTGATG CCTGGCGACA ACGTGACCAT 780

CGACGTTGAA TTGATRCACC CAATCGCTC 809

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 823 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Gardnerella vaginalis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135:

TGGCGCAATC CTCGTGGTTG CTGCTACCGA CGGTCCAATG GCTCAGACCC GTGAACACGT 60

CTTGCTTGCT AAGCAGGTCG GCGTTCCAAA AATTCTTGTT GCTTTGAACA AGTGCGATAT 120

GGTTGACGAC GAAGAGCTTA TCGATCTCGT TGAAGAAGAG GTCCGTGACC TCCTCGAAGA 180

AAACGGCTTC GATCGCGATT GCCCAGTCYT CCGTACTTCC GCTTACGGCG CTTTGCATGA 240

TGACGCTCCA GACCACGACA AGTGGGTAGA GACCGTCAAG GAACTCATGA AGGCTGTTGA 300

CGAGTACATC CCAACCCCAA CTCACGATCT TGACAAGCCA TTCTTGATGC CAATCGAAGA 360

TGTGTTCACC ATCTCCGGTC GTGGTYCCGT TGTCACCGGT CGTGTTGAGC GTGGTAAGCT 420

CCCAATCAAC ACCCCAGTTG AGATCGTTGG TTTGCGCGAT ACCCAGACCA CCACCGTCAC 480

CTCTATCGAG ACCTTCCACA AGCAGATGGA TGAGGCAGAG GCTGGCGATA ACACTGGTCT 540

TCTTCTCCGC GGTATCAACC GTACCGACGT TGAGCGTGGT CAGGTTGTGG CTGCTCCAGG 600

TTCTGTGACT CCACACACCA AGTTCGAAGG CGAAGTTTAC GTCTTGACCA AGGACGAAGG 660

TGGCCGTCAC TCGCCATTCT TCTCCAACTA CCGTCCACAG TTCTACTTCC GTACCACCGA 720

TGTTACTGGC GTTATCACCT TGCCAGACGG CATCGAAATG GTTCAGCCAG GCGATCACGC 780

AACCTTCACT GTTGAGTTGA TCCAGGCTAT CGCAATGGAA GAG 823

(2) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Listeria innocua*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:

CGGAGCTATC TTAGTAGTAT CTGCTGCTGA TGGCCCAATG CCACAAACTC GTGAACATAT 60

CTTACTTTCA CGTCAAGTTG GTGTTCCATA CATCGTTGTA TTCATGAACA AATGTGACAT 120

GGTTGACGAT GAAGAATTAC TAGAATTAGT TGAAATGGAA ATTCGTGATC TATTAACTGA 180

ATATGAATTC CCTGGCGATG ACATTCCTGT AATCAAAGGT TCAGCTCTTA AAGCACTTCA 240

AGGTGAAGCT GACTGGGAAG CTAAAATTGA CGAGTTAATG GAAGCTGTAG ATTCTTACAT 300

TCCAACTCCA GAACGTGATA CTGACAAACC ATTCATGATG CCAGTTGAGG ATGTATTCTC 360

AATCACTGGT CGTGGAACAG TTGCAACTGG ACGTGTTGAA CGTGGACAAG TTAAAGTTGG 420

TGACGAAGTA GAAGTTATCG GTATTGAAGA AGAAAGCAAA AAAGTAGTAG TAACTGGAGT 480

AGAAATGTTC CGTAAATTAC TAGACTACGC TGAAGCTGGC GACAACATTG GCGCACTTCT 540

ACGTGGTGTT GCTCGTGAAG ATATCCAACG TGGTCAAGTA TTAGCTAAAC CAGGTTCGAT 600

TACTCCACAC ACTAACTTCA AAGCTGAAAC TTATGTTTTA ACTAAAGAAG AAGGTGGACG 660

TCACACTCCA TTCTTCAACA ACTACCGCCC ACAATTCTAT TTCCGTACTA CTGACGTAAC 720

TGGTATTGTT ACACTTCCAG AAGGTACTGA AATGGTAATG CCTGGTGATA ACATTGAGCT 780

TGCAGTTGAA CTAATTGCAC CAATCGCTAT CGAAGAC 817

(2) INFORMATION FOR SEQ ID NO: 137:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 818 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Listeria ivanovii*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

CGGAGCTATC TTAGTAGTAT CTGCTGCTGA TGGTCCAATG CCACAAACTC GTGAACATAT 60

TCTTACTTTC ACGTCAAGTT GGTGTTCCAT ACATCGTTGT ATTCATGAAC AAATGTGACA 120

TGGTTGACGA TGAAGAATTA CTTGAATTAG TTGAAATGGA AATTCGTGAT CTATTAACTG 180

AATATGAATT CCCTGGCGAC GACATTCCTG TAATCAAAGG TTCAGCTCTT AAAGCACTTC 240

AAGGTGAAGC TGATTGGGAA GCTAAAATTG ACGAGTTAAT GGAAGCTGTA GATTCTTACA 300

TTCCAACTCC AGAACGTGAT ACTGACAAAC CATTCATGAT GCCAGTTGAG GATGTATTCT 360

CAATCACTGG TCGTGGAACA GTTGCAACTG GACGTGTTGA ACGTGGACAA GTTAAAGTTG 420

GTGACGAAGT AGAAGTTATC GGTATTGAAG AAGAAAGCAA AAAAGTAGTA GTAACTGGAG 480

TAGAAATGTT CCGTAAATTA CTAGACTACG CTGAAGCTGG CGACAACATT GGCGCACTTC 540

TACGTGGTGT TGCTCGTGAA GATATCCAAC GTGGTCAAGT ATTAGCTAAA CCAGGTTCGA 600

TTACTCCACA TACTAACTTC AAAGCTGAAA CTTATGTTTT AACTAAAGAA GAAGGTGGAC 660

GTCATACTCC ATTCTTCAAC AACTACCGCC CACAATTCTA TTTCCGTACT ACTGACGTAA 720

CTGGTATTGT TACACTTCCA GAAGGTACTG AAATGGTAAT GCCTGGTGAT AACATTGAGC 780

TTGCAGTTGA ACTAATTGCA CCAATCGCTA TCGAAGAC 818

(2) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Listeria monocytogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

CGGAGCTATC TTAGTAGTAT CTGCTGCTGA TGGCCCAATG CCACAAACTC GTGAACATAT 60

CTTACTTTCA CGTCAAGTTG GTGTTCCATA CATCGTTGTA TTCATGAACA AATGTGACAT 120

GGTTGACGAT GAAGAATTAC TAGAATTAGT TGAAATGGAA ATTCGTGATC TATTAACTGA 180

ATATGAATTC CCTGGCGATG ACATTCCTGT AATCAAAGGT TCAGCTCTTA AAGCACTTCA 240

AGGTGAAGCT GACTGGGAAG CTAAAATTGA CGAGTTAATG GAAGCTGTAG ATTCTTACAT 300

TCCAACTCCW GAACGTGATA CTGACAAACC ATTCATGATG CCAGTTGAGG ATGTATTCTC 360

AATCACTGGT CGTGGAACAG TTGCAACTGG ACGTGTTGAA CGTGGACAAG TTAAAGTTGG 420

TGACGAAGTA GAAGTTATCG GTATCGAAGA AGAAAGCAAA AAAGTAGTAG TAACTGGAGT 480

AGAAATGTTC CGTAAATTAC TAGACTACGC TGAAGCTGGC GACAACATTG GCGCACTTCT 540

ACGTGGTGTT GCTCGTGAAG ATATCCAACR TGGTCAAGTA TTAGCTAAAC CAGGTTCGAT 600

TACTCCACAC ACTAACTTCA AAGCTGAAAC TTATGTTTTA ACTAAAGAAG AAGGTGGACG 660

TCACACTCCA TTCTTCAACA ACTACCGCCC ACAATTCTAT TTCCGTACTA CTGACGTAAC 720

TGGTATTGTT ACACTTCCAG AAGGTACTGA AATGGTAAYG CCTGGTGATA ACATTGAGCT 780

TGCAGTTGAA CTAATTGCAC CAATCGCTAT CGAAGAC 817

(2) INFORMATION FOR SEQ ID NO: 139:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Listeria seeligeri*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139:

CGGAGCTATC TTAGTAGTAT CTGCTGCTGA TGGCCCAATG CCACAAACTC GTGAACATAT 60

CTTACTTTCA CGTCAAGTTG GTGTTCCATA CATCGTTGTA TTCATGAACA AATGTGACAT 120

GGTTGACGAT GAAGAATTAC TTGAATTAGT TGAAATGGAA ATTCGTGATC TATTAACTGA 180

ATATGAATTC CCTGGTGATG ACATTCCTGT AATCAAAGGT TCAGCTCTTA AAGCACTTCA 240

AGGTGAAGCT GACTGGGAAG CTAAAATTGA CGAGTTAATG GAAGCTGTAG ATTCTTACAT 300

TCCAACTCCA GAACGTGATA CTGACAAACC ATTCATGATG CCAGTTGAGG ATGTATTCTC 360

AATCACTGGT CGTGGAACTG TTGCAACTGG ACGTGTTGAA CGTGGACAAG TTAAAGTTGG 420

TGACGAAGTA GAAGTTATCG GTATTGAAGA AGAAAGCAAA AAAGTAATAG TAACTGGAGT 480

AGAAATGTTC CGTAAATTAC TAGACTACGC TGAAGCTGGC GACAACATTG GCGCACTTCT 540

ACGTGGTGTT GCTCGTGAAG ATATCCAACG TGGTCAAGTA TTAGCTAAAC CAGGTTCGAT 600

TACTCCACAT ACTAACTTCA AAGCTGAAAC TTATGTTTTA ACTAAAGAAG AAGGTGGACG 660

TCACACTCCA TTCTTCAACA ACTACCGCCC ACAATTCTAT TTCCGTACTA CTGACGTAAC 720

TGGTATTGTT ACACTTCCAG AAGGTACTGA AATGGTAATG CCTGGTGATA ACATTGAGCT 780

TGCAGTTGAA CTAATTGCAC CAATCGCTAT CGAAGAC 817

(2) INFORMATION FOR SEQ ID NO: 140:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Staphylococcus aureus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140:

CGGTGGTATC TTAGTAGTAT CTGCTGCTGA CGGTCCAATG CCACAAACTC GTGAACACAT 60

TCTTTTATCA CGTAACGTTG GTGTACCAGC ATTAGTAGTA TTCTTAAACA AAGTTGACAT 120

GGTTGACGAT GAAGAATTAT TAGAATTAGT AGAAATGGAA GTTCGTGACT TATTAAGCGA 180

ATATGACTTC CCAGGTGACG ATGTACCTGT AATCGCTGGT TCAGCATTAR AAGCTTTAGA 240

AGGCGATGCT CAATACGAAG AAAAAATCTT AGAATTARTG GAAGCTGTAG ATACTTACAT 300

TCCAACTCCA GAACGTGATT CTGACAAACC ATTCATGATG CCAGTTGAGG ACGTATTCTC 360

AATCACTGGT CGTGGTACTG TTGCTACAGG CCGTGTTGAA CGTGGTCAAA TCAAAGTTGG 420

TGAAGAAGTT GAAATCATCG GTTTACATGA CACATCTAAA ACAACTGTTA CAGGTGTTGA 480

AATGTTCCGT AAATTATTAG ACTACGCTGA AGCTGGTGAC AACATTGGTG CATTATTACG 540

TGGTGTTGCT CGTGAAGACG TACAACGTGG TCAAGTATTA GCTGCTCCTG GTTCAATTAC 600

ACCACATACT GAATTCAAAG CAGAAGTATA CGTATTATCA AAAGACGAAG GTGGACGTCA 660

CACTCCATTC TTCTCAAACT ATCGTCCACA ATTCTATTTC CGTACTACTG ACGTAACTGG 720

TGTTGTTCAC TTACCAGAAG GTACTGAAAT GGTAATGCCT GGTGATAACG TTGAAATGAC 780

AGTAGAATTA ATCGCTCCAA TCGCGATTGA AGAC 814

(2) INFORMATION FOR SEQ ID NO: 141:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Staphylococcus epidermidis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141:

CGGCGGTATC TTAGTTGTAT CTGCTGCTGA CGGTCCAATG CCACAAACTC GTGAACACAT 60

CTTATTATCA CGTAACGTTG GTGTACCAGC ATTAGTTGTA TTCTTAAACA AAGTTGACAT 120

GGTAGACGAC GAAGAATTAT TAGAATTAGT TGAAATGGAA GTTCGTGACT TATTAAGCGA 180

ATATGACTTC CCAGGTGACG ATGTACCTGT AATCGCTGGT TCTGCATTAA AAGCATTAGA 240

AGGCGATGCT GAATACGAAC AAAAAATCTT AGACTTAATG CAAGCAGTTG ATGATTACAT 300

TCCAACTCCA GAACGTGATT CTGACAAACC ATTCATGATG CCAGTTGAGG ACGTATTCTC 360

AATCACTGGT CGTGGTACTG TTGCTACAGG CCGTGTTGAA CGTGGTCAAA TCAAAGTWGG 420

TGAAGAAGTT GAAATCATCG GTATGCACGA AACTTCTAAA ACAACTGTTA CTGGTGTAGA 480

AATGTTCCGT AAATTATTAG ACTACGCTGA AGCTGGTGAC AACATCGGTG CTTTATTACG 540

TGGTGTTGCA CGTGAAGACG TACAACGTGG TCAAGTATTA GCTGCTCCTG GTTCTATTAC 600

ACCACACACA AAATTCAAAG CTGAAGTATA CGTATTATCT AAAGATGAAG GTGGACGTCA 660

CACTCCATTC TTCACTAACT ATCGCCCACA ATTCTATTTC CRTACTACTG ACGTAACTGG 720

TGTTGTAAAC TTACCAGAAG GTACAGAAAT GGTTATGCCT GGCGACAACG TTGAAATGAC 780

AGTTGAATTA ATCGCTCCAA TCGCTATCGA AGAC 814

(2) INFORMATION FOR SEQ ID NO: 142:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Staphylococcus saprophyticus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142:

CGGAGCTATC TTAGTAGTAT CTGCTGCTGA TGGCCCAATG CCACAAACTC GTGAACACAT 60

TCTTTTATCA CGTRACGTTG GTGYTCCAGC ATTAGTTGTA TTCTTAAACA AAGTTGACAT 120

GGTTGACGAY GAAGAATTAT TAGAATTRGT AGAAATGGAA GTTCGTGRCT TATTAAGCGA 180

ATATGACTTC CCAGGTGACG ATGTACCTGT AATCTCTGGT TCTGCATTAA AAGCTTTAGA 240

AGGCGACGCT GACTATGAGC AAAAAATCTT AGACTTAATG CAAGCTGTTG ATGACTYCAT 300

TCCAACACCA GAACGTGATT CTGACAAACC ATTCATGATG CCAGTTGAGG ACGTATTCTC 360

AATCACTGGT CGTGGTACTG TTGCTACAGG CCGTGTTGAA CGTGGTCAAA TCAAAGTCGG 420

TGAAGAAATC GARATCATCG GTATGCAAGA AGAATCAAGC AAAACAACTG TTACTGGTGT 480

AGAAATGTTC CGTAAATTAT TAGACTACGC TGAAGCTGGT GACAACATTG GTGCATTATT 540

ACGTGGTGTT TCACGTGATG ATGTACAACG TGGTCAAGTT TTAGCTGCTC CTGGTACTAT 600

CACACCACAT ACAAAATTCA AAGCGGATGT TTACGTTTTA TCTAAAGATG AAGGTGGTCG 660

TCATACGCCA TTCTTCACTA ACTACCGCCC ACAATTCTAT TTCCGTACTA CTGACGTAAC 720

TGGTGTTGTT AACTTACCAG AAGGTACTGA AATGGTTATG CCTGGCGATA ACGTTGAAAT 780

GGATGTTGAA TTAATTTCTC CAATCGCTAT TGAAGAC 817

(2) INFORMATION FOR SEQ ID NO: 143:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Staphylococcus simulans*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143:

CGGCGGTATC TTAGTAGTAT CTGCTGCAGA TGGTCCAATG CCACAAACTC GTGAACACAT 60

CTTATTATCA CGTAACGTTG GTGTACCAGC TTTAGTTGTA TTCTTAAACA AAGCTGACAT 120

GGTTGACGAC GAAGAATTAT TAGAATTAGT TGAAATGGAA GTTCGTGACT TATTATCTGA 180

ATACGACTTC CCTGGTGACG ATGTACCAGT TATCGTTGGT TCTGCATTAA AAGCTTTAGA 240

AGGCGACCCA GAATACGAAC AAAAAATCTT AGACTTAATG CAAGCTGTAG ATGACTACAT 300

CCCAACTCCA GAACGTGACT CTGATAAACC ATTCATGATG CCAGTTGAGG ACGTATTCTC 360

AATCACTGGT CGTGGTACTG TAGCAACAGG CCGTGTTGAA CGTGGTCAAA TCAAAGTCGG 420

TGAAGAAGTT GAAATCATCG GTATCACTGA AGAAAGCAAG AAAACAACAG TTACAGGTGT 480

AGAAATGTTC CGTAAATTAT TAGACTACGC TGAAGCTGGT GACAACATCG GTGCTTTATT 540

ACGTGGTGTT GCACGTGAAG ACGTACAACG TGGACAAGTA TTAGCAGCTC CTGGCTCTAT 600

TACTCCACAC ACAAAATTCA AAGCTGATGT TTACGTTTTA TCTAAAGAAG AAGGTGGACG 660

TCATACTCCA TTCTTCACTA ACTACCGCCC ACAATTCTAC TTCCGTACTA CTGACGTAAC 720

TGGCGTTGTT CACTTACCAG AAGGTACTGA AATGGTTATG CCTGGCGATA ACGTAGAAAT 780

GACTGTTGAA TTGATCGCTC CAATCGCGAT TGAAGAC 817

(2) INFORMATION FOR SEQ ID NO: 144:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus agalactiae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:

CGGAGCTATC CTTGTAGTTG CTTCAACTGA TGGACCAATG CCACAAACTC GTGAGCACAT 60

CCTTCTTTCA CGTCAAGTTG GTGTTAAACA CCTTATCGTA TTCATGAACA AAGTTGACCT 120

TGTTGATGAT GAAGAATTGC TTGAATTGGT TGAAATGGAA ATTCGTGACC TTCTTTCAGA 180

ATACGACTTC CCAGGTGATG ACCTTCCAGT TATCCAAGGT TCAGCTCTTA AAGCACTTGA 240

AGGCGACGAA AAATACGAAG ACATCATCAT GGAATTGATG AGCACTGTTG ATGAGTACAT 300

TCCAGAACCA GAACGTGATA CTGACAAACC TTTACTTCTT CCAGTTGAAG ATGTATTCTC 360

AATCACTGGA CGTGGTACAG TTGCTTCAGG ACGTATCGAC CGTGGTACTG TTCGTGTCAA 420

CGACGAAGTT GAAATCGTTG GTATTAAAGA AGATATCCAA AAAGCAGTTG TTACTGGTGT 480

TGAAATGTTC CGTAAACAAC TTGACGAAGG TCTTGCAGGG GACAACGTTG GTGTTCTTCT 540

TCGTGGTGTT CAACGTGATG AAATCGAACG TGGTCAAGTT CTTGCTAAAC CAGGTTCAAT 600

CAACCCACAC ACTAAATTTA AAGGTGAAGT TTACATCCTT TCTAAAGAAG AAGGTGGACG 660

TCATACTCCA TTCTTCAACA ACTACCGTCC ACAATTCTAC TTCCGTACAA CTGACGTAAC 720

AGGTTCAATC GAACTTCCAG CAGGAACAGA AATGGTTATG CCTGGTGATA ACGTTACTAT 780

CGAAGTTGAA TTGATTCACC CAATCGCCGT AGAACAA 817

(2) INFORMATION FOR SEQ ID NO: 145:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus pneumoniae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145:

CGGAGCTATC CTTGTAGTAG CTTCAACTGA CGGACCAATG CCACAAACTC GTGAGCACAT 60

CCTTCTTTCA CGTCAGGTTG GTGTTAAACA CCTTATCGTC TTCATGAACA AAGTTGACTT 120

GGTTGACGAC GAAGAATTGC TTGAATTGGT TGAAATGGAA ATCCGTGACC TATTGTCAGA 180

ATACGACTTC CCAGGTGACG ATCTTCCAGT TATCCAAGGT TCAGCACTTA AAGCTCTTGA 240

AGGTGACTCT AAATACGAAG ACATCGTTAT GGAATTGATG AACACAGTTG ATGAGTATAT 300

CCCAGAACCA GAACGTGACA CTGACAAACC ATTGCTTCTT CCAGTCGAGG ACGTATTCTC 360

AATCACTGGA CGTGGTACAG TTGCTTCAGG ACGTATCGAC CGTGGTATCG TTAAAGTCAA 420

CGACGAAATC GAAATCGTTG GTATCAAAGA AGAAACTCRA AAAGCAGTTG TTACTGGTGT 480

TGAAATGTTC CGTAAACAAC TTGACGAAGG TCTTGCTGGA GATAACGTAG GTGTCCTTCT 540

TCGTGGTGTT CAACGTGATG AAATCGAACG TGGACAAGTT ATCGCTAAAC CAGGTTCAAT 600

CAACCCACAC ACTAAATTCA AAGGTGAAGT CTACATCCTT ACTAAAGAAG AAGGTGGACG 660

TCACACTCCA TTCTTCAACA ACTACCGTCC ACAATTCTAC TTCCGTACTA CTGACGTTAC 720

AGGTTCAATC GAACTTCCAG CAGGTACTGA AATGGTAATG CCTGGTGATA ACGTGACAAT 780

CGACGTTGAG TTGATTCACC CAATCGCCGT AGAACAA 817

(2) INFORMATION FOR SEQ ID NO: 146:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 817 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus salivarius*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:

CGGTGCGATC CTTGTAGTAG CATCTACTGA CGGACCAATG CCACAAACTC GTGAGCACAT 60

CCTTCTTTCA CGTCAGGTTG GTGTTAAACA CCTTATCGTC TTCATGAACA AAGTTGACTT 120

GGTTGACGAT GAAGAATTGC TTGAATTGGT TGAAATGGAA ATCCGTGACC TTCTTTCAGA 180

ATACGATTTC CCAGGTGATG ACATTCCAGT TATCCAAGGT TCAGCTCTTA AAGCTCTTGA 240

AGGTGATTCT AAATACGAAG ACATCATCAT GGACTTGATG AACACTGTTG ACGAATACAT 300

CCCAGAACCA GAACGTGACA CTGACAAACC ATTGTTGCTT CCAGTCGAAG ACGTATTCTC 360

AATCACTGGT CGTGGTACTG TTGCTTCAGG ACGTATCGAC CGTGGTGTTG TTCGTGTCAA 420

TGACGAAGTT GAAATCGTTG GTCTTAAAGA AGACATCCAA AAAGCAGTTG TTACTGGTGT 480

TGAAATGTTC CGTAAACAAC TTGACGRAGG TATTGCCGGA GATAACGTCG GTGTTCTTCT 540

TCGTGGTATC CAACGTGATG AAATCGAACG TGGTCAAGTA TTGGCTGCAC CTGGTTCAAT 600

CAACCCACAC ACTAAATTCA AAGGTGAAGT TTACATCCTT TCTAAAGAAG AAGGTGGACG 660

TCACACTCCA TTCTTCAACA ACTACCGTCC ACAGTTCTAC TTCCGTACAA CTGACGTAAC 720

AGGTTCAATC GAACTTCCTG CAGGTACTGA AATGGTTATG CCTGGTGATA ACGTGACTAT 780

CGACGTTGAG TTGATCCACC CAATCGCCGT TGAACAA 817

(2) INFORMATION FOR SEQ ID NO: 147:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 897 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Agrobacterium tumefaciens*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

AACATGATCA CCGGTGCTGC CGAGATGGAC GGCGCGATCC TGGTTTGCTC GGCTGCCGAC 60

GGCCCGATGC CACAGACCCG CGAGCACATC CTGCTTGCCC GTCAGGTGGG CGTTCCGGCC 120

ATCGTCGTGT TCCTCAACAA GGTCGACCAG GTTGACGACG CCGAGCTTCT CGAGCTCGTC 180

GAGCTTGAAG TTCGCGAACT TCTGTCGTCC TACGACTTCC CGGGCGACGA TATCCCGATC 240

ATCAAGGGTT CGGCACTTGC TGCTCTTGAA GATTCTGACA AGAAGATCGG TGAAGACGCG 300

ATCCGCGAGC TGATGGCTGC TGTCGACGCC TACATCCCGA CGCCTGAGCG TCCGATCGAC 360

CAGCCGTTCC TGATGCCGAT CGAAGACGTG TTCTCGATCT CGGGTCGTGG TACGGTTGTG 420

ACGGGTCGCG TTGAGCGCGG TATCGTCAAG GTTGGTGAAG AAGTCGAAAT CGTCGGCATC 480

CGTCCGACCT CGAAGACGAC TGTTACCGGC GTTGAAATGT TCCGCAAGCT GCTCGACCAG 540

GGCCAGGCCG GCGACAACAT CGGTGCACTC GTTCGCGGCG TTACCCGTGA CGGCGTCGAG 600

CGTGGTCAGA TCCTGTGCAA GCCGGGTTCG GTCAAGCCGC ACAAGAAGTT CATGGCAGAA 660

GCCTACATCC TGACGAAGGA AGAAGGCGGC CGTCATACGC CGTTCTTCAC GAACTACCGT 720

CCGCAGTTCT ACTTCCGTAC GACTGACGTT ACCGGTATCG TTTCGCTTCC TGAAGGCACG 780

GAAATGGTTA TGCCTGGCGA CAACGTCACT GTTGAAGTCG AGCTGATCGT TCCGATCGCG 840

ATGGAAGAAA AGCTGCGCTT CGCTATCCGC GAAGGCGGCC GTACCGTCGG CGCCGGC 897

(2) INFORMATION FOR SEQ ID NO: 148:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 885 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Bacillus subtilis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148:

ATGATCACTG GTGCTGCGCA AATGGACGGA GCTATCCTTG TAGTATCTGC TGCTGATGGC 60

CCAATGCCAC AAACTCGTGA GCACATCCTT CTTTCTAAAA ACGTTGGTGT ACCATACATC 120

GTTGTATTCT TAAACAAATG CGACATGGTA GACGACGAAG AGCTTCTTGA ACTAGTTGAA 180

ATGGAAGTTC GCGATCTTCT TAGCGAATAC GACTTCCCTG GTGATGATGT ACCAGTTGTT 240

AAAGGTTCTG CTCTTAAAGC TCTTGAAGGA GACGCTGAGT GGGAAGCTAA AATCTTCGAA 300

CTTATGGATG CGGTTGATGA GTACATCCCA ACTCCAGAAC GCGACACTGA AAAACCATTC 360

ATGATGCCAG TTGAGGACGT ATTCTCAATC ACTGGTCGTG GTACAGTTGC TACTGGCCGT 420

GTAGAACGCG GACAAGTTAA AGTCGGTGAC GAAGTTGAAA TCATCGGTCT TCAAGAAGAG 480

AACAAGAAAA CAACTGTTAC AGGTGTTGAA ATGTTCCGTA AGCTTCTTGA TTACGCTGAA 540

GCTGGTGACA ACATTGGTGC CCTTCTTCGC GGTGTATCTC GTGAAGAAAT CCAACGTGGT 600

CAAGTACTTG CTAAACCAGG TACAATCACT CCACACAGCA AATTCAAAGC TGAAGTTTAC 660

GTTCTTTCTA AAGAAGAGGG TGGACGTCAT ACTCCATTCT TCTCTAACTA CCGTCCTCAG 720

TTCTACTTCC GTACAACTGA CGTAACTGGT ATCATCCATC TTCCAGAAGG CGTAGAAATG 780

GTTATGCCTG GAGATAACAC TGAAATGAAC GTTGAACTTA TTTCTACAAT CGCTATCGAA 840

GAAGGAACTC GTTTCTCTAT TCGTGAAGGC GGACGTACTG TTGGT 885

(2) INFORMATION FOR SEQ ID NO: 149:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 882 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Bacteroides fragilis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

ATGGTTACTG GTGCTGCTCA GATGGACGGT GCTATCATTG TAGTTGCTGC TACTGATGGT 60

CCGATGCCTC AGACTCGTGA GCACATCCTT TTGGCTCGTC AGGTAAACGT TCCGAAGCTG 120

GTTGTATTCA TGAACAAGTG CGATATGGTT GAAGATGCTG AGATGTTGGA ACTTGTTGAA 180

ATGGAAATGA GAGAATTGCT TTCATTCTAT GATTTCGACG GTGACAATAC TCCGATCATT 240

CAGGGTTCTG CTCTTGGTGC ATTGAACGGC GTAGAAAAAT GGGAAGACAA AGTAATGGAA 300

CTGATGGAAG CTGTTGATAC TTGGATTCCA CTGCCTCCGC GCGATGTTGA TAAACCTTTC 360

TTGATGCCGG TAGAAGACGT GTTCTCTATC ACAGGTCGTG GTACTGTAGC TACAGGTCGT 420

ATCGAAACTG GTGTTATCCA TGTAGGTGAT GAAATCGAAA TCCTCGGTTT GGGTGAAGAT 480

AAGAAATCAG TTGTAACAGG TGTTGAAATG TTCCGCAAAC TTCTGGATCA GGGTGAAGCT 540

GGTGACAACG TAGGTCTGTT GCTTCGTGGT GTTGACAAGA ACGAAATCAA ACGTGGTATG 600

GTTCTTTGTA AACCGGGTCA GATTAAACCT CACTCTAAAT TCAAAGCAGA GGTTTATATC 660

CTGAAGAAAG AAGAAGGTGG TCGTCACACT CCATTCCATA ACAAATATCG TCCTCAGTTC 720

TACCTGCGTA CTATGGACTG TACAGGTGAA ATCACTCTTC CGGAAGGAAC TGAAATGGTA 780

ATGCCGGGTG ATAACGTAAC TATCACTGTA GAGTTGATCT ATCCGGTTGC ACTGAACATC 840

GGTCTTCGTT TCGCTATCCG CGAAGGTGGA CGTACAGTAG GT 882

(2) INFORMATION FOR SEQ ID NO: 150:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 888 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Borrelia burgdorferi*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150:

AATATGATTA CAGGAGCAGC TCAAATGGAT GCAGCGATAC TTTTAGTTGC TGCTGATAGT 60

GGTGCTGAGC CTCAAACAAA AGAGCATTTG CTTCTTGCTC AAAGAATGGG AATAAAGAAA 120

ATAATAGTTT TTTTAAATAA ATTGGACTTA GCAGATCCTG AACTTGTTGA GCTTGTTGAA 180

GTTGAAGTTT TAGAACTTGT TGAAAAATAT GGCTTTTCAG CTGATACTCC AATAATCAAA 240

GGTTCAGCTT TTGGGGCTAT GTCAAATCCA GAAGATCCTG AATCTACAAA ATGCGTTAAA 300

GAACTTCTTG AATCTATGGA TAATTATTTT GATCTTCCAG AAAGAGATAT TGACAAGCCA 360

TTTTTGCTTG CTGTTGAAGA TGTATTTTCT ATTTCAGGAA GAGGCACTGT TGCTACTGGG 420

CGTATTGAAA GAGGTATTAT TAAAGTTGGT CAAGAAGTTG AAATAGTTGG AATTAAAGAA 480

ACCAGAAAAA CTACTGTTAC TGGTGTTGAA ATGTTCCAGA AAATTCTTGA GCAAGGTCAA 540

GCAGGGGATA ATGTTGGTCT TCTTTTGAGA GGCGTTGATA AAAAAGACAT TGAGAGGGGG 600

CAAGTTTTGT CAGCTCCAGG TACAATTACT CCACACAAGA AATTTAAAGC TTCAATTTAT 660

TGTTTGACTA AAGAAGAAGG CGGTAGGCAC AAGCCATTTT TCCCAGGGTA TAGACCACAG 720

TTCTTTTTTA GAACAACCGA TGTTACTGGA GTTGTTGCTT TAGAGGGCAA AGAAATGGTT 780

ATGCCTGGTG ATAATGTTGA TATTATTGTT GAGCTGATCT CTTCAATAGC TATGGATAAG 840

AATGTAGAAT TTGCTGTTCG AGAAGGTGGA AGAACCGTTG CTTCAGGA 888

(2) INFORMATION FOR SEQ ID NO: 151:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 894 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Brevibacterium linens*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151:

AACATGATCA CCGGTGCCGC TCAGATGGAC GGTGCGATCC TCGTCGTCGC CGCTACCGAC 60

GGACCGATGC CCCAGACCCG TGAGCACGTG CTGCTCGCGC GTCAGGTCGG CGTTCCCTAC 120

ATCGTCGTGG CTCTGAACAA GTCCGACATG GTCGATGACG AGGAGCTCCT CGAGCTCGTC 180

GAATTCGAGG TCCGCGACCT GCTCTCGAGC CAGGACTTCG ACGGAGACAA CGCTCCGGTC 240

ATTCCGGTGT CCGCTCTCAA GGCGCTGGAA GGCGACGAGA AGTGGGTCAA GAGCGTTCAG 300

GATCTCATGG CTGCCGTCGA TGACAACGTT CCGGAGCCGG AGCGCGATGT CGACAAGCCG 360

TTCCTCATGC CCGTCGAGGA CGTCTTCACG ATCACCGGTC GTGGAACCGT CGTCACCGGT 420

CGTGTCGAGC GCGGCGTGCT CCTGCCTAAC GACGAAATCG AAATCGTCGG CATCAAGGAG 480

AAGTCGTCCA AGACGACTGT CACCGCTATC GAGATGTTCC GCAAGACCCT GCCGGATGCC 540

CGTGCAGGTG AGAACGTCGG TCTGCTCCTC CGCGGCACCA AGCGCGAGGA TGTTGAGCGC 600

GGTCAGGTCA TCGTGAAGCC GGGTTCGATC ACCCCGCACA CCAAGTTCGA GGCTCAGGTC 660

TACATCCTGA GCAAGGACGA GGGCGGACGT CACAACCCGT TCTACTCGAA CTACCGTCCG 720

CAGTTCTACT TCCGGACCAC GGACGTCACC GGTGTCATCA CGCTGCCCGA GGGCACCGAG 780

ATGGTCATGC CCGGCGACAA CACCGATATG TCGGTCGAGC TCATCCAGCC GATCGCTATG 840

GAGGACCGCC TCCGCTTCGC AATCCGCGAA GGTGGCCGCA CCGTCGGCGC CGGT 894

(2) INFORMATION FOR SEQ ID NO: 152:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 888 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Burkholderia cepacia*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152:

ATGATCACGG GCGCAGCGCA GATGGACGGC GCGATCCTGG TTTGCTCGGC AGCAGACGGC 60

CCGATGCCGC AAACGCGTGA GCACATCCTG CTGGCGCGTC AGGTTGGTGT TCCGTACATC 120

ATCGTGTTCC TGAACAAGTG CGACAGTGTG GACGACGCTG AACTGCTCGA GCTGGTCGAG 180

ATGGAAGTTC GCGAACTCCT GTCGAAGTAC GACTTCCCGG GCGACGACAC GCCGATCGTG 240

AAGGGTTCGG CCAAGCTGGC GCTGGAAGGC GACACGGGCG AGCTGGGCGA AGTGGCGATC 300

ATGAGCCTGG CAGACGCGCT GGACACGTAC ATCCCGACGC CGGAGCGTGC AGTTGACGGC 360

GCGTTCCTGA TGCCGGTGGA AGACGTGTTC TCGATCTCGG GCCGTGGTAC GGTGGTGACG 420

GGTCGTGTCG AGCGCGGCAT CGTGAAGGTC GGCGAAGAAA TCGAAATCGT CGGTATCAAG 480

CCGACGGTGA AGACGACCTG CACGGGCGTT GAAATGTTCC GCAAGCTGCT GGACCAAGGT 540

CAGGCAGGCG ACAACGTCGG TATCCTGCTG CGCGGCACGA AGCGTGAAGA CGTGGAGCGT 600

GGCCAGGTTC TGGCGAAGCC GGGTTCGATC ACGCCGCACA CGCACTTCAC GGCTGAAGTG 660

TACGTGCTGA GCAAGGACGA AGGCGGCCGT CACACGCCGT TCTTCAACAA CTACCGTCCG 720

CAGTTCTACT TCCGTACGAC GGACGTGACG GGCTCGATCG AGCTGCCGAA GGACAAGGAA 780

ATGGTGATGC CGGGCGACAA CGTGTCGATC ACGGTGAAGC TGATTGCTCC GATCGCGATG 840

GAAGAAGGTC TGCGCTTCGC AATCCGTGAA GGCGGCCGTA CGGTCGGC 888

(2) INFORMATION FOR SEQ ID NO: 153:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Chlamydia trachomatis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153:

AACATGATCA CCGGTGCGGC TCAAATGGAC GGGGCTATTC TAGTAGTTTC TGCAACAGAC 60

GGAGCTATGC CTCAAACTAA AGAGCATATT CTTTTGGCAA GACAAGTTGG GGTTCCTTAC 120

ATCGTTGTTT TTCTCAATAA AATTGACATG ATTTCCGAAG AAGACGCTGA ATTGGTCGAC 180

TTGGTTGAGA TGGAGTTGGC TGAGCTTCTT GAAGAGAAAG GATACAAAGG GTGTCCAATC 240

ATCAGAGGTT CTGCTCTGAA AGCTTTGGAA GGAGATGCTG CATACATAGA GAAAGTTCGA 300

GAGCTAATGC AAGCCGTCGA TGATAATATC CCTACTCCAG AAAGAGAAAT TGACAAGCCT 360

TTCTTAATGC CTATTGAGGA CGTGTTCTCT ATCTCCGGAC GAGGAACTGT AGTAACTGGA 420

CGTATTGAGC GTGGAATTGT TAAAGTTTCC GATAAAGTTC AGTTGGTCGG TCTTAGAGAT 480

ACTAAAGAAA CGATTGTTAC TGGGGTTGAA ATGTTCAGAA AAGAACTCCC AGAAGGTCGT 540

GCAGGAGAGA ACGTTGGATT GCTCCTCAGA GGTATTGGTA AGAACGATGT GGAAAGAGGA 600

ATGGTTGTTT GCTTGCCAAA CAGTGTTAAA CCTCATACAC AGTTTAAGTG TGCTGTTTAC 660

GTTCTGCAAA AAGAAGAAGG TGGACGACAT AAGCCTTTCT TCACAGGATA TAGACCTCAA 720

TTCTTCTTCC GTACAACAGA CGTTACAGGT GTGGTAACTC TGCCTGAGGG AGTTGAGATG 780

GTCATGCCTG GGGATAACGT TGAGTTTGAA GTGCAATTGA TTAGCCCTGT GGCTTTAGAA 840

GAAGGTATGA GATTTGCGAT TCGTGAAGGT GGTCGTACAA TCGGTGCTGG A 891

(2) INFORMATION FOR SEQ ID NO: 154:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Escherichia coli*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154:

AACATGATCA CCGGTGCTGC GCAGATGGAC GGCGCGATCC TGGTAGTTGC TGCGACTGAC 60

GGCCCGATGC CGCAGACTCG TGAGCACATC CTGCTGGGTC GTCAGGTAGG CGTTCCGTAC 120

ATCATCGTGT TCCTGAACAA ATGCGACATG GTTGATGACG AAGAGCTGCT GGAACTGGTT 180

GAAATGGAAG TTCGTGAACT TCTGTCTCAG TACGACTTCC CGGGCGACGA CACTCCGATC 240

GTTCGTGGTT CTGCTCTGAA AGCGCTGGAA GGCGACGCAG AGTGGGAAGC GAAAATCCTG 300

GAACTGGCTG GCTTCCTGGA TTCTTACATT CCGGAACCAG AGCGTGCGAT TGACAAGCCG 360

TTCCTGCTGC CGATCGAAGA CGTATTCTCC ATCTCCGGTC GTGGTACCGT TGTTACCGGT 420

CGTGTAGAAC GCGGTATCAT CAAAGTTGGT GAAGAAGTTG AAATCGTTGG TATCAAAGAG 480

ACTCAGAAGT CTACCTGTAC TGGCGTTGAA ATGTTCCGCA AACTGCTGGA CGAAGGCCGT 540

GCTGGTGAGA ACGTAGGTGT TCTGCTGCGT GGTATCAAAC GTGAAGAAAT CGAACGTGGT 600

CAGGTACTGG CTAAGCCGGG CACCATCAAG CCGCACACCA AGTTCGAATC TGAAGTGTAC 660

ATTCTGTCCA AAGATGAAGG CGGCCGTCAT ACTCCGTTCT TCAAAGGCTA CCGTCCGCAG 720

TTCTACTTCC GTACTACTGA CGTGACTGGT ACCATCGAAC TGCCGGAAGG CGTAGAGATG 780

GTAATGCCGG GCGACAACAT CAAAATGGTT GTTACCCTGA TCCACCCGAT CGCGATGGAC 840

GACGGTCTGC GTTTCGCAAT CCGTGAAGGC GGCCGTACCG TTGGCGCGGG C 891

(2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Fibrobacter succinogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155:

AACATGGTGA CTGGTGCTGC TCAGATGGAC GGCGCTATCC TCGTTGTTGC CGCTACTGAC 60

GGTCCGATGC CGCAGACTCG CGAACACATC CTTCTCGCTC ACCAGGTTGG CGTGCCGAAG 120

ATCGTCGTGT TCATGAACAA GTGCGACATG GTTGACGATG CTGAAATTCT CGACCTCGTC 180

GAAATGGAAG TTCGCGAACT CCTCTCCAAG TATGACTTCG ACGGTGACAA CACCCCGATC 240

ATCCGTGGTT CCGCTCTCAA GGCCCTCGAA GGCGATCCGG AATACCAGGA CAAGGTCATG 300

GAACTCATGA ACGCTTGCGA CGAATACATC CCGCTCCCGC AGCGCGATAC CGACAAGCCG 360

TTCCTCATGC CGATCGAAGA CGTGTTCACG ATTACTGGCC GCGGCACTGT CGCTACTGGC 420

CGTATCGAAC GCGGTGTCGT TCGCTTGAAC GACAAGGTTG AACGTATCGG TCTCGGTGAA 480

ACCACCGAAT ACGTCATCAC CGGTGTTGAA ATGTTCCGTA AGCTCCTCGA CGACGCTCAG 540

GCAGGTGACA ACGTTGGTCT CCTCCTCCGT GGTGCTGAAA AGAAGGACAT CGTCCGTGGC 600

ATGGTTCTCG CAGCTCCGAA GTCTGTCACT CCGCACACCG AATTTAAGGC TGAAATCTAC 660

GTTCTCACGA AGGACGAAGG TGGCCGTCAC ACGCCGTTCA TGAATGGCTA CCGTCCGCAG 720

TTCTACTTCC GCACCACCGA CGTTACTGGT ACGATCCAGC TCCCGGAAGG TGTCGAAATG 780

GTTACTCCGG GTGACACGGT CACGATCCAC GTGAACCTCA TCGCTCCGAT CGCTATGGAA 840

AAGCAGCTCC GCTTCGCTAT CCGTGAAGGT GGACGTACTG TTGGTGCTGG C 891

(2) INFORMATION FOR SEQ ID NO: 156:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 894 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Flavobacterium ferrugineum*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156:

AACATGATCA CCGGTGCTGC CCAGATGGAC GGTGCTATCT TAGTTGTGGC TGCATCAGAC 60

GGTCCTATGC CTCAAACAAA AGAACACATC CTGCTTGCTG CCCAGGTAGG TGTACCTAAA 120

ATGGTTGTGT TTCTGAATAA AGTTGACCTC GTTGACGACG AAGAGCTCCT GGAGCTGGTT 180

GAGATCGAGG TTCGCGAAGA ACTGACTAAA CGCGGTTTCG ACGGCGACAA CACTCCAATC 240

ATCAAAGGTT CCGCTACAGG CGCCCTCGCT GGTGAAGAAA AGTGGGTTAA AGAAATTGAA 300

AACCTGATGG ACGCTGTTGA CAGCTACATC CCACTGCCTC CTCGTCCGGT TGATCTGCCG 360

TTCCTGATGA GCGTAGAGGA CGTATTCTCT ATCACTGGTC GTGGTACTGT TGCTACCGGT 420

CGTATCGAGC GTGGCCGTAT CAAAGTTGGT GAGCCTGTTG AGATCGTAGG TCTGCAGGAG 480

TCTCCCCTGA ACTCTACCGT TACAGGTGTT GAGATGTTCC GCAAACTCCT CGACGAAGGT 540

GAAGCTGGTG ATAACGCCGG TCTCCTCCTC CGTGGTGTTG AAAAAACACA GATCCGTCGC 600

GGTATGGTAA TCGTTAAACC CGGTTCCATC ACTCCGCACA CGGACTTCAA AGGCGAAGTT 660

TACGTACTGA GCAAAGACGA AGGTGGCCGT CACACTCCAT TCTTCAACAA ATACCGTCCT 720

CAATTCTACT TCCGTACAAC TGACGTTACA GGTGAAGTAG AACTGAACGC AGGAACAGAA 780

ATGGTTATGC CTGGTGATAA CACCAACCTG ACCGTTAAAC TGATCCAACC GATCGCTATG 840

GAAAAAGGTC TGAAATTCGC GATCCGCGAA GGTGGCCGTA CCGTAGGTGC AGGA 894

(2) INFORMATION FOR SEQ ID NO: 157:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Haemophilus influenzae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157:

AATATGATTA CTGGTGCGGC ACAAATGGAT GGTGCTATTT TAGTAGTAGC AGCAACAGAT 60

GGTCCTATGC CACAAACTCG TGAACACATC TTATTAGGTC GCCAAGTAGG TGTTCCATAC 120

ATCATCGTAT TCTTAAACAA ATGCGACATG GTAGATGACG AAGAGTTATT AGAATTAGTC 180

GAAATGGAAG TTCGTGAACT TCTATCTCAA TATGACTTCC CAGGTGACGA TACACCAATC 240

GTACGTGGTT CAGCATTACA AGCGTTAAAC GGCGTAGCAG AATGGGAAGA AAAAATCCTT 300

GAGTTAGCAA ACCACTTAGA TACTTACATC CCAGAACCAG AACGTGCGAT TGACCAACCG 360

TTCCTTCTTC CAATCGAAGA TGTGTTCTCA ATCTCAGGTC GTGGTACTGT AGTAACAGGT 420

CGTGTAGAAC GAGGTATTAT CCGTACAGGT GATGAAGTAG AAATCGTCGG TATCAAAGAT 480

ACAGCGAAAA CTACTGTAAC GGGTGTTGAA ATGTTCCGTA AATTACTTGA CGAAGGTCGT 540

GCAGGTGAAA ACATCGGTGC ATTATTACGT GGTACCAAAC GTGAAGAAAT CGAACGTGGT 600

CAAGTATTAG CGAAACCAGG TTCAATCACA CCACACACTG ACTTCGAATC AGAAGTGTAC 660

GTATTATCAA AAGATGAAGG TGGTCGTCAT ACTCCATTCT TCAAAGGTTA CCGTCCACAA 720

TTCTATTTCC GTACAACAGA CGTGACTGGT ACAATCGAAT TACCAGAAGG CGTGGAAATG 780

GTAATGCCAG GCGATAACAT CAAGATGACA GTAAGCTTAA TCCACCCAAT TGCGATGGAT 840

CAAGGTTTAC GTTTCGCAAT CCGTGAAGGT GGCCGTACAG TAGGTGCAGG C 891

(2) INFORMATION FOR SEQ ID NO: 158:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 906 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Helicobacter pylori*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158:

AACATGATCA CCGGTGCGGC GCAAATGGAC GGAGCGATTT TGGTTGTTTC TGCAGCTGAT 60

GGCCCTATGC CTCAAACTAG GGAGCATATC TTATTGTCTC GTCAAGTAGG CGTGCCTCAC 120

ATCGTTGTTT TCTTAAACAA ACAAGACATG GTAGATGACC AAGAATTGTT AGAACTTGTA 180

GAAATGGAAG TGCGCGAATT GTTGAGCGCG TATGAATTTC CTGGCGATGA CACTCCTATC 240

GTAGCGGGTT CAGCTTTAAG AGCTTTAGAA GAAGCAAAGG CTGGTAATGT GGGTGAATGG 300

GGTGAAAAAG TGCTTAAACT TATGGCTGAA GTGGATGCCT ATATCCCTAC TCCAGAAAGA 360

GACACTGAAA AAACTTTCTT GATGCCGGTT GAAGATGTGT TCTCTATTGC GGGTAGAGGG 420

ACTGTGGTTA CAGGTAGGAT TGAAAGAGGC GTGGTGAAAG TAGGCGATGA AGTGGAAATC 480

GTTGGTATCA GACCTACACA AAAAACGACT GTAACCGGTG TAGAAATGTT TAGGAAAGAG 540

TTGGAAAAAG GTGAAGCCGG CGATAATGTG GGCGTGCTTT TGAGAGGAAC TAAAAAAGAA 600

GAAGTGGAAC GCGGTATGGT TCTATGCAAA CCAGGTTCTA TCACTCCGCA CAAGAAATTT 660

GAGGGAGAAA TTTATGTCCT TCTAAAGAA GAAGGCGGGA GACACACTCC ATTCTTCACC 720

AATTACCGCC CGCAATTCTA TGTGCGCACA ACTGATGTGA CTGGCTCTAT CACCCTTCCT 780

GAAGGCGTAG AAATGGTTAT GCCTGGCGAT AATGTGAAAA TCACTGTAGA GTTGATTAGC 840

CCTGTTGCGT TAGAGTTGGG AACTAAATTT GCGATTCGTG AAGGCGGTAG GACCGTTGGT 900

GCTGGT 906

(2) INFORMATION FOR SEQ ID NO: 159:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Micrococcus luteus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 159:

AACATGATCA CCGGCGCCGC TCAGATGGAC GGCGCGATCC TCGTGGTCGC CGCTACCGAC 60

GGCCCGATGG CCCAGACCCG TGAGCACGTG CTCCTGGCCC GCCAGGTCGG CGTGCCGGCC 120

CTGCTCGTGG CCCTGAACAA GTCGGACATG GTGGAGGACG AGGAGCTCCT CGAGCGTGTC 180

GAGATGGAGG TCCGGCAGCT GCTGTCCTCC AGGAGCTTCG ACGTCGACGA GGCCCCGGTC 240

ATCCGCACCT CCGCTCTGAA GGCCCTCGAG GGCGACCCCC AGTGGGTCAA GTCCGTCGAG 300

GACCTCATGG ATGCCGTGGA CGAGTACATC CCGGACCCGG TGCGCGACAA GGACAAGCCG 360

TTCCTGATGC CGATCGAGGA CGTCTTCACG ATCACCGGCC GTGGCACCGT GGTGACCGGT 420

CGCGCCGAGC GCGGCACCCT GAAGATCAAC TCCGAGGTCG AGATCGTCGG CATCCGCGAC 480

GTGCAGAAGA CCACTGTCAC CGGCATCGAG ATGTTCCACA AGCAGCTCGA CGAGGCCTGG 540

GCCGGCGAGA ACTGCGGTCT GCTCGTGCGC GGTCTGAAGC GCGACGACGT CGAGCGCGGC 600

CAGGTGCTGG TGGAGCCGGG CTCCATCACC CCGCACACCA ACTTCGAGGC GAACGTCTAC 660

ATCCTGTCCA AGGACGAGGG TGGGCGTCAC ACCCCGTTCT ACTCGAACTA CCGCGCGCAG 720

TTCTACTTCC GCACCACCGA CGTCACCGGC GTCATCACGC TGCCCGAGGG CACCGAGATG 780

GTCATGCCCG GCGACACCAC CGAGATGTCG GTCGAGCTCA TCCAGCCGAT CGCCATGGAG 840

GAGGGCCTCG GCTTCGCCAT CCGCGAGGGT GGCCGCACCG TGGGCTCCGG C 891

(2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Mycobacterium tuberculosis*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

AACATGATCA CCGGCGCCGC GCAGATGGAC GGTGCGATCC TGGTGGTCGC CGCCACCGAC 60

GGCCCGATGC CCCAGACCCG CGAGCACGTT CTGCTGGCGC GTCAAGTGGG TGTGCCCTAC 120

ATCCTGGTAG CGCTGAACAA GGCCGACGCA GTGGACGACG AGGAGCTGCT CGAACTCGTC 180

GAGATGGAGG TCCGCGAGCT GCTGGCTGCC CAGGAATTCG ACGAGGACGC CCCGGTTGTG 240

CGGGTCTCGG CGCTCAAGGC GCTCGAGGGT GACGCGAAGT GGGTTGCCTC TGTCGAGGAA 300

CTGATGAACG CGGTCGACGA GTCGATTCCG GACCCGGTCC GCGAGACCGA CAAGCCGTTC 360

CTGATGCCGG TCGAGGACGT CTTCACCATT ACCGGCCGCG GAACCGTGGT CACCGGACGT 420

GTGGAGCGCG GCGTGATCAA CGTGAACGAG GAAGTTGAGA TCGTCGGCAT TCGCCCATCG 480

ACCACCAAGA CCACCGTCAC CGGTGTGGAG ATGTTCCGCA AGCTGCTCGA CCAGGGCCAG 540

GCGGGCGACA ACGTTGGTTT GCTGCTGCGG GGCGTCAAGC GCGAGGACGT CGAGCGTGGC 600

CAGGTTGTCA CCAAGCCCGG CACCACCACG CCGCACACCG AGTTCGAAGG CCAGGTCTAC 660

ATCCTGTCCA AGGACGAGGG CGGCCGGCAC ACGCCGTTCT TCAACAACTA CCGTCCGCAG 720

TTCTACTTCC GCACCACCGA CGTGACCGGT GTGGTGACAC TGCCGGAGGG CACCGAGATG 780

GTGATGCCCG GTGACAACAC CAACATCTCG GTGAAGTTGA TCCAGCCCGT CGCCATGGAC 840

GAAGGTCTGC GTTTCGCGAT CCGCGAGGGT GGCCGCACCG TGGGCGCCGG C 891

(2) INFORMATION FOR SEQ ID NO: 161:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycoplasma genitalium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161:

AATATGATCA CAGGTGCTGC ACAAATGGAT GGAGCTATTC TAGTTGTTTC AGCAACTGAT 60

AGTGTGATGC CCCAAACCCG CGAGCACATC TTACTTGCCC GCCAAGTAGG GGTTCCTAAA 120

ATGGTAGTTT TTCTAAACAA GTGTGATATT GCTAGTGATG AAGAGGTACA AGAACTTGTT 180

GCTGAAGAAG TACGTGATCT GTTAACTTCC TATGGTTTTG ATGGTAAGAA CACTCCTATT 240

ATTTATGGCT CAGCTTTAAA AGCATTGGAA GGTGATCCAA AGTGGGAGGC TAAGATCCAT 300

GATTTGATTA AAGCAGTTGA TGAATGGATT CCAACTCCTA CACGTGAAGT AGATAAACCT 360

TTCTTATTAG CAATTGAAGA TACGATGACC ATTACTGGTA GAGGTACAGT TGTTACAGGA 420

AGAGTTGAAA GAGGTGAACT CAAAGTAGGT CAAGAAGTTG AAATTGTTGG TTTAAAACCA 480

ATTAGAAAAG CAGTTGTTAC TGGAATTGAA ATGTTCAAAA AGGAACTTGA TTCAGCAATG 540

GCTGGTGACA ATGCTGGGGT ATTATTACGT GGTGTTGAAC GTAAAGAAGT TGAAAGAGGT 600

CAAGTTTTAG CAAAACCAGG CTCTATTAAA CCGCACAAGA AATTTAAAGC TGAGATCTAT 660

GCTTTAAAGA AAGAAGAAGG TGGTAGACAC ACTGGTTTTT TAAACGGTTA CCGTCCTCAA 720

TTCTATTTCC GTACCACTGA TGTAACTGGT TCTATTGCTT TAGCTGAAAA TACTGAAATG 780

GTTCTACCTG GTGATAATGC TTCTATTACT GTTGAGTTAA TTGCTCCTAT CGCTTGTGAA 840

AAAGGTAGTA AGTTCTCAAT TCGTGAAGGT GGTAGAACTG TAGGGGCAGG C 891

(2) INFORMATION FOR SEQ ID NO: 162:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Neisseria gonorrheae*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162:

AACATGATTA CCGGCGCCGC ACAAATGGAC GGTGCAATCC TGGTATGTTC TGCTGCCGAC 60

GGCCCTATGC CGCAAACCCG CGAACACATC CTGCTGGCCC GTCAAGTAGG CGTACCTTAC 120

ATCATCGTGT TCATGAACAA ATGCGACATG GTCGACGATG CCGAGCTGTT CCAACTGGTT 180

GAAATGGAAA TCCGCGACCT GCTGTCCAGC TACGACTTCC CCGGCGACGA CTGCCCGATC 240

GTACAAGGTT CCGCACTGAA AGCCTTGGAA GGCGATGCCG CTTACGAAGA AAAAATCTTC 300

GAACTGGCTA CCGCATTGGA CAGATACATC CCGACTCCCG AGCGTGCCGT GGACAAACCA 360

TTCCTGCTGC CTATCGAAGA CGTGTTCTCC ATTTCCGGCC GCGGTACCGT AGTCACCGGC 420

CGTGTAGAGC GAGGTATCAT CCACGTTGGT GACGAGATTG AAATCGTCGG TCTGAAAGAA 480

ACCCAAAAAA CCACCTGTAC CGGCGTTGAA ATGTTCCGCA AACTGCTGGA CGAAGGTCAG 540

GCGGGCGACA ACGTAGGCGT ATTGCTGCGC GGTACCAAAC GTGAAGACGT AGAACGCGGT 600

CAGGTATTGG CCAAACGGGG TACTATCACT CCTCACACCA AGTTCAAAGC AGAAGTGTAC 660

GTATTGAGCA AAGAAGAGGG CGGCCCCCAT ACCCCGTTTT TCGCCAACTA CCGTCCCCAA 720

TTCTACTTCC GTACCACTGA CGTAACCGGC ACGATTACTT TGGAAAAAGG TGTGGAAATG 780

GTAATGCCGG GTGAGAACGT AACCATTACT GTAGAACTGA TTGCGCCTAT CGCTATGGAA 840

GAAGGTCTGC GCTTTGCGAT TCGCGAAGGC GGCCGTACCG TGGGTGCCGG C 891

(2) INFORMATION FOR SEQ ID NO: 163:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Rickettsia prowazekii*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163:

AATATGATAA CTGGTGCCGC TCAGATGGAT GGTGCTATAT TAGTAGTTTC TGCTGCTGAT 60

GGTCCTATGC CTCAAACTAG AGAACATATA TTACTGGCAA AACAGGTAGG TGTACCTGCT 120

ATGGTAGTAT TTTTGAATAA AGTAGATATG GTAGATGATC CTGACCTATT AGAATTAGTT 180

GAGATGGAAG TAAGAGAATT ATTATCAAAA TATGGTTTCC CTGGTAATGA AATACCTATT 240

ATTAAAGGTT CTGCACTTCA AGCTTTAGAA GGAAAACCTG AAGGTGAAAA AGCTATTAAT 300

GAGTTAATGA ATGCAGTAGA TACGTATATA CCTCAGCCTA TAGAGCTACA AGATAAACCT 360

TTTTTAATGC CAATAGAGGA TGTATTTTCT ATTTCAGGCA GAGGTACCGT TGTAACTGGT 420

AGAGTGGAGT CAGGCATAAT TAAGGTGGGT GAAGAAATTG AAATAGTAGG TCTAAAAAAT 480

ACGCAAAAAA CGACTTGTAC AGGTGTAGAA ATGTTCAGAA AATTACTTGA TGAAGGACAA 540

TCTGGAGATA ATGTCGGTAT ATTACTACGT GGTACAAAAA GAGAAGAAGT AGAAAGAGGA 600

CAAGTACTTG CAAAACCTGG GAGCATAAAA CCGCATGATA AATTTGAAGC TGAAGTGTAT 660

GTGCTTAGTA AAGAGGAAGG TGGACGTCAT ACCCCATTTA CTAATGATTA TCGCCCACAG 720

TTCTATTTTA GAACAACAGA TGTTACCGGC ACAATAAAAT TGCCTTCTGA TAAGCAGATG 780

GTTATGCCTG GAGATAATGC TACTTTTTCA GTAGAATTAA TTAAGCCGAT TGCTATGCAA 840

GAAGGGTTAA AATTCTCTAT ACGTGAAGGT GGTAGAACAG TAGGAGCCGG T 891

(2) INFORMATION FOR SEQ ID NO: 164:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Salmonella typhimurium*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164:

AACATGATCA CCGGTGCTGC TCAGATGGAC GGCGCGATCC TGGTTGTTGC TGCGACTGAC 60

GGCCCGATGC CGCAGACCCG TGAGCACATC CTGCTGGGTC GTCAGGTAGG CGTTCCGTAC 120

ATCATCGTGT TCCTGAACAA ATGCGACATG GTTGATGACG AAGAGCTGCT GGAACTGGTT 180

GAGATGGAAG TTCGCGAACT GCTGTCTCAG TACGACTTCC CGGGCGACGA CACTCCGATC 240

GTTCGTGGTT CTGCTCTGAA AGCGCTGGAA GGCGACGCAG AGTGGGAAGC GAAAATCATC 300

GAACTGGCTG GCTTCCTGGA TTCTTATATT CCGGAACCAG AGCGTGCGAT TGACAAGCCG 360

TTCCTGCTGC CGATCGAAGA CGTATTCTCC ATCTCCGGTC GTGGTACCGT TGTTACCGGT 420

CGTGTAGAGC GCGGTATCAT CAAAGTGGGC GAAGAAGTTG AAATCGTTGG TATCAAAGAG 480

ACTCAGAAGT CTACCTGTAC TGGCGTTGAA ATGTTCCGCA AACTGCTGGA CGAAGGCCGT 540

GCCGGTGAGA ACGTAGGTGT TCTGCTGCGT GGTATCAAAC GTGAAGAAAT CGAACGTGGT 600

CAGGTACTGG CTAAGCCGGG CACCATCAAG CCGCACACCA AGTTCGAATC TGAAGTGTAC 660

ATTCTGTCCA AAGATGAAGG CGGCCGTCAT ACTCCGTTCT TCAAAGGCTA CCGTCCGCAG 720

TTCTACTTCC GTACTACTGA CGTGACTGGT ACCATCGAAC TGCCGGAAGG CGTAGAGATG 780

GTAATGCCGG GCGACAACAT CAAAATGGTT GTTACCCTGA TCCACCCGAT CGCGATGGAC 840

GACGGTCTGC GTTTCGCAAT CCGTGAAGGC GGCCGTACCG TTGGCGCGGG C 891

(2) INFORMATION FOR SEQ ID NO: 165:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 881 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Shewanella putida*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:

ATGATCACTG GTGCTGCACA GATGGACGGC GCGATTCTGG TAGTCGCTTC AACAGACGGT 60

CCAATGCCAC AGACTCGTGA GCACATCCTG CTTTCTCGTC AGGTTGGCGT ACCATTCATC 120

ATCGTATTCA TGAACAAATG TGACATGGTA GATGACGAAG AGCTGTTAGA GCTAGTTGAG 180

ATGGAAGTGC GTGAACTGTT ATCAGAATAC GATTTCCCAG GTGATGACTT ACCGGTAATC 240

CAAGGTTCAG CTCTGAAAGC GCTAGAAGGC GAGCCAGAGT GGGAAGCAAA AATCCTTGAA 300

TTAGCAGCGG CGCTGGATTC TTACATTCCA GAACCACAAC GTGACATCGA TAAGCCGTTC 360

CTACTGCCAA TCGAAGACGT ATTCTCAATT TCAGGCCGTG GTACAGTAGT AACAGGTCGT 420

GTTGAGCGTG GTATTGTACG CGTAGGCGAC GAAGTTGAAA TCGTTGGTGT ACGTGCGACA 480

ACTAAGACAA CGTGTACTGG TGTAGAAATG TTCCGTAAAC TGCTTGACGA AGGTCGTGCA 540

GGTGAGAACT GTGGTATTTT GTTACGTGGT ACTAAGCGTG ATGACGTAGA ACGTGGTCAA 600

GTATTAGCGA AGCCAGGTTC AATCAACCCA CACACTACTT TTGAATCAGA AGTTTACGTA 660

CTGTCAAAAG AAGAAGGTGG TCGTCACACG CCATTCTTCA AAGGCTACCG TCCACAGTTC 720

TACTTCCGTA CAACTGACGT AACCGGTACT ATCGAACTGC CAGAAGGCGT AGAGATGGTA 780

ATGCCAGGCG ATAACATCAA GATGGTAGTG ACACTGATTT GCCCAATCGC GATGGACGAA 840

GGTTTACGCT TCGCAATCCG TGAAGGCGGT CGTACAGTGG T 881

(2) INFORMATION FOR SEQ ID NO: 166:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 897 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Stigmatella aurantiaca*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:

AACATGATCA CGGGCGCGGC GCAGATGGAC GGAGCGATTC TGGTGGTGTC CGCGGCCGAC 60

GGCCCGATGC CCCAGACGCG TGAGCACATC CTGCTGGCCA GGCAGGTGGG CGTGCCCTAC 120

ATCGTCGTCT TCCTGAACAA GGTGGACATG CTGGACGATC CGGAGCTGCG CGAGCTGGTG 180

GAGATGGAGG TGCGCGACCT GCTCAAGAAG TACGAGTTCC CGGGCGACAG CATCCCCATC 240

ATCCCTGGCA GCGCGCTCAA GGCGCTGGAG GGAGACACCA GCGACATCGG CGAGGGAGCG 300

ATCCTGAAGC TGATGGCGGC GGTGGACGAG TACATCCCGA CGCCGCAGCG TGCGACGGAC 360

AAGCCGTTCC TGATGCCGGT GGAAGACGTG TTCTCCATCG CAGGCCGAGG AACGGTGGCG 420

ACGGGCCGAG TGGAGCGCGG CAAGATCAAG GTGGGCGAGG AAGTGGAGAT CGTGGGGATC 480

CGTCCGACGC AGAAGACGGT CATCACGGGG GTGGAGATGT TCCGCAAGCT GCTGGACGAG 540

GGCATGGCGG GAGACAACAT CGGAGCGCTG CTGCGAGGCC TGAAGCGCGA GGACCTGGAG 600

CGTGGGCAGG TGCTGGCGAA CTGGGGGAGC ATCAACCCGC ACACGAAGTT CAAGGCGCAG 660

GTGTACGTGC TGTCGAAGGA AGAGGGAGGG CGGCACACGC CGTTCTTCAA GGGATACCGG 720

CCGCAGTTCT ACTTCCGGAC GACGGACGTG ACCGGAACGG TGAAGCTGCC GGACAACGTG 780

GAGATGGTGA TGCCGGGAGA CAACATCGCC ATCGAGGTGG AGCTCATTAC TCCGGTCGCC 840

ATGGAGAAGG AGCTGCCGTT CGCCATCCGT GAGGGTGGCC GCACGGTGGG CGCCGGC 897

(2) INFORMATION FOR SEQ ID NO: 167:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 894 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Streptococcus pyogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167:

AACATGATCA CTGGTGCCGC TCAAATGGAC GGAGCTATCC TTGTAGTTGC TTCAACTGAT 60

GGACCAATGC CACAAACTCG TGAGCACATC CTTCTTTCAC GTCAGGTTGG TGTTAAACAC 120

CTTATCGTGT TCATGAACAA AGTTGACCTT GTTGATGACG AAGAGTTGCT TGAATTAGTT 180

GAGATGGAAA TTCGTGACCT TCTTTCAGAA TACGATTTCC CAGGTGATGA CCTTCCAGTT 240

ATCCAAGGTT CAGCTCTTAA AGCTCTTGAA GGCGACACTA AATTTGAAGA CATCATCATG 300

GAATTGATGG ATACTGTTGA TTCATACATT CCAGAACCAG AACGCGACAC TGACAAACCA 360

TTGCTTCTTC CAGTCGAAGA CGTATTCTCA ATTACAGGTC GTGGTACAGT TGCTTCAGGA 420

CGTATCGACC GTGGTACTGT TCGTGTCAAC GACGAAATCG AAATCGTTGG TATCAAAGAA 480

GAAACTAAAA AAGCTGTTGT TACTGGTGTT GAAATGTTCC GTAAACAACT TGACGAAGGT 540

CTTGCAGGAG ACAACGTAGG TATCCTTCTT CGTGGTGTTC AACGTGACGA AATCGAACGT 600

GGTCAAGTTA TTGCTAAACC AAGTTCAATC AACCCACACA CTAAATTCAA AGGTGAAGTA 660

TATATCCTTT CTAAAGACGA AGGTGGACGT CACACTCCAT TCTTCAACAA CTACCGTCCA 720

CAATTCTACT TCCGTACAAC TGACGTAACA GGTTCAATCG AACTTCCAGC AGGTACAGAA 780

ATGGTTATGC CTGGTGATAA CGTGACAATC AACGTTGAGT TGATCCACCC AATCGCCGTA 840

GAACAAGGTA CTACTTTCTC AATCCGTGAA GGTGGACGTA CTGTTGGTTC AGGT 894

(2) INFORMATION FOR SEQ ID NO: 168:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 897 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Thiobacillus cuprinus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168:

AACATGATCA CCGGTGCGGC CCAGATGGAC GGCGCCATCC TGGTCGTGTC CGCCGCCGAC 60

GGCCCCATGC CCCAAACCCG CGAGCACATC CTGCTGGCGC GTCAGGTGGG CGTGCCCTAC 120

ATCATCGTGT TCCTCAACAA GTGCGACATG GTCGACGACG CCGAGCTGCT CGAACTCGTC 180

GAGATGGAAG TGCGCGAGCT GCTGTCCAAG TACGACTTCC CCGGTGACGA CACCCCCATC 240

ATCAAGGGCT CGGCCAAGCT GGCCCTCGAA GGCGACAAGG GCGAACTGGG CGAAGGCGCC 300

ATTCTCAAGC TGGCCGAGGC CCTGGACACC TACATCCCCA CGCCCGAGCG GGCCGTCGAC 360

GGCGCGTTCC TCATGCCCGT GGAAGACGTG TTCTCCATCT CCGGGCGCGG CACGGTGGTC 420

ACCGGGCGTG TGGAGCGCGG CATCATCAAG GTCGGCGAGG AAATCGAGAT TGTCGGCCTC 480

AAGCCCACCC TCAAGACCAC CTGCACCGGC GTGGAAATGT TCAGGAAGCT GCTCGACCAG 540

GGCCAGGCCG GCGACAACGT CGGCATCTTG CTGCGCGGCA CCAAGCGCGA GGAAGTCGAG 600

CGCGGCCAGG TGCTGTGCAA ACCCGGCTCG ATCAAGCCCC ACACCCACTT CACCGCCGAG 660

GTGTACGTGC TGAGCAAGGA CGAGGGCGGC CGCCACACCC CCTTCTTCAA CAACTACCGC 720

CCGCAGTTCT ACTTCCGCAC CACCGACGTC ACCGGCGCCA TCGAACTGCC CAAGGACAAG 780

GAAATGGTCA TGCCCGGCGA TAATGTGAGC ATCACCGTCA AGCTCATCGC CCCCATCGCC 840

ATGGAAGAAG GCCTGCGCTT CGCCATCCGC GAAGGCGGCC GCACCGTCGG CGCCGGC 897

(2) INFORMATION FOR SEQ ID NO: 169:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 894 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Treponema pallidum*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169:

AATATGATCA CGGGTGCTGC GCAGATGGAC GGTGGTATTC TCGTCGTGTC TGCGCCTGAC 60

GGCGTTATGC CACAGACGAA GGAGCATCTT CTGCTCGCCC GTCAGGTTGG TGTTCCCTCC 120

ATCATTGTTT TTTTGAACAA GGTTGATTTG GTTGATGATC CTGAGTTGCT AGAGCTGGTG 180

GAAGAAGAGG TGCGTGATGC GCTTGCTGGA TATGGGTTTT CGCGTGAGAC GCCTATCGTC 240

AAGGGGTCTG CGTTTAAAGC TCTGCAGGAT GGCGCTTCCC CGGAGGATGC AGCTTGTATT 300

GAGGAACTGC TTGCGGCCAT GGATTCCTAC TTTGAAGACC CAGTGCGTGA CGACGCAAGA 360

CCTTTCTTGC TCTCTATCGA GGATGTGTAC ACTATTTCTG GGCGTGGTAC CGTTGTCACG 420

GGGCGCATCG AATGTGGGGT AATTAGTCTG AATGAAGAGG TCGAGATCGT CGGGATTAAG 480

CCCACTAAGA AAACAGTGGT TACTGGCATT GAGATGTTTA ATAAGTTGCT TGATCAGGGA 540

ATTGCAGGTG ATAACGTGGG GCTGCTTTTG CGCGGGGTGG ATAAAAAAGA GGTTGAGCGC 600

GGTCAGGTGC TTTCTAAGCC CGGTTCTATT AAGCCACACA CCAAGTTTGA GGCGCAGATC 660

TACGTGCTCT CTAAGGAAGA GGGTGGCCGT CACAGTCCTT TTTTTCAAGG TTATCGTCCG 720

CAGTTTTATT TTAGAACTAC TGACATTACC GGTACGATTT CTCTTCCTGA AGGGGTAGAC 780

ATGGTGAAGC CGGGGGATAA CACCAAGATT ATAGGTGAGC TCATCCACCC GATAGCTATG 840

GACAAGGGTC TGAAGCTTGC GATTCGTGAA GGGGGGCGCA CTATTGCTTC TGGT 894

(2) INFORMATION FOR SEQ ID NO: 170:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 891 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Ureaplasma urealyticum*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170:

AATATGATTA CAGGGGCAGC ACAAATGGAT GGAGCAATTT TAGTTATTGC TGCATCTGAT 60

GGGGTTATGG CTCAAACTAA AGAACATATT TTATTAGCAC GTCAAGTTGG TGTTCCAAAA 120

ATCGTTGTTT TCTTAAACAA ATGTGATTTC ATGACAGATC CAGATATGCA AGATCTTGTT 180

GAAATGGAAG TTCGTGAATT ATTATCTAAA TATGGATTTG ATGGCGATAA CACACCAGTT 240

ATTCGTGGTT CAGGTCTTAA GGCTTTAGAA GGAGATCCAG TTTGAGAAGC AAAAATTGAT 300

GAATTAATGG ACGCAGTTGA TTCATGAATT CCATTACCAG AACGTAGTAC TGACAAACCA 360

TTCTTATTAG CAATTGAAGA TGTATTCACA ATTTCAGGAC GTGGTACAGT AGTAACTGGA 420

CGTGTTGAAC GTGGTGTATT AAAAGTTAAT GATGAGGTTG AAATTGTTGG TCTAAAAGAC 480

ACTCAAAAAA CTGTTGTTAC AGGAATTGAA ATGTTTAGAA AATCATTAGA TCAAGCTGAA 540

GCTGGTGATA ATGCTGGTAT TTTATTACGT GGTATTAAAA AAGAAGATGT TGAACGTGGT 600

CAAGTACTTG TAAAACCAGG ATCAATTAAA CCTCACCGTA CTTTTACTGC TAAAGTTTAT 660

ATTCTTAAAA AAGAAGAAGG TGGACGTCAT ACACCTATTG TTTCAGGATA CCGTCCACAA 720

TTCTATTTTA GAACAACAGA TGTAACAGGT GCTATTTCAT TACCTGCTGG TGTTGATTTG 780

GTTATGCCAG GTGATGACGT TGAAATGACT GTAGAATTAA TTGCTCCAGT TGCGATTGAA 840

GATGGATCTA AATTCTCAAT CCGTGAAGGT GGTAAAACTG TAGGTCATGG T 891

(2) INFORMATION FOR SEQ ID NO: 171:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 909 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Wolinella succinogenes*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171:

AACATGATTA CAGGTGCTGC TCAAATGGAT GGCGCGATTC TTGTTGTTTC TGCGGCGGAT 60

GGCCCCATGC CCCAAACTAG GGAGCACATT CTTCTTTCTC GACAAGTAGG CGTTCCTTAC 120

ATCGTGGTTT TCTTGAACAA AGAAGATATG GTTGATGACG CTGAGCTTCT TGAGCTTGTT 180

GAAATGGAAG TTAGAGAACT TCTTAGCAAC TACGACTTCC CTGGAGATGA CACTCCTATC 240

GTTGCAGGTT CCGCTCTTAA AGCTCTTGAA GAGGCTAACG ACCAGGAAAA TGTTGGCGAG 300

TGGGGCGAGA AAGTATTGAA GCTTATGGCT GAGGTTGACC GATATATTCC TACGCCTGAG 360

CGAGATGTGG ATAAGCCTTT CCTTATGCCT GTTGAAGACG TATTCTCCAT CGCGGGTCGT 420

GGAACCGTTG TGACAGGAAG AATTGAAAGA GGCGTGGTTA AAGTCGGTGA CGAAGTAGAA 480

ATCGTTGGTA TCCGAAACAC ACAAAAAACA ACCGTAACTG GCGTTGAGAT GTTCCGAAAA 540

GAGCTCGACA AGGGTGAGGC GGGTGACAAC GTTGGTGTTC TTTTGAGAGG CACCAAGAAA 600

GAAGATGTTG AGAGAGGTAT GGTTCTTTGT AAAATAGGTT CTATCACTCC TCACACTAAC 660

TTTGAAGGTG AAGTTTACGT TCTTTCCAAA GAGGAAGGCG GACGACACAC TCCATTCTTC 720

AATGGATACC GACCTCAGTT CTATGTTAGA ACTACAGACG TTACCGGTTC TATCTCTCTT 780

CCTGAGGGCG TAGAGATGGT TATGCCTGGT GACAACGTTA AGATCAATGT TGAGCTTATC 840

GCTCCTGTAG CCCTCGAAGA GGGAACACGA TTCGCGATCC GTGAAGGTGG TCGAACCGTT 900

GGTGCGGGT 909

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:6
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:12
(D) OTHER INFORMATION:/note= "n = inosine"

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:18
(D) OTHER INFORMATION:/note= "n = inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172:

TARTCNGTRA ANGCYTCNAC RCACAT 26

(2) INFORMATION FOR SEQ ID NO: 173:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

TCTTTAGCAG AACAGGATGA A 21

(2) INFORMATION FOR SEQ ID NO: 174:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

GAATAATTCC ATATCCTCCG 20

CLAIMS

What is claimed is:

1. A method using probes and/or amplification primers which are specific, ubiquitous and sensitive for determining the presence and/or amount of nucleic acids:

- from a bacterial antibiotic resistance gene selected from the group consisting of bla_{tem}, bla_{shv}, bla_{rob}, bla_{oxa}, *blaZ, aadB, aacC1, aacC2, aacC3, aac6'-IIa, aacA4, aad(6'), vanA, vanB, vanC, msrA, satA, aac(6')-aph(2"), vat, vga, ermA, ermB, ermC, mecA, int* and *sul*, and

- from specific bacterial and fungal species selected from the group consisting of *Enterococcus faecium*, *Listeria monocytogenes, Neisseria meningitidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Candida albicans, Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species,

in any sample suspected of containing said bacterial and/or fungal nucleic acids,

wherein each of said nucleic acid or variant or part thereof comprises a selected target region hybridizable with said probes or primers;

said method comprising the following steps: contacting said sample with said probes or primers and detecting the presence and/or amount of hybridized probes or amplified products as an indication of the presence and/or amount of said specific bacterial and/or fungal species and bacterial antibiotic resistance genes.

2. A method according to claim 1, which further makes use of probes and/or primers which are specific, ubiquitous and sensitive for determining the presence and/or amount of nucleic acids from any bacterium or fungus.

3. The method of claim 1, which is performed directly from a test sample.

4. The method of claim 1, which is performed directly from a test sample consisting of a bacterial and/or fungal culture or suspension.

5. The method of claim 1, wherein said nucleic acids are all detected under uniform hybridization or amplification conditions.

6. The method of claim 1, wherein said nucleic acids are amplified by a method selected from the group consisting of:

a) polymerase chain reaction (PCR),

b) ligase chain reaction (LCR),

c) nucleic acid sequence-based amplification (NASBA),

d) self-sustained sequence replication (3SR),

e) strand displacement amplification (SDA),

f) branched DNA signal amplification (bDNA),

g) transcription-mediated amplification (TMA),

h) cycling probe technology (CPT),

i) nested PCR, and

j) multiplex PCR.

7. The method of claim 6, wherein said nucleic acids are amplified by PCR.

8. The method of claim 7, wherein the PCR protocol achieves within one hour under uniform amplification conditions the determination of the presence of said nucleic acids by performing for each amplification cycle an annealing step of thirty seconds at 45-55°C and a denaturation step of only one second at 95°C without any time specifically allowed to an elongation step.

9. A method for the detection, identification and/or quantification of a microorganism selected from the group consisting of *Enterococcus faecium*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Candida albicans*, *Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, directly from a test sample or from bacterial and/or fungal cultures, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the said microorganism DNA of the sample or of a substantially homogeneous population of said microorganism isolated from this sample, or

inoculating said sample or said substantially homogeneous population of microorganism isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or said isolated microorganism to release the said microorganism DNA,

said microorganism DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleic acid which nucleotide sequence is selected from the group consisting of SEQ ID NOs: 26, 27, 28, 29, 30, 120, 131 to 134, 31, 140 to 143, 32 to 36, 120 to 124, a sequence complementary thereof, a part thereof having at least 12 nucleotides in length, and a variant thereof, which specifically and ubiquitously anneals with strains or representatives of *Enterococcus faecium*, *Listeria*

monocytogenes, Neisseria meningitidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Candida albicans, Enterococcus species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, respectively, under conditions such that the nucleic acid of said probe can selectively hybridize with said microorganism DNA, whereby a hybridization complex is formed; and

c) detecting the presence of said hybridization complex on said inert support or in said solution as an indication of the presence and/or amount of said microorganism, in said test sample.

10. A method for detecting the presence and/or amount of a microorganism selected from the group consisting of *Enterococcus faecium, Listeria monocytogenes, Neisseria meningitidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Candida albicans, Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, in a test sample which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of oligonucleotide primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said microorganism DNA that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template, said at least one pair of primers being chosen from a nucleotide sequence within the group consisting of SEQ ID NOs: 26, 27, 28, 29, 30, 120, 131 to 134, 31, 140 to 143, 32 to 36, 120 to 124, respectively with regard to said microorganism, a sequence complementary thereof, and a variant thereof;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of the presence and/or amount of said microorganisms, in said test sample.

11. The method of claim 10, wherein said pair of primers is defined in SEQ ID NOs: 1 and 2, 3 and 4, 5 and 6, 7 and 8, 9 and 10, 11 and 12, 13 and 14, 15 and 16, 17 to 20, 21 and 22, respectively, for each of *Enterococcus faecium, Listeria monocytogenes, Neisseria meningitidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Candida albicans, Enterococcus* species, *Neisseria* species, *Staphylococcus* species and *Streptococcus* species.

12. A method for detecting the presence and/or amount of any bacterium directly from a test sample or a bacterial culture, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the bacterial DNA of the sample or of a substantially homogeneous population of bacteria isolated from this sample, or

inoculating said sample or said substantially homogeneous population of bacteria isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or isolated bacteria to release the bacterial DNA,

said bacterial DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleic acid which nucleotide sequence is selected from the group consisting of SEQ ID NOs: 118, 119, 125 to 171, a sequence complementary thereof, a part thereof having at least 12 nucleotides in length, and a variant thereof, which specifically and ubiquitously anneals with strains or representatives of any bacterial species, under conditions such that the nucleic acid of said probe can selectively hybridize with said bacterial DNA, whereby a hybridization complex is formed; and

c) detecting the presence of said hybridization complex on said inert support or in said solution as an indication of the presence and/or amount of any bacterium in said test sample.

13. A method for detecting the presence and/or amount of any bacterium in a test sample which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of oligonucleotide primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of any bacterial DNA that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template, said at least one pair of primers being chosen from a nucleotide sequence within the group consisting of SEQ ID NO: 118, 119, 125 to 171, a sequence complementary thereof, and a variant thereof;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of the presence and/or amount of any bacterium in said test sample.

14. The method of claim 13, wherein said pair of primers is defined in SEQ ID NOs: 23 and 24.

15. A method for obtaining *tuf* sequences from any bacterium directly from a test sample or a bacterial culture, which comprises the following steps:

a) treating said sample with an aqueous solution containing a pair of primers having a sequence selected within the nucleotide sequences defined in SEQ ID NOs: 107 and 108, a part thereof having at least 12 nucleotides in length, a sequence complementary thereof, and a variant thereof, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said bacterial *tuf* gene that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence; and

d) determining the nucleotide sequence of the said amplified target sequence by using any DNA sequencing method.

16. A method for detecting the presence and/or amount of any fungus directly from a test sample or a fungal culture, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the fungal DNA of the sample or of a substantially homogeneous population of fungi isolated from this sample, or

inoculating said sample or said substantially homogeneous population of fungi isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or isolated fungi to release the fungal DNA,

said fungal DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleotide sequence selected from the group consisting of SEQ ID NOs: 120 to 124, a sequence complementary thereof, a part thereof having at least 12 nucleotides in length, and a variant thereof, which specifically and ubiquitously anneals with strains or representatives of any fungus, under conditions such that the nucleic acid of said probe can selectively hybridize with said fungal DNA, whereby a hybridization complex is formed; and

c) detecting the presence of said hybridization complex on said inert support or

in said solution as an indication of the presence and/or amount of any fungus in said test sample.

17. A method for detecting the presence and/or amount of any fungus in a test sample which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of oligonucleotide primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of any fungal DNA that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template, said at least one pair of primers being chosen from a nucleotide sequence within the group consisting of SEQ ID NOs: 120 to 124, a sequence complementary thereof, and a variant thereof;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of the presence and/or amount of any fungus in said test sample.

18. A method for obtaining *tuf* sequences from any fungus directly from a test sample or a fungal culture, which comprises the following steps:

a) treating said sample with an aqueous solution containing a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 109 and 172, a part thereof having at least 12 nucleotides in length, a sequence complementary thereof, and a variant thereof, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said fungal *tuf* gene that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence; and

d) determining the nucleotide sequence of the said amplified target sequence by using any DNA sequencing method.

19. A method as defined in claim 1, which comprises the evaluation of the presence of a bacterial resistance mediated by a bacterial antibiotic resistance gene selected

from the group consisting of *bla*$_{oxa}$, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *vanB*, *vanC*, directly from a test sample or a bacterial culture, which comprises the following steps:

a) depositing and fixing on an inert support or leaving in solution the bacterial DNA of the sample or of a substantially homogeneous population of bacteria isolated from this sample, or

inoculating said sample or said substantially homogeneous population of bacteria isolated from this sample on an inert support, and lysing *in situ* said inoculated sample or isolated bacteria to release the bacterial DNA,

said bacterial DNA being made in a substantially single-stranded form;

b) contacting said single-stranded DNA with a probe, said probe comprising at least one single-stranded nucleotide sequence having at least 12 nucleotide in length is selected from the group consisting of SEQ ID NOs: 110, 111, 112, 113, 114 115, 116, 117, a sequence complementary thereof, and a variant thereof, which specifically hybridizes with said bacterial antibiotic resistance gene, respectively; and

c) detecting the presence of a hybridization complex as an indication of a bacterial resistance mediated by said one of said bacterial antibiotic resistance genes.

20. A method as defined in claim 1, which comprises the evaluation of the presence of a bacterial resistance mediated by a bacterial antibiotic resistance gene selected from the group consisting of *bla*$_{oxa}$, *blaZ*, *aac6'-IIa*, *ermA*, *ermB*, *ermC*, *vanB*, *vanC*, directly from a test sample or a bacterial culture, which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of primers having at least 12 nucleotides in length, one of said primers being capable of hybridizing selectively with one of the two complementary strands of said bacterial antibiotic resistance gene that contains a target sequence, and the other of said primers being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template, said at least one pair of primers being chosen from a nucleotide sequence within the group consisting of SEQ ID NOs: 110, 111, 112, 113, 114, 115, 116, 117, respectively with regard to said bacterial antibiotic resistance gene, a sequence complementary thereof, and a variant thereof;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of a bacterial resistance mediated by one of said bacterial antibiotic resistance genes.

21. A method as defined in claim 1, which comprises the evaluation of the presence of a bacterial resistance gene selected from the group consisting of *bla*$_{tem}$, *bla*$_{shv}$, *bla*$_{rob}$, *bla*$_{oxa}$, *blaZ*, *aadB*, *aacC1*, *aacC2*, *aacC3*, *aac6'-IIa*, *aacA4*, *aad(6')*, *vanA*, *vanB*, *vanC*, *msrA*, *satA*, *aac(6')-aph(2")*, *vat*, *vga*, *ermA*, *ermB*, *ermC*, *mecA*, *int* and *sul*, directly from a test sample or a bacterial culture, which comprises the following steps:

a) treating said sample with an aqueous solution containing at least one pair of primers having a sequence selected in the group consisting of SEQ ID NOs: 37 to 40, 41 to 44, 45 to 48, 49 and 50, 51 and 52, 53 and 54, 55 and 56, 57 and 58, 59 to 60, 61 to 64, 65 and 66, 173 and 174, 67 to 70, 71 to 74, 75 and 76, 77 to 80, 81 and 82, 83 to 86, 87 and 88, 89 and 90, 91 and 92, 93 and 94, 95 and 96, 97 and 98, 99 to 102, 103 to 106, a part thereof having at least 12 nucleotides in length, a sequence complementary thereof, a variant thereof, and mixtures thereof, one of said primers of said pair being capable of hybridizing selectively with one of the two complementary strands of its respective bacterial antibiotic resistance gene that contains a target sequence, and the other of said primers of said pairs being capable of hybridizing with the other of said strands so as to form an extension product which contains the target sequence as a template;

b) synthesizing an extension product of each of said primers, said extension product containing the target sequence, and amplifying said target sequence, if any, to a detectable level; and

c) detecting the presence and/or amount of said amplified target sequence as an indication of a bacterial resistance mediated by one of said bacterial antibiotic resistance genes.

22. A nucleic acid having the nucleotide sequence of any one of SEQ ID NOs: 26 to 36, 110 to 171, a part thereof, a sequence complementary thereof, and variant thereof which, when in single-stranded form, ubiquitously and specifically hybridizes with a target bacterial or fungal DNA as a probe or as a primer.

23. An oligonucleotide having the nucleotide sequence of any one of SEQ ID NOs: 1 to 25, 37 to 109, 172 to 174, a part thereof, a sequence complementary thereof, and variant thereof, which ubiquitously and specifically hybridizes with a target bacterial or fungal DNA as a probe or as a primer.

24. A recombinant plasmid comprising a nucleic acid as defined in claim 22.

25. A recombinant host which has been transformed by a recombinant plasmid according to claim 24.

26. A recombinant host according to claim 25 wherein said host is *Escherichia coli*.

27. A diagnostic kit for the detection and/or quantification of the nucleic acids of any

combination of the microbial species and/or genera selected from the group consisting of *Enterococcus faecium, Listeria monocytogenes, Neisseria meningitidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Candida albicans, Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, comprising any suitable combination of probes of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 26 to 36, 120 to 124, 131 to 134, 140 to 143, sequences complementary thereof, and variants thereof.

28. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the microbial species and/or genera selected from the group consisting of *Enterococcus faecium, Listeria monocytogenes, Neisseria meningitidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Candida albicans, Enterococcus* species, *Neisseria* species, *Staphylococcus* species, *Streptococcus* species and *Candida* species, comprising any suitable combination of primers of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 26 to 36, 120 to 124, 131 to 134, 140 to 143, sequences complementary thereof, and variants thereof.

29. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the microbial species and/or genera selected from the group consisting of *Enterococcus faecium, Listeria monocytogenes, Neisseria meningitidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Candida albicans, Enterococcus* species, *Neisseria* species, *Staphylococcus* species and *Streptococcus* species, comprising any suitable combination of primers selected from the group consisting of SEQ ID NOs: 1 to 22, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof.

30. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the bacterial resistance genes selected from the group consisting of bla_{oxa}, *blaZ, aac6'-IIa, ermA, ermB, ermC, vanB, vanC,* comprising any suitable combination of probes of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 110 to 117, sequences complementary thereof, and variants thereof.

31. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the bacterial resistance genes selected from the group consisting of bla_{oxa}, *blaZ, aac6'-IIa, ermA, ermB, ermC, vanB, vanC,* comprising any suitable combination of primers of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 110 to 117, sequences complementary thereof, and variants thereof.

32. A diagnostic kit for the detection and/or quantification of the nucleic acids of any combination of the bacterial resistance genes selected from the group consisting of *bla*$_{tem}$, *bla*$_{shv}$, *bla*$_{rob}$, *bla*$_{oxa}$, *blaZ*, *aadB*, *aacC1*, *aacC2*, *aacC3*, *aac6'-IIa*, *aacA4*, *aad(6')*, *vanA*, *vanB*, *vanC*, *msrA*, *satA*, *aac(6')-aph(2")*, *vat*, *vga*, *ermA*, *ermB*, *ermC*, *mecA*, *int* and *sul*, comprising any suitable combination of primers selected from the group consisting of SEQ ID NOs: 37 to 106, 173 and 174, a part thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof.

A diagnostic kit for the detection and/or quantification of the nucleic acids of any bacterium and/or fungus, comprising any combination of probes of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof.

34. A diagnostic kit for the detection and/or quantification of the nucleic acids of any bacterium and/or fungus, comprising any suitable combination of primers of at least 12 nucleotides in length selected from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof.

35. A diagnostic kit for the detection and/or quantification of the nucleic acids of any bacterium, comprising a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 23 and 24, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof.

36. A diagnostic kit, as defined in claim 27, further comprising any combination of probes of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

37. A diagnostic kit, as defined in claim 28, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

38. A diagnostic kit, as defined in claim 29, further comprising a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 23 and 24, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium.

39. A diagnostic kit, as defined in claim 27, further comprising any combination of probes of at least 12 nucleotides in length selected within a nucleotide sequence from

the group consisting of SEQ ID NOs: 110 to 117, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterial antibiotic resistance gene selected from the group consisting of *bla*$_{oxa}$, *blaZ, aac6'-IIa, ermA, ermB, ermC, vanB, vanC.*

40. A diagnostic kit, as defined in claim 28, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 110 to 117, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterial antibiotic resistance gene selected from the group consisting of *bla*$_{oxa}$, *blaZ, aac6'-IIa, ermA, ermB, ermC, vanB, vanC.*

41. A diagnostic kit, as defined in claim 29, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 37 to 106, 173 and 174, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterial antibiotic resistance gene selected from the group consisting of *bla*$_{tem}$, *bla*$_{rob}$ *bla*$_{shv}$ *bla*$_{oxa}$ *blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-IIa, aad(6'), ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2"), vat, vga, msrA, sul* and *int.*

42. A diagnostic kit, as defined in claim 30, further comprising any combination of probes of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

43. A diagnostic kit, as defined in claim 31, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

44. A diagnostic kit, as defined in claim 32, further comprising a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 23 and 24, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium.

45. A diagnostic kit, as defined in claim 39, further comprising any combination of probes of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic

acids of any bacterium and/or fungus.

46. A diagnostic kit, as defined in claim 40, further comprising any suitable combination of primers of at least 12 nucleotides in length selected within a nucleotide sequence from the group consisting of SEQ ID NOs: 118 to 171, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium and/or fungus.

47. A diagnostic kit, as defined in claim 41, further comprising a pair of primers having a sequence selected within the nucleotide sequence defined in SEQ ID NOs: 23 and 24, parts thereof having at least 12 nucleotides in length, sequences complementary thereof, and variants thereof, for the simultaneous detection and/or quantification of nucleic acids of any bacterium.

INTERNATIONAL SEARCH REPORT

Inter. onal Application No
PCT/CA 97/00829

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 08582 A (BERGERON MICHEL G ;OUELLETTE MARC (CA); ROY PAUL H (CA)) 21 March 1996 see whole document, esp claims 1-3 ---	1-14, 19-38, 40-47
X	FR 2 699 539 A (PASTEUR INSTITUT) 24 June 1994 see whole document, esp. abstract and claims ---	1-8,19, 32

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 June 1998	01. 07. 98

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Müller, F

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter. nal Application No
PCT/CA 97/00829

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FLEISCHMANN R D ET AL: "WHOLE-GENOME RANDOM SEQUENCING AND ASSEMBLY OF HAEMOPHILUS INFLUENZAE RD" SCIENCE, vol. 269, no. 5223, 28 July 1995, pages 496-498, 507 - 512, XP000517090 see the whole document & DATABASE EMPRO EMBL AC:U32739; L42023 ---	13,31, 33,36, 37,42, 43,45,46
X	QUELETTE M. ET AL.,: "Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 b-lactamase gene" PROC: NATL. ACAD. SCI. USA, vol. 84, - November 1987 pages 7378-7382, XP002066855 see the whole document & DATABASE EMPRO EMBL AC:J02967 ---	1,20,22, 30,39,40
X	EVERS S. ET AL.,: "Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583" GENE, vol. 140, - 1994 pages 97-102, XP002066856 see the whole document & DATABASE EMPRO EMBL AC:U00456 ---	1,19,20, 22,30, 31,39,40
X	DUTKA-MALEN S. ET AL.,: "Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase related protein necessary for vancomycin resistance" GENE, vol. 112, - 1992 pages 53-58, XP002066857 see the whole document & DATABASE EMPRO EMBL AC:M75132 ---	1,19,20, 22,30, 31,39,40

-/--

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inten nal Application No
PCT/CA 97/00829

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LOECHEL S. ET AL.,: "Nucleotide sequence of the tuf gene from Mycoplasma genitalium" NUCLEIC ACID RESEARCH, vol. 17, no. 23, - 1989 page 10127 XP002066858 see the whole document & DATABASE EMPRO EMBL AC:X16463 ---	12,13, 33,34, 36,37, 42,43,45
X	WO 96 18745 A (SMITHKLINE BEECHAM CORP ;HOYER LOIS L (US); LIVI GEORGE P (US); SH) 20 June 1996 see the whole document & DATABASE GENESEQ DERWENT AC:T29069, ---	1-12,16, 17, 22-29, 33,34, 36,37, 42,43, 45,46
X	US 5 523 205 A (COSSART PASCALE ET AL) 4 June 1996 see the whole document ---	1-9
A,P	EP 0 761 815 A (SANDOZ AG ;SANDOZ LTD (CH); SANDOZ AG (DE)) 12 March 1997 see the whole document & DATABASE GENESEQ DERWENT AC:T87876 ---	1,21
X	PORCELLA S. ET AL.,: "Identification of an EF-Tu protein that is priplasm-associated and processed in Neisseria gonorrhoeae" MICROBIOLOGY, vol. 142, - September 1996 pages 2481-2489, XP002066859 see the whole document & DATABASE EMPRO EMBL AC:L36380 --- -/--	1-8,12, 13,22, 33,34, 36,37, 42,43, 45,46

3

INTERNATIONAL SEARCH REPORT

Intern nal Application No
PCT/CA 97/00829

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BREMAUD L. ET AL.,: "genetic and molecular analysis of the tRNA-tufB operon of the mycobactreium Stigmatella aurantiaca" NUCLEIC ACID RESEARCH, vol. 23, no. 10, - 1995 pages 1737-1743, XP002067242 see the whole document & DATABASE EMPRO EMBL AC:X82820 ---	22,33
X	DATABASE EMPRO EMBL 2 July 1986 MURPHY E. ET AL.,: XP002067252 AC:X03216 ---	22
X	EAST A.K. & DYKE K.G.H.: "Cloning and sequence dtermination of six staphylococcus aureus b-lactamases and their expression in E. coli and S. aureus" J. GEN. MICROBIOL., vol. 135, - 4 April 1989 pages 1001-1015, XP002067243 see the whole document & DATABASE EMPRO EMBL AC:M25253 ---	22
X	BRISSON-NOEL A. ET AL.,: "Evidence for natural gene transfer from gram-positive cocci to E. coli" J. BACTERIOL, vol. 170, - April 1988 pages 1739-1745, XP002067244 see the whole document & DATABASE EMPRO EMBL AC:M19270 ---	22
X	AN G. & FRIESEN J.D.: "The nucleotide sequence of tufB and four nearby tRNA structural genes of E. coli" GENE, vol. 12, - December 1980 pages 33-39, XP002067245 see the whole document & DATABASE EMPRO EMBL AC:X57091 ---	22

-/--

3

INTERNATIONAL SEARCH REPORT

Inter ...nal Application No
PCT/CA 97/00829

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OHAMA T. ET AL.,: "Organization and codon usage of the streptomycin operon in micrococcus luteus, a bacterium with a high genomic G+C content" J. BACTERIOL., vol. 169, - October 1987 pages 4770-4777, XP002067246 see the whole document & DATABASE EMPRO EMBL AC:M17788 ---	22
X	MONOD M. ET AL.,: "Sequence and properties of pIM13, a macrolide-lincosamide-steptogramin B resistance plasmid from bacillus subtilis" J. BACTERIOL., vol. 167, - July 1986 pages 138-147, XP002067247 see the whole document & DATABASE EMPRO embl AC:X63539 ---	22
X	CARLIN N. ET AL.,: "Monoclonal antibodies specific for elongation factor Tu and complete nucleotide sequence of the tuf gene in M. tuberculosis" INFECT. IMMUN., vol. 60, August 1992, pages 3136-3142, XP002067248 see the whole document & DATABASE EMPRO EMBL AC:X63539 ---	22
X	ZHANG Y-X. ET AL.,: "Cloning, sequencing, and expression in E. coli of the gene encoding a 45-kilodalton protein, elongation factor Tu, from chlamydia trachomatis serovar F" J. BACTERIOL, vol. 176, no. 4, - February 1994 pages 1184-1187, XP002067249 see the whole document & DATABASE EMPRO EMBL AC:L22216 ---	22
X	DATABASE EMPRO embl 13 August 1995 PERLEE L. & SCHWARTZ I.: XP002067253 AC:L23125 ---	22

3 -/--

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter onal Application No
PCT/CA 97/00829

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMPRO EMBL 27 October 1996 YOSHIKAWA H.: XP002067254 AC:D64127 ---	22
X	DATABASE EMPRO EMBL thesis, 8 June 1994 KAMLA V.: XP002067255 AC:Z34275 ---	22
X	ANDERSSON S.G.E.: "Unusual organization of the rRNA genes in Rickettsia prowazekii" J. BACTERIOL., vol. 177, no. 4, - July 1995 pages 4171-4175, XP002067250 see the whole document & DATABASE EMPRO EMBL AC:z54170 see abstract ---	22
X	SHAW K.J. ET AL.,: "Isolation, characterization and DNA sequence analysis of an AAC(6')_II gene from Pseudomonas aeruginosa" ANTIMICROBIAL. AGNETS AND CHEMOTHERAPY, vol. 33, no. 12, - December 1989 pages 2052-2062, XP002067251 see the whole document & DATABASE EMPRO EMBL AC:X55116 ---	22
X	DATABASE EMPRO EMBL LUDWIG W. ET AL.,: "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase-beta subunit genes; Antonie van leeuwenhoek 64; 285-305 (1993)" XP002067256 AC: X76863, X76866, X76867, X76871, X76872 ---	22
P,X	EP 0 786 519 A (HUMAN GENOME SCIENCES INC) 30 July 1997 seq id 4 -----	22

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 97/00829

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-13,19,21-29,32-34,36,41-43,45,46 (partly)

   Nucleic acids (SEQ. ID.:1,2,13,14,67-70,51,52, 71-76, 81-86,131-134, 173,174) specific for Enterococcus spp., methods using them, and plasmids, hosts and kits containing them

2. Claims: 1-9,11-13,22-26,29,33,34,36,37,42,43,45,46 (partly)

   Nucleic acids (SEQ ID.: 3,4, 136-139) specific for Listeria monocytogenes, methods using them, and plasmids, hosts and kits containing them

3. Claims: 1-9,11-13,22-26,29,33,34,36,37,42,43,45,46 (partly)

   Nucleic acids (SEQ. ID.: 5,6,15,16,162) specific for Neisseria spp., methods using them, and plasmids, hosts and kits containing them

4. Claims: 1-9,11-13,21-26,32-34,36,37,42,43,45,46 (partly)

   Nucleic acids (SEQ ID.: 7,8,17-20,77-80,89-98, 140-143) specific for Staphylococcus spp., methods using them, and plasmids, hosts and kits containing them

5. Claims: 1-9,11-13,22-26,29,33,34,36,37,42,43,45,46 (partly)

   Nucleic acids (SEQ. ID.: 9,10,21,22,144-146,167) specific for Streptococcus spp., methods using them, and plasmids, hosts and kits containing them

6. Claims: 1-12,22-29,33,34,36,37,42,43,45,46 (partly), 16, 17 (complete)

   Nucleic acids (SEQ ID.: 11,12,120-124) specific for Candida albicans, methods using them, and plasmids, hosts and kits containing them

7. Claims: 14,19,20,30,31,35,38,39,40,44,47 (complete), 23, 32 (partly)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Nucleic acids (SEQ ID.: 23-24, 99-106, 110-117, 118,119, 125-130, 135, 147-161, 163-166, 168-171) specific for universal detection of bacteria and fungus species, methods using them, and plasmids, hosts and kits containing them

8. Claims: 15,18 (complete)

Methods for obtaining tuf sequences by using SEQ ID.: 107,108,109 and 172

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter ...nal Application No
PCT/CA 97/00829

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9608582 A	21-03-1996	AU 3468195 A	29-03-1996
		CA 2199144 A	21-03-1996
		EP 0804616 A	05-11-1997
		NO 971111 A	09-05-1997
FR 2699539 A	24-06-1994	CA 2152066 A	07-07-1994
		EP 0672147 A	20-09-1995
		WO 9414961 A	07-07-1994
		FR 2699537 A	24-06-1994
		JP 8505050 T	04-06-1996
WO 9618745 A	20-06-1996	US 5668263 A	16-09-1997
		AU 4468696 A	03-07-1996
		CA 2207816 A	20-06-1996
		EP 0820523 A	28-01-1998
US 5523205 A	04-06-1996	AT 121460 T	15-05-1995
		DE 68922252 D	24-05-1995
		DE 68922252 T	24-08-1995
		WO 8906699 A	27-07-1989
		EP 0355147 A	28-02-1990
		JP 2502880 T	13-09-1990
		US 5389513 A	14-02-1995
EP 0761815 A	12-03-1997	AU 6429796 A	06-03-1997
		CA 2184301 A	01-03-1997
		JP 9182590 A	15-07-1997
EP 0786519 A	30-07-1997	CA 2194411 A	06-07-1997
		JP 9322781 A	16-12-1997